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T Peduru Hewa          Summary 
 
SUMMARY 
The Quartz-crystal microbalance (QCM) is a very sensitive device that measures mass 
by detecting the change in vibrational frequency of the quartz crystal. The change in 
frequency of the crystal upon binding is proportional to mass of the binding substances 
(Vaughan et al., 1999; 2003). 
 
The aim of this thesis was to develop a QCM-based biosensor for the rapid diagnosis of 
influenza viruses and to compare the suitability and limitations of currently available 
diagnostic methods. Five widely used methods for the diagnosis of influenza, including 
the standard cell culture method, the shell vial method, a conventional and real-time 
RT-PCR and the Directigen Flu A test, were evaluated together with the currently 
developed QCM for sensitivity and rapidity, using 67 clinical samples (nasal washes) 
received during the 2005 Australian winter. 
 
ELISAs were developed to allow detection of all influenza A or B viruses, respective of 
changes to their HA and NA surface antigens, and for their eventual application to 
clinical specimens. The type-specific and conserved viral M1 proteins of both 
A/PR/8/34 and B/Lee/40 viruses, which do not vary between subtypes, were used to 
prepare polyclonal antisera. The M1 proteins of A/PR/8/34 and B/Lee/40 were 
separated from other viral proteins and their specificity and biological activity was 
confirmed. Polyclonal antisera prepared in chickens induced antibody titres of 1:12,900 
for A/PR/8/34 M1 and 1: 78,000 for B/Lee/40 M1. There were no cross-reactions 
between the antisera and the M1 proteins of A/PR/8/34 and B/Lee/40.   
 
The sensitivity and the specificity of the M1-specific MAbs and polyclonal antisera 
against A/PR/8/34 and B/Lee/40 were analysed and compared for their suitability to 
detect influenza viruses through the development of ELISAs, as preliminary steps in the 
development of the QCM. The sensitivities of the ELISAs for the detection of purified 
A/PR/8/34 and B/Lee/40 viruses were 20μg/mL and 14 μg/mL using polyclonal 
antibodies and 30 μg/mL and 20 μg/mL for MAbs, respectively. The limit for detection 
of each virus was 104 pfu/mL, irrespective of whether antisera or MAbs were used for 
capture. Non-purified cell culture-grown preparations of either virus could be detected 
at 103 pfu/mL  
1 
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The QCM was developed, utilising the same reagents used for the development of the 
ELISAs described in Chapter 4. A number of parameters were then further optimised to 
improve the sensitivity of detection. These included blocking of non-specific binding, 
examination of the flow cell compression effect, the role of buffer pH, flow rate, 
antibody concentration and the use of Protein A on the crystal surfaces of the biosensor.  
 
The lowest virus concentration that could be detected under these conditions was 104 
pfu/mL for egg-grown preparations of both A/PR/8/34 and B/Lee/40, which could be 
detected within 30 min. Conjugation of 13 nm gold nanoparticles to the second (detect) 
antibody resulted in a 10-fold increase in sensitivity with a detection limit of 103 
pfu/mL within 1 h. The sensitivity obtained with this sensor allowed its evaluation with 
clinical samples from patients infected with influenza viruses. However, direct detection 
of the influenza viruses in nasal samples was not possible by QCM because of the 
significant frequency fluctuation that was probably caused by the viscosity of the 
samples. Therefore, an additional culture step of 12 h was required, which increased the 
processing period to 2 days. 
 
The conventional RT-PCR method was shown to be the most sensitive for the detection 
of influenza viruses in nasal samples, followed by the standard cell culture method, the 
shell vial method, an ELISA and the Directigen Flu A test. The QCM/nanoparticle 
method has shown equally as sensitive as the standard cell culture method and the QCM 
method equally sensitive as the shell vial method. The times for diagnosis were 20 min 
for Directigen Flu A test, 1 day for the conventional RT-PCR, 1 day for the ELISA, 2 
days for the shell vial method and up to 14 days for the standard cell culture method. 
The times for the QCM and QCM/nanoparticle methods were 2 days. 
 
Both the QCM and QCM/nanoparticle methods were highly sensitive (81 and 87%) and 
specific (100%) compared with RT-PCR. Overall, when considered for use in rapid 
diagnosis, improvements to the QCM method are required to remove frequency 
fluctuation resulting from the direct use of nasal samples. However, there is a great 
potential for the QCM method to be further developed as a better method for influenza 
diagnosis. 
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1.1 General Introduction 
The contribution of the viral diagnostic laboratory to patient management has increased 
considerably in the last 10-15 years. These changes have been brought about by 
improved technologies that allow rapid, accurate and sensitive diagnosis of viral 
pathogens for an expanded range of infections. Rapid diagnosis allows doctors access to 
the effective antiviral treatments, avoiding the unnecessary delays that may cause risks 
to patients. It has also contributed to the management of viral infections in 
immunocompromised patients.   
 
Newer viral diagnostic methodologies allow the rapid establishment of the viral 
aetiology of an infection rather than diagnosis by exclusion of other pathogens. Many 
hospitals and clinics currently offer viral diagnostic services. Those that do not are 
usually able to send samples to a reference facility to obtain these services in a timely 
fashion. As a consequence, physicians are now more likely to request laboratory 
confirmation of viral infections.  
 
Currently viral culture, usually in combination with immunofluorescence, is the gold 
standard for the laboratory diagnosis of respiratory viruses (McQuillin et al., 1970). 
However, these tests are not rapid and their clinical value, especially for respiratory 
viruses, is limited. In general, the diagnosis of most common respiratory viruses by 
culture takes several days to complete. For example influenza virus isolation requires 2-
14 days for an illness whose duration is typically 5-7 days (Covalciuc et al., 1999). 
 
Rapid antigen detection tests are now widely used in diagnostic laboratories but, for 
respiratory viral infections, have been shown to be less sensitive and specific than 
culture or PCR. However, results are available in less than 1 h and can be used as a 
guide in the use of antiviral agents (Storch, 2003; Templeton et al., 2004). In addition, 
PCR is a valuable method in confirmation of certain viral infections caused by as 
rotaviruses and hepatitis viruses which do not readily grow in standard cell lines 
(Leland and French, 1988; Garson, 1994; Fischer and Gentsch, 2004). 
 
In recent years much research has been directed towards the development of biosensors 
for the detection of viruses, especially those that involve the use of one-step methods. 
(Nakanishi et al., 1996; Uttenthaler et al., 1998). The potential of biosensors for viral 
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diagnosis has been recognised because of their low cost, high sensitivity, simplicity of 
operation and ease of interpretation. In order to receive effective antiviral treatment, 
timely diagnosis is necessary. Delays are still common in patient diagnosis because of 
the time for laboratory diagnosis often results in the disappearance of a therapeutic 
window for treatment. Therefore, a clinical diagnosis kit or a point-of-care device in a 
hospital or a doctor’s office would be useful in allowing a decision to be made on-site 
as to whether a particular treatment could be prescribed (Linde, 2001).  
 
1.2 Viruses and respiratory infections 
Respiratory viral infections are the most frequent reason for medical consultations in all 
countries (Abed and Boivin, 2006). They can be associated with a wide range of clinical 
manifestations from self-limited infections of the upper respiratory tract to more life 
threatening conditions affecting the lower respiratory tract, such as pneumonia. In the 
United States, alone, these infections are responsible for 20 million absences from work 
and 22 million absences of children from school each year. The annual burden of 
epidemic influenza alone averages millions of physician visits, 150,000 hospitalisations, 
and 36,000 deaths (CDC, 2005). The costs of non-influenza related respiratory viral 
infection may reach 40 billion dollars annually (Fenderick et al., 2003). Each year, 
consumers spend 2–3 billion dollars on a myriad of products, such as antihistamines, 
analgesics, antitussive and anti-inflammatory agents marketed to treat cold symptoms 
(Temte, 2000; Abed and Boivin, 2006).  
 
Currently, there are approximately 200 known viruses that typically produce respiratory 
syndromes (Abed and Boivin, 2006). They are grouped into five viral families including 
one family of DNA viruses: the Adenoviridae, which include adenoviruses and four 
families of RNA viruses: the Orthomyxoviridae: influenza A, B and C viruses; the 
Paramyxoviridae: respiratory syncytial virus, parainfluenza viruses, and 
metapneumoviruses; the Picornaviridae: rhinoviruses, enteroviruses, coxsackieviruses 
and the Coronaviridae: the SARS, 229E and OC-43 viruses (Abed and Boivin, 2006). 
 
Influenza is a globally important disease. About 20% of children and 5% of adults 
throughout the world develop symptomatic influenza A or B each year (Nicholson et 
al., 2003). Annual influenza epidemics affect 5-15% of the population with upper 
respiratory tract infections. Hospitalisation and deaths mainly occur in high-risk groups  
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(the elderly and chronically ill). Although difficult to assess, these annual epidemics are 
thought to result in between 3-5 million cases of severe illness and 250,000-500,000 
deaths in all countries. Most deaths associated with influenza in industrialised countries 
occur among those over 65 years of age (www.who.int/mediacentre/factsheets/fs211/en/ 
print.html). 
 
In Australia the overall level of influenza-like illness has been moderate in recent years. 
In 2004, for example, 2,116 cases of laboratory–confirmed influenza-like illness were 
reported which was 41% lower than the previous year. The influenza virus that 
circulated in Australia was mainly caused by influenza A A/Fujian/411/2002-like 
(H3N2) viruses, which accounted for 75.2% of infections followed by influenza B 
B/Shanghai/361/2002-like viruses (23.9%) and influenza A A/New Caledonia/20/99-
like (H1N1) viruses (0.9%) (Li et al., 2005). 
 
1.3 Influenza viruses 
Influenza is an acute respiratory disease characterised by inflammation of the 
respiratory tract and by fever, chills, muscular pain, and prostration. Influenza virus 
belongs to the Orthomyxoviridae family (Wright and Webster, 2001), which consists of 
four genera: influenza A, B, C viruses and thogotoviruses (Lamb and Krug, 2001). 
Influenza viruses were named Orthomyxoviridae because of their ability to bind to 
mucus and to distinguish them from another family of enveloped negative-stranded 
RNA viruses, the family Paramyxoviridae (e.g. measles virus, and mumps virus), which 
are larger and more irregular in shape. Paramyxoviridae contain a single linear genome, 
whereas influenza viruses have a segmented genome (Wright and Webster, 2001; 
Portela and Digard, 2002). Epidemics caused by influenza A viruses can alternate with 
those caused primarily by influenza B viruses, either within or between seasons. 
Influenza C viruses typically cause localised out breaks of mild upper respiratory tract 
infection in children and young adults (Lamb and Krug, 2001). 
 
1.3.1 Classification 
Influenza viruses are classified into A, B or C types based on antigenic differences in 
their NP and M1 proteins. Further, subtyping is based on the antigenicity of two surface 
glycoproteins, the HA and the NA glycoprotein (Horimoto and Kawaoka, 2001; Lamb 
and Krug, 2001). Based on their HA, there are 16 subtypes of influenza A viruses (H1- 
T. Peduru Hewa     Chapter One: Review of the literature 
 7
H16) and 9 NAs (N1-N9) (Horimoto and Kawaoka, 2001; Wong and Yuen, 2006). 
However, viruses which have circulated widely in humans are restricted to three HA 
and two NA sub types - H1, H2 and H3; N1 and N2 (Horimoto and Kawaoka, 2001). 
Only one subtype of HA and one NA are known for influenza B viruses. Influenza A 
viruses infect a wide variety of avian species, humans, and other mammalian species, 
including swine and horses, while influenza B viruses only infect humans (Lin et al., 
2000; Horimoto and Kawaoka, 2001; Lamb and Krug, 2001; Nicholson et al., 2003). 
Individual strains of influenza are named according to their antigenic group, their place 
of isolation, the number of the isolate, the year of isolation and the subgroup to which 
they belong to [e.g. A/Puerto Rico/8/34(H1N1)] (Wright and Webster, 2001).   
 
1.3.2 Physical structure of Influenza virus  
The structure of type A and B influenza viruses is similar, whereas influenza C has a 
different pattern of surface projections. When examined by electron microscopy, 
negatively-stained preparations reveal irregularly shaped spherical particles 
approximately 120 nm in diameter (Wright and Webster, 2001). Viruses of the 
Orthomyxoviridae Family comprise approximately 1% RNA, 70% protein, 20% lipid 
and 5% to 8% carbohydrate (Lamb and Krug, 2001). 
The structure of the influenza A virus particle or virion is shown in Figure 1.1a. 
 
1.3.3 Outer surface of influenza viruses 
Three viral polypeptides are inserted into the lipid envelope: the HA and NA, which are 
glycoproteins, and M2 which is unglycosylated. In the virus membrane, 400–500 spikes 
project from the influenza A or B virus particle (Potter, 1994; de Jong et al., 2000). 
Each of these projections consists of a glycoprotein, either HA or NA. The HA and NA 
spikes occur in a ratio of about 8:1 (Ruigrok, 1998); the HA glycoprotein constitutes 
about 40% of the total mass of the virus particle and this percentage is important for 
efficient replication of the virus (de Jong et al., 2000). The HA molecule is a rod-
shaped, 135oA trimer (Figure 1.1b) and the NA molecule a mushroom-shaped, 60oA 
tetramer (Figure 1.1c). Both extend approximately 10-12 nm from the virion envelope. 
Influenza C viruses possess only one type of surface spike which has both HA and NA 
activity (Brooks et al., 1998; Lamb and Krug, 2001). The M2 protein is abundantly 
expressed at the plasma membrane of influenza A virus-infected cells.  
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 (Reproduced from Lamb and Krug, 2001). 
Figure 1.1a: A schematic diagram of the structure of the influenza A virus particle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1b: Haemagglutinin (HA) antigenic 
regions. 
HA is a viral protein anchored in the lipid bilayer  
that recognizes and binds to host cell’s sialic acid. 
 
Figure 1.1c: Neuraminidase (NA) antigenic 
region. 
 
(Reproduced from Brooks et al., 1998). 
NA is a viral protein anchored in the lipid 
bilayer that after infection, cleaves off sialic 
acid from the host cell to prevent “recapturing” 
of the newly created virions  
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RNA-dependent RNA polymerase.  
(Reproduced from Compans et al., 1972; Portela and Digard, 2002). 
 
Figure 1.1d: Structural organisation of influenza virus RNPs. 
 
Blue spheres represent NP monomers with associated vRNA molecule (black line). The 
single-stranded vRNA is coiled into a hairpin structure with a short region of duplex 
(formed between the 5’ and the 3’ends) which forms the binding site for the heterotrimeric 
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However, it is greatly underrepresented and only 20-60 molecules are present in each 
progeny virion (Lamb et al., 1985; Zebedee et al., 1985). It is not present in influenza B 
viruses. Influenza B and C viruses encode other integral membrane proteins, the NB and 
CM2, proteins respectively (Lamb and Krug, 2001).  
 
1.3.4 Matrix protein  
Near the inner surface of the viral envelope is the M1 protein (Potter, 1994), which is 
the major protein of the virus particle, occupying 35-45% of the particle mass; there are 
approximately 3000 molecules of M1 in each virus particle (Rm=27.8 kDa) (Potter, 
1994).  
 
1.3.5 The nucleocapsid 
The nucleocapsid consists of NP subunits closely associated with eight single-stranded 
RNA molecules of negative-sense and is known as the RNP (Potter, 1994). RNPs lie 
immediately beneath the shell of the M1 protein. The genomic RNA segments are 
associated with trimeric RNA polymerase or non-glycosylated P-proteins (PB1, PB2 
and PA sub-units). The nucleoprotein-RNA-polymerase complex occurs as a helix 
within the virion. Two virus-coded nonstructural proteins (NS1 and NS2) are found in 
infected cells (Figure1.1d) (Portela and Digard, 2002).  
 
1.3.6 Nature of the genome 
Influenza A and B viruses each contain 8 segments of single-stranded RNA encoding 10 
identified polypeptides (Wright and Webster, 2001; Portela and Digard, 2002). 
Influenza C viruses contain 7 segments of single-stranded RNA and contain only one 
surface glycoprotein (Racaniello and Palese, 1979; Lamb and Krug, 2001). The genome 
segments are packaged into the inner virus core. The RNP occurs in a helical form with 
the three polymerase polypeptides being associated with each segment. The 5' and 3' 
terminal sequences of all the genome segments are highly conserved (Lamb and Krug, 
2001). For influenza A viruses the three largest genomic segments, 1, 2 and 3 encode 
the polymerase proteins PB2, PB1 and PA. The three intermediate sized segments, 4, 5 
and 6, encode the HA, NA and NP proteins. Segment 7 encodes the matrix proteins, M1 
and M2 and segment 8 encodes two non-structural proteins, NS1 and NS2 (Lamb and 
Krug, 2001). The NB protein of influenza B virus, which corresponds functionally to 
the M2 protein, is encoded by RNA segment 6 (NA gene).  
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Genome
segment 
Length 
nucleotides 
(nt)a
mRNA 
length 
(nt) 
Gene 
(s) 
Protein 
length  
(aa) 
Molecular 
weight 
(Mr) (kDa) 
Protein function 
1 2,341 2,320 PB2 759 87 Recognition of host cell RNA; component of RNA transcriptase 
complex: cap binding 
2 2,341 2,320 PB1 757 96 Endonuclease activity; catalyses nucleotide addition; component 
of RNA transcriptase: elongation, and replication complex 
3 2,233 2,211 PA 716 85 Component of RNA transcriptase: protease activity (?) and 
replicase complex  
4 1,778 1,757 HA 566 62 Major surface glycoprotein;  receptor (sialic acid) binding; 
proteolytic cleavage activation; low-pH-induced conformational 
change and fusion activity; major antigenic determinant 
5 1,565 1,540 NP 498 56 Monomer binds to RNA to form coiled ribonucleoprotein; 
involved in switch from mRNA to template RNA synthesis and in 
virion RNA synthesis 
6 1,413 1,392 NA 454 55 Surface glycoprotein; neuraminidase activity: release virus; 
antigenic determinant 
1,005 M1 252 27.8 Matrix protein; major protein of virion, underlies lipid bilayer; 
interacts with RNPs and NS2
7 1,027 
315 
 
M2 
 
97 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a For A/PR/8/34 strain 
 (Lamb and Krug, 2001). 
 
           
11
Integral membrane protein; ion channel activity essential for virus 
uncoating   
868 NS1 230 26.8 
 
High abundance, non-structural protein in cytoplasm and nucleus; 
inhibits cellular pre-mRNA splicing;  reduces  interferon response 
Minor component of virion; cytoplasmic and nuclear location; 
interacts with M1 and involved in nuclear export of RNPs 
8 890 
395 NS2 121 14 
Table 1.1: Influenza A virus genome RNA segments, proteins and their functions.  
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Table 1.1 indicates the size of these proteins and their functions. 
 
1.3.7 Molecular events in the growth cycle of influenza A viruses 
Early events in virus replication: 
Infection of influenza A viruses is initiated when HA binds to cellular sialic acid 
receptors on glycoproteins or glycolipids on the cell surface (Mitnaul et al., 2000; 
Yohannes et al., 2003). Different HA types have different specificities for sialic acid 
linked to galactose by α(2,3) or α(2,6) linkages. Specificity is dependent on particular 
amino acids in the HA receptor-binding pocket. The specificities of avian influenza HA 
for sialic acid α(2,3) and human influenza HA α(2,6) are key determinants in restricting 
direct infection of human by avian influenza viruses (Lamb and Krug, 2001). The high 
abundance of HA molecules on the virion surface permits a sufficient number of low-
affinity interactions which allows virus attachment and entry into host cells through 
receptor-mediated endocytosis (Lamb and Krug, 2001).   
 
Within the endosome, the M2 proton channel exposes the viral core, resulting in 
dissociation of M1 from RNP and leading to the release of RNP into the cytoplasm 
before being transported to the nucleus (Horimoto and Kawaoka, 2001). Studies with 
the antiviral drug amantadine have indicated that M2 ion channel activity is essential for 
uncoating. Amantadine blocks replication at early stage in the virus life cycle between 
penetration and uncoating for all influenza A viruses but not influenza B viruses. 
Influenza B viruses do not have an M2 protein, but possess a protein called NB with 
similar functions that are not affected by amantadine (Skehel et al., 1978; Stiver, 2003). 
In the presence of amantadine, the M1 protein fails to dissociate from the RNP 
complexes, thereby blocking RNP transport to the nucleus (Martin et al., 1992).  
 
Replication of the virus: 
The mechanism of viral RNA transcription is unique. The 5’ cap from cellular mRNAs 
is cleaved by a viral endonuclease and used as a primer for transcription by the viral 
transcriptase (Krug et al., 1979; Plotch et al., 1981). Six of eight RNA segments are 
transcribed into mRNAs in a monocistronic manner and are translated into HA, NA, 
NP, PB1, PB2, and PA. For both the M and NS genes, these mRNAs are translated in 
different reading frames, generating M1 and M2 and NS1 and NS2 proteins, 
respectively. Newly synthesized vRNAs are encapsidated by NP in the nucleus, where 
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they function as templates for secondary transcription of viral mRNAs (Horimoto and 
Kawaoka, 2001; Portela and Digard, 2002). 
 
Later in infection, the principal translation products are HA and NA. HA and NA are 
glycosylated in the rough endoplasmic reticulum, before being further processed in the 
Golgi apparatus and then transported to the cell surface. Nuclear localisation of M1 and 
NS2 proteins is essential for the migration of RNP from the nucleus for assembly into 
progeny viral particles in the cytoplasm (Martin and Helenius, 1991; O’Neill et al., 
1998). The RNP-M1 complex presumably interacts with M1 proteins associated with 
the plasma membrane and then buds outwards through the cell membrane (Horimoto 
and Kawaoka, 2001). The mechanism(s) by which new virions bud from the plasma 
membrane are unknown, but virion release requires the receptor destroying activity of 
the NA for both viral surface glycoproteins and the cellular membrane. In the presence 
of NA inhibitors virions stay attached to the membrane of infected cells and to each 
other and virus spread is inhibited (Woods et al., 1993; Laver et al., 1999; Gubareva et 
al., 2000; Skehel and Wiley, 2000; Portela and Digard, 2002; Donatelli et al., 2003). 
Events in the growth cycle of the influenza A virus are shown in Figure 1.2. 
 
1.4 Influenza virus transmission, symptoms, pathology, disease 
progress and immune responses to infection 
Transmission: 
Influenza infections may occur throughout the year in tropical regions of the world, but 
are more commonly detected during the winter season in temperate climates (Yohannes 
et al., 2004). Transmission of influenza viruses from person-to-person is thought to 
occur by virus- laden respiratory droplets and aerosols that are expelled during coughing 
and sneezing. Dried secretions (containing infectious virus) or fomites may also be 
responsible for transmission (Hemmes et al., 1960). Influenza A and B viruses remain 
viable and infectious for up to 24 h on hard, smooth surfaces, and for 4-6 h on more 
porous surfaces (Bean et al., 1982; Sarubbi, 2003 a,b). 
 
Influenza viruses are not readily transmitted between species, but influenza A viruses 
have been isolated from a variety of animals, including humans, pigs, sea mammals and 
birds. Phylogenetic studies of these viruses have revealed species-specific lineages of          
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Figure 1.2: Events in the growth cycle of the influenza A virus.  
 
Virus attachment through HA to receptors containing terminal sialic acid residues on the 
cell and penetration into host cell; transcription of viral RNA and translation of viral 
proteins; replication of viral RNA and assembly of virion, budding, and subsequent 
release from host cell. 
(Reproduced from Gubareva, et al., 2000). 
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viral genes, as well as genes that cross species barriers. Such studies have also revealed 
that aquatic birds are probably the source of all influenza viruses in other species. Avian 
influenza viruses have been transmitted to pigs, horses, and even sea mammals. Humans 
and nonhuman primates can also be experimentally infected with avian viruses (Beare 
and Webster, 1991; Lin et al., 2000). Limited viral replication in these hosts has led to 
the notion that avian influenza viruses are not directly transmitted to humans in nature 
(Horimoto and Kawaoka, 2001).   
 
In man, inhalation of small aerosol droplets can result in the development of upper 
and/or lower respiratory tract infections (Couch et al; 1966; Knight et al., 1970). 
Initiation of upper respiratory tract infections has been reported to require 120-300 
TCID50 of virus (Couch, 1973). Airborne droplets of less than 2 μm, which contain less 
than 3 TCID50 of infectious virus, are believed to be preferentially deposited in the 
lower respiratory tract where they may initiate infections (Knight, 1973).   
 
Symptoms: 
During the incubation period of 1-5 days infectious virus is shed (Murphy et al., 1973). 
Couch et al (1971) found a direct correlation between the titre of virus shed in nasal 
secretions and the severity of the clinical response. The period of virus shedding 
associated with natural infection and measured from the onset of illness is normally 3-5 
days, although in children and immunocompromised patients its duration is frequently 
longer; the variation in time is probably dependent on the size of the infecting dose 
(Greenberg et al., 1974; Frank et al., 1981). 
 
The first sign of influenzal illness may be the abrupt onset of fever (temperature 37.7oC-
40.0oC) and dry cough. The temperature gradually declines but fever may be present for 
up to 1 week, as shown in Figure 1.3. Other symptoms may include chills, anorexia, 
generalised or frontal headaches, severe myalgia and arthralgia, weakness and fatigue. 
Symptoms of respiratory illness may predominate and patients may also have a sore 
throat and a persistent non-productive cough, with or without substernal or pleuritic 
chest pain (Montalto, 2003). However there is a great variation between individuals in 
the appearance of symptoms. Disease prognosis in influenza is affected by the patient’s  
age, the degree of pre-existing immunity, properties of the virus, smoking, the use of 
immunosuppressants, and pregnancy (Nicholson et al., 2003). Influenza A virus 
T. Peduru Hewa     Chapter One: Review of the literature 
 16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Reproduced from Montalto, 2003). 
Figure 1.3: Clinical characteristics of naturally occurring influenza A in an otherwise 
healthy 28-year-old male patient. 
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infections are usually associated with more severe outcomes than those caused by 
influenza B or C viruses (Abed and Boivin, 2006).  
 
Pathology:  
Influenza viruses induce pathological changes throughout the respiratory tract, 
especially the lower respiratory tract (Hers et al., 1958; Hers and Mulder, 1961; Hers, 
1966). During bronchoscopy of persons with uncomplicated influenza infections, acute 
diffuse inflammation of the larynx, trachea, and bronchi have been observed with 
mucosal inflammation and oedema. Studies of infected cells have revealed that the 
columnar ciliated cells become vacuolated, oedematous and lose cilia before becoming 
desquamated. Within 1 day after the onset of symptoms, desquamation of the ciliated 
and mucus-producing epithelial cells to a single cell basal layer has been observed; in 
other areas, the thickened and hyalinised basement membrane is exposed. Submucosal 
oedema and hyperaemia are accompanied by infiltration by neutrophils and 
mononuclear cells (Martin et al., 1959). Viral antigen is present predominantly in 
epithelial cells and mononuclear cells and is infrequently found in the basal cell layer 
(Wright and Webster, 2001). 
 
At the cellular level, influenza virus shuts off cell protein synthesis and induces 
apoptosis as an additional means of cell destruction (Hinshaw et al., 1994). From the 
third to fifth day after the onset of illness, mitosis appears in the basal cell layer and 
regeneration of the epithelium begins. During this time, reparative and destructive 
processes may be present simultaneously. Complete resolution of the epithelial necrosis 
probably takes up to a month (Hall et al., 1976).  
 
Primary viral pneumonia occurs predominantly in high-risk individuals, such as the 
elderly or patients with cardiopulmonary disease. It develops abruptly after the onset of 
influenza illness and progresses within 6-24 h to a severe pneumonia with rapid rates of 
respiration, tachycardia, cyanosis, high fever and hypotension. Microscopically, 
influenza pneumonia is characterised by tracheitis, bronchitis and bronchiolitis, with 
relatively small amounts of cellular infiltration and haemorrhage and a loss of ciliated 
epithelium (Hers and Mulder, 1961). Infection and necrosis occur in the alveolar 
epithelium resulting in a predominantly mononuclear infiltrate in the interstitium of the 
lung. Intra-alveolar oedema, exudates and haemorrhage, and hyaline membrane 
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deposition on alveolar walls are also characteristic of primary pneumonia (Hers and 
Mulder, 1961). 
 
Secondary bacterial infections can seriously complicate influenza and are most 
commonly caused by Streptococcus pneumoniae, Staphylococcus aureus and 
Haemophilus influenzae (Louria et al., 1959).   
 
Disease progress:  
Although the initial site of replication is thought to be the tracheobronchial ciliated 
epithelium, the whole respiratory tract may be involved. Virus can be detected in 
secretions shortly before the onset of illness, usually within 24 h. The viral load rises to 
a peak of 103–107 TCID50/mL of nasopharyngeal wash, remaining high for 24–72 h, and 
falls to low values by the fifth day (Nicholson et al., 2003). The pattern of virus 
replication, in relation to the onset of clinical symptoms, the presence of antigen in 
infected cells, as detected by IFA, and serum and nasal wash antibody responses in six 
adult volunteers administered an influenza A/Bethesda/1015/68 virus is presented in 
Figure 1.4 (Richman et al., 1976; Wright and Webster, 2001). Individuals who shed less 
than 103 TCID50/mL were either asymptomatic or had only minor upper respiratory tract 
symptoms. Even after infectious virus could no longer be recovered, viral antigen can 
be detected for several days in cells and secretions of infected individuals (Ebisawa and 
Kitamoto, 1969; Berg et al., 1980).   
 
Immune responses to infection:  
The respiratory tract has a series of protective mechanisms against influenza infection, 
including the mucin layer, ciliary action and protease inhibitors that may prevent 
effective cell entry and virus uncoating. Once the epithelial cell is infected, 
proinflammatory cytokines, interleukin-6 (IL-6) and IFN-α are induced and released 
from these cells. These cytokines reach their peak by day 2 (Figure 1.4). These two 
cytokines correspond in their release with the highest clinical symptom score, mucus 
production, fever and viral load (Hayden et al., 1998). 
 
1.5 Antigenic variation in influenza 
The surface antigens of influenza A undergo two types of antigenic variation, referred to 
as antigenic shift and antigenic drift. Antigenic shift involves replacement of either or 
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Figure 1.4: Time course of an influenza infection by A/Bethesda/1015/68 in six 
seronegative volunteers.  
   (Reproduced from Wright and Webster, 2001). 
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both the HA or NA surface antigens resulting in major antigenic changes. Antigenic 
drift involves continuous minor changes of the HA and/or NA surface antigens so that 
isolates within a single year are distinct from those of previous years. Such changes in 
the antigenicity of human influenza virus necessitate the frequent replacement of 
vaccine strains (Horimoto and Kawaoka, 2001). 
 
1.5.1 Antigenic shift  
Antigenic shift is caused by either direct transmission of nonhuman influenza viruses to 
humans or the reassortment of genes from two different influenza viruses that have 
infected a single cell. Theoretically, 256 different combinations of RNA can be 
produced from the shuffling of the eight different genomic segments of the virus. 
Genetic reassortment is well documented both in vitro and in vivo under laboratory 
conditions. Mixed infections occur relatively frequently in nature and can lead to 
genetic reassortment. e.g. The 1957 (Asian H2N2) and the 1968 (Hong Kong H3N2) 
strains which arose in this way (Horimoto and Kawaoka, 2001; Laver and Garman, 
2001; Potter, 2001; Wright and Webster, 2001). Figure 1.5.  
 
Although direct avian-to-human influenza transmission was unrecognised before 1997, 
there have been several instances in recent years (Horimoto and Kawaoka, 2001). The 
avian influenza virus (subtype H5N1 A/Hong kong/156/97) that infected 18 Hong Kong 
residents in 1997, killing six, was not a reassortant as all of its genes were of avian 
origin. This highly lethal chicken virus had spread from chickens to people but not from 
person-to-person. The epidemic was stopped by killing all chickens in Hong Kong. 
Because human populations lacked immunity to the H5 influenza virus subtype, there 
was great concern about the possibility that a major pandemic may have been caused by 
this virus (Lin et al., 2000). In 2001, another H5N1 virus appeared in the live chicken 
markets of Hong Kong, but did not appear to infect humans and differed from the 1997 
H5N1 virus in its internal genes. Nevertheless, all of the chickens in Hong Kong were 
again slaughtered as a precaution (Lin et al., 2000; Laver and Garman, 2001). In 1997, 
also in Hong Kong, a less virulent H9N2 virus was isolated from live birds and again in 
1998 from pigs (Lin et al., 2000). Isolation in July and August of H9N2 viruses from 
five patients with influenza-like illnesses in the Guangdong province of China was 
reported early in 1999. In 1999, H9N2 viruses were also isolated from two sick children 
in Hong Kong (Lin et al., 2000). In 2003, highly pathogenic strains of avian influenza 
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Figure 1.5: Postulated evolution of the influenza A viruses currently circulating in 
humans. 
 
(Wright and Webster, 2001) 
 
 
        (Reproduced from Wright and Webster, 2001). 
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virus, including the H5N1 and H7N7 subtypes, again crossed the species barrier from 
birds to humans and caused fatal disease (Webby and Webster, 2003; Horimoto and 
Kawaoka, 2005). Finally, in early 2004 there were reports of widespread transmission 
of H5N1 viruses between chickens in various regions of South East Asia, with evidence 
of transmission from birds to humans (Donatelli et al., 2003; Webby and Webster, 
2003; Horimoto and Kawaoka, 2005).  
 
In Australia from 1988 to 1998 influenza A (H1N1) viruses were prominent in only 2 
years, influenza A (H3N2) viruses in 6 years and influenza B in 4 years. Overall, 
influenza activity was moderate to high in 8 of the 10 years. During that period a drifted 
form of the A/Taiwan/1/86 (H1N1) virus, A/Victoria/36/88, produced a major outbreak 
in 1988. Two H3N2 variants (A/Beijing/32/92 in 1992 and A/Sydney/7/97) became 
significant, and B/Quingdao/102/91-like strains, similar to B/Beijing/184/93 virus, were 
seen in 1993 (Hampson, 1999). Since 1998 only one major outbreak of influenza has 
been reported. During 2003, Australia and New Zealand experienced substantial 
outbreaks of influenza and the reassortant strain responsible was an influenza A (H3N2) 
virus described as A/Fujian/411/2002-like. While the HA sequence of these viruses 
demonstrated only minor differences from the A/ Fujian/411/2002 reference strain, the 
NA gene was clearly different from that of other recently circulating H3 viruses and 
most closely matched an earlier reference strain, A/Chile/6416/ 2001. Three internal 
genes (NS, NP, M) in the reassortant viruses were also more closely related to the 
A/Chile/6416/2001 lineage (Barr et al., 2005). 
 
1.5.2 Antigenic drift 
The HA and NA genes of influenza viruses undergo continuous minor antigenic 
variation. In the HA gene, the accumulation of point mutations results in amino acid 
substitution in five principal antigenic regions (Wiley and Skehel, 1987). These small 
continuous changes occur in influenza types A, B and C and are referred to as antigenic 
drift. Antigenic drift has also been detected among avian influenza viruses although to a 
lesser extent than in human viruses, possibly because of limited immunological pressure 
in short-lived birds (Horimoto and Kawaoka, 2001, 2005). 
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1.6 Prevention and control of influenza  
The global influenza surveillance network was set up by WHO in 1948 as a worldwide 
alert system. It is responsible for the identification of new influenza viruses. The 
network collects information from 110 participating laboratories in 82 countries. These 
laboratories include four principal WHO collaborating centres for influenza reference 
and research in Atlanta, London, Melbourne and Tokyo. This network helps WHO to 
monitor influenza activity throughout the world and provides viral isolates and 
information, as required (Kitler et al., 2002). Vaccine manufacturers update vaccine 
formulations each year according to WHO recommendations. Influenza infections can 
also be prevented by vaccination or the use of antiviral drugs. The most effective 
control of influenza is provided by vaccination, which can indirectly control influenza 
by reducing the proportion of the population that is susceptible to infection. Antivirals 
can be used to inhibit virus replication or infectivity as a means of controlling influenza 
infections.  
 
1.6.1 Vaccines 
The main focus of vaccination is the prevention of severe complications, such as 
pneumonia, hospitalisation and death (Wheeler, 2001).  Vaccination is recommended 
for the at-risk individuals, i.e. elderly patients (> 65 years), patients with chronic 
pulmonary or cardiovascular disease, diabetics and healthcare personnel (Nichol, 2001).  
 
1.6.1.1 Current vaccines 
Inactivated vaccines: 
Inactivated influenza vaccines were first developed in the 1930’s and have been 
licensed for human use over 40 years (Audsley and Tannock, 2004). Those currently in 
use are designated whole-virus vaccines, split virus vaccines or subunit vaccines 
(Gluck, 1997). Because of their high reactogenicity, whole vaccines are rarely used. 
Influenza vaccines are usually trivalent, and are formulated to contain 15 μg HA per 
virus strain per dose from A H1N1 and H3N2 influenza subtypes and from an influenza 
B strain (Bardiya and Bae, 2005). Most current vaccines are produced from virus grown 
in the allantoic cavity of fertile chicken eggs, which is then concentrated and purified by 
zonal centrifugation and inactivated by either formaldehyde or β-propiolactone (Gerdil, 
2003; Nicholson et al., 2003; Audsley and Tannock, 2004). The purified viruses in most 
inactivated whole vaccines are further disrupted to reduce reactogenicity by treatment 
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with ethyl ether, SDS in other detergents to produce split vaccines; subunit vaccines 
consist solely of the HA and NA glycoproteins (Gerdil, 2003). However, subunit or split 
vaccines induce lower serum antibody levels to the HA and NA glycoproteins than 
whole virus vaccines (Wareing and Tannock 2001).  
 
Inactivated influenza virus vaccines are safe and effective. Vaccine efficacy is 70–90% 
among healthy young adults during years when there is a good match between the 
vaccine strains and the circulating virus strains based on data obtained from tests of 
antigenicity and gene identity. However, for elderly populations, the vaccine is only 
about 50% effective in preventing influenzal illness, although they are more efficient in 
preventing the more serious complications of influenza (Nichol, 2001). Once the virus 
strains for the next season’s vaccine are determined, seed strains with high growth 
potential are prepared by the WHO Collaborating Centres for use in production. Fig 1.6 
show a typical influenza vaccine production timetable (Gerdil, 2003). 
 
Effective vaccines induce sufficiently high levels of antibody to bind and neutralise the 
virus and so prevent infection. Specific immunity to influenza is associated with 
systemic immune responses, local respiratory immune responses (mediated by virus-
specific local IgA and IgG antibodies), and by cell-mediated immune responses. 
Inactivated influenza vaccines induce virus-specific serum antibodies which can protect 
against infection by viruses possessing similar surface antigens (Ghendon, 1990). 
However current inactivated vaccines do not induce mucosal IgA antibodies, which are 
important for protection against influenza virus infection in the upper respiratory tract 
(Asanuma et al., 2001). During the past decade, there have been many new 
developments in vaccine technology that have aided vaccine production or are aimed to 
improve vaccine immunogenicity and acceptability. 
 
Adjuvanted vaccines:  
Vaccine adjuvants are substances that, when added to vaccine antigens enhance and/or 
target immune responses to antigens. A number of new vaccine adjuvants, such as oil 
emulsions and virosomes, are currently in use for human vaccines (Sesardic and 
Dobbelaer, 2004). Influenza vaccine with the adjuvant MF59, an emulsion of squalene 
in water for parenteral use, is licensed in European countries but not the UK. MF59  
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Figure 1.6: Typical influenza vaccine production timetable. 
 
 
 
 
   (Reproduced from Gerdil, 2003). 
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have been shown to increase haemagglutination inhibition antibody responses to 
interpandemic influenza A H3N2 and to influenza B antigens. People with chronic 
diseases were shown to satisfactorily tolerate this vaccine, despite slightly higher rates 
in the incidence of transient mild local reactions, compared with other vaccines 
(Banzhoff et al., 2003). 
 
Immunostimulating complexes (ISCOMs) are potent adjuvants and delivery systems for 
use in parenteral immunisation. ISCOMs are cage-like structures that were originally 
formed as a complex between cholesterol and saponin, which is derived from the tree 
Quillaia saponaria. Vaccines containing a defined saponin, called Iscoprep 703, have 
been shown to stimulate accelerated serum antibody responses in humans and to induce 
improved proliferative T-cell responses, and cytotoxic T-cell responses compared with 
normal inactivated vaccines (Hu et al., 2001; Nicholson et al., 2003). 
 
Virosomes consist of bilayers of phospholipids (liposomes) containing virus surface 
proteins embedded within the bilayer. Influenza virosomes have been evaluated in 
various human populations (Holm and Goa, 1999). Typically, they induce higher 
concentrations of antibody after vaccination, with higher rates of seroconversion, and a 
greater proportion of individuals with protective levels of antibody than conventional 
inactivated vaccines. Virosomal influenza vaccines for parenteral use became available 
in the UK during the 2002–2003 season (Nicholson et al., 2003; Huckriede et al., 2005). 
 
Cell culture vaccines:  
Vaccines prepared from cell-culture-grown viruses have the potential to be rapidly 
assembled in response to epidemics or pandemics and to avoid the risks from 
contaminated eggs. The cell cultures used are prepared from continuous cell lines have 
to be used for the manufacture of pandemic vaccines. However, at present, only certain 
preparations of the Vero lines are acceptable to all regulatory authorities and are not yet 
available to all vaccine manufacturers (Montagnon, 1989; Audsley and Tannock, 2004). 
Influenza vaccines prepared with MDCK cells and African green monkey (Vero) lines 
as substrates have been licensed for use in the Netherlands but are not available in the 
other countries (Nicholson et al., 2003). In general, the seed viruses used for human 
influenza vaccines are prepared in eggs. Yields of infectious virus and HA for vaccine 
preparation are generally higher in eggs. However, a vaccine prepared from viruses 
grown in a cell line could be expected to produce a superior response compared to one 
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grown in eggs. The deduced amino acid sequences over the region of HA1 encoding 
residues of the viruses, passaged in the mammalian cell types have been shown to be 
identical to the epidemic viruses grown in the human lung continuous cell line (MRC-5) 
and to viruses isolated from infected humans (Katz and Webster, 1992; Audsley and 
Tannock, 2004). 
 
1.6.1.2 New approaches to vaccination 
Live attenuated influenza vaccines: 
Intranasal delivery of live attenuated influenza vaccines offers the advantage of 
mimicking natural infection, providing a broader immunological response and more 
durable protection than is possible with inactivated vaccines. Three types of live 
influenza vaccines have been studied - temperature sensitive (ts), the host range (hr), 
and the cold-adapted (ca) mutants (Murphy et al., 1972; Clements et al., 1986). 
However, due to genetic instability and possibility of reversion to the virulent 
phenotype, interest in the ts and hr vaccines has declined (Wareing and Tannock 2001).  
Ca attenuation of the master strains was carried out by serial passage in either chicken 
kidney cells or chicken eggs at low temperatures of 33-25°C. These attenuated donor 
strains are unable to cause illness in humans but are able to donate the genes to current 
epidemic strain by reassortment. Reassortants with the HA and NA of the epidemic 
strain and the required degree of avirulence is provided by stable mutations in all three 
polymerase genes (PA, PB1 and PB2).  Live attenuated ca vaccines were been used in 
Russia for many years and were approved in June, 2003 by the US Food and Drug 
Administration for use in healthy individuals aged 5-49 years (Belshe et al., 2000; 
Nicholson et al., 2003). 
 
DNA vaccines: 
DNA vaccines present a promising new approach to vaccination, evoking a full range of 
immune responses, including antibody, cytotoxic- T-cell and helper-T-cell responses. 
DNA vaccines are prepared from genes that encode antigenic proteins, which are 
integrated into a bacterial plasmid. DNA vaccines with constructs encoding the NP, HA, 
NA, M1, and non-structural protein of influenza virus have been studied in several 
animal models, either singly, or in combination with one another, or together with DNA 
encoding various cytokines (Ulmer, 2002; Nicholson et al., 2003). During vaccination  
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with DNA, the foreign gene is endogenously expressed, and the proteins processed, 
mimicking the processing of viral proteins during actual infection (Bardiya and Bae, 
2005).  
 
Despite its many advantages DNA vaccines still face several problems: the efficiency of 
the DNA-uptake has been shown to be sub-optimal and dose-dependent. A high amount 
of DNA has to be injected to elicit protective immune response (Gluck and Metcalfe, 
2002). There are many DNA vaccines in clinical and pre-clinical trials, including 
vaccines for hepatitis B, HSV-2, HIV-1 and influenza.  However, all have unique safety 
concerns which include the potential for genomic integration, biodistribution, tolerance, 
auto-immunity and the potential to induce irrelevant responses. DNA vaccines currently 
under clinical evaluation are subject to a specific regulatory policy (Smith, 2000). 
 
1.6.2 Antiviral drugs 
Currently, two drug classes are available to manage influenza: the inhibitors of M2, 
amantadine and rimantadine, and the neuraminidase inhibitors, zanamivir and 
oseltamivir.  
 
1.6.2.1 Amantadine and rimantadine 
Amantadine and rimantadine, an analogue of amantadine, are currently licensed in 
many countries for prophylactic and therapeutic use against influenza A viruses. Their 
primary mode of action is the blocking of the acid-activated ion channel by viral M2 
protein of the influenza A virus. These drugs have no effect on influenza B viruses (van 
Voris and Newell, 1992). Influenza B viruses do not have an M2 protein, but have an 
analogous protein NB, which is not affected by these drugs. A secondary effect of these 
drugs consists of blocking the maturation of HA in the host cell during transport from 
the endoplasmic reticulum to the plasma membrane (Hay, 1992). These drugs have 
some limitations, in that they are effective against only influenza A viruses; drug 
resistance emerges during treatment and they cause undesirable side effects (e.g. 
insomnia, light-headedness, dizziness, headache) which are a problem particularly in the 
elderly (Nicholson et al., 2003).  
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1.6.2.2 Neuraminidase inhibitors 
Zanamivir and Oseltamivir are NA inhibitors which are active against both influenza A 
and B viruses and have minimal side-effects (Gubareva et al., 2000; McKimm-
Breschkin, 2002). The design of these drugs was based on knowledge of the three-
dimensional structure of the influenza virus NA and the complex formed between the 
NA and the neuraminic acid component of sialic acid in the respiratory epithelial cell 
haemagglutinin receptors. The NA inhibitors bind to the active site on the viral 
neuraminidase, blocking its activity. Thus, viral particles cannot be released easily from 
the cell after the viral replication has occurred. As a result, viral particles tend to clump 
within the cell and are prevented from dispersing. This impedes their ability to infect 
new cells and attenuates the infection (Stiver, 2003). Zanamivir has poor oral 
bioavailability and is delivered through an inhaler. It is licensed for the treatment of 
influenza A and B in people aged 12 years and over (Nicholson et al., 2003). 
Oseltamivir is an orally active prodrug of oseltamivir carboxylate. It is licensed for the 
treatment of influenza A and B in individuals aged 1 year or older and for the 
prophylaxis of influenza A and B for those aged 13 years or older (Nicholson et al., 
2003).  
 
These anti-influenza drugs are recommended for use within 48 h of the onset of 
influenza infections because proliferation of influenza virus reaches a peak after 2 days 
and the incubation period is only 24 h. Patients who miss the 48 h window should be 
treated only with anti-symptomic therapies (Kashiwagi, 2003). In order to obtain the 
maximum advantage with antiviral therapy, rapid diagnostic kits or methods with high 
accessibility and easy and accurate interpretation of the test results are required. 
 
1.7 Diagnosis of influenza 
The clinical diagnosis of influenza virus infections is often difficult because many 
respiratory viruses, such as the parainfluenza viruses, respiratory syncytial virus, adeno 
and coxsackieviruses cause similar signs and symptoms. Data indicates that up to 70% 
of influenza-like illnesses are not caused by influenza viruses (Stiver, 2003). Because of 
the rapidity with which influenza spreads, rapid clinical diagnosis is highly desirable in 
order to interrupt its transmission. To satisfy these requirements, the diagnostic 
laboratory has to select appropriate diagnostic tests which are suitable for the resources 
available. Each test has its own advantages and disadvantages. In addition, rapid 
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recognition of influenza outbreaks can also help prevent spread of the virus in particular 
settings. Laboratory diagnosis of influenza virus infections is also the foundation for 
global surveillance of influenza. Viruses isolated from clinical specimens may be 
antigenically and genetically characterised in specialised laboratories, and the epidemic 
spread of new antigenic variants is monitored through a global influenza surveillance 
network. This information provides the basis for annually selecting appropriate 
influenza virus strains to be included in vaccines. Thus, an influenza virus isolated from 
a clinical sample collected anywhere in the world may be selected as a vaccine strain. 
 
1.7.1 Laboratory diagnostic methods for the detection of influenza infections 
Rapid laboratory tests are indicated for all patients at risk from severe disease to allow 
for correct treatment and to diminish the risk of complications. Such tests reduce the 
mortality rates associated with influenza. It has been indicated that early antiviral 
treatment of at-risk groups significantly diminishes the risk of later bacterial 
complications (Stiver, 2003). Influenza diagnosis is more of a challenge in vaccinated 
persons, as it excludes the possibility of using serological tests that are available in most 
diagnostic laboratories (Linde, 2001). 
 
Diagnostic tests for influenza fall into four broad categories: virus isolation, detection of 
viral protein or glycoprotein antigens, detection of viral nucleic acids, and serological 
diagnosis. The best clinical samples to use with the first three diagnostic methods are 
combinations of nasopharyngeal and throat swabs and/or nasal and throat washings.  
 
1.7.1.1 Virus diagnosis by virus isolation in standard cell cultures  
Cell culture is still the only comprehensive method readily available to detect the wide 
range of respiratory viruses i.e. influenza- respiratory syncytial- parainfluenza- adeno- 
rhino- and enteroviruses using MDCK, MRC5 and Hep 2 cell lines. However, the 
method is generally slow, often taking up to 14 days before results become available 
(Bartholoma and Forbes, 1989; Doing et al., 1998; Navarro-Mari et al., 1999; Liolios et 
al., 2001). These days diagnostic laboratories generally use rapid and often more 
sensitive methods for viral detection (Leland, 1999; Stamboulian et al., 2000). 
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Influenza virus detection in standard cell cultures: 
Influenza viral isolation using standard cell culture methods followed by 
immunocytological identification is the gold standard for the detection of respiratory 
viruses (Leland, 1999; Stamboulian et al., 2000). Patient’s samples are inoculated to a 
variety of cell cultures that are  incubated for 3-7 days and examined periodically for 
evidence of viral proliferation. Many viruses infect susceptible cell cultures and produce 
degenerative cellular changes, which can be observed microscopically. These changes 
are called cytopathic effects (CPEs) and are characteristic of particular viruses. A blind 
passage of negative cultures after 10-14 days of incubation may increase the rate of 
virus isolation (Leland, 1999). In the past, influenza A and B viruses were isolated in 
cultures of primary rhesus or cynomolgus monkey kidney cells (Harmon, 1999). 
However, the cost and periodic contamination by adventitious viruses reduces the utility 
and frequency of their use. More recently, it has been shown the use of the MDCK a 
continuous cell line was as sensitive as primary cells in supporting the growth of 
influenza A or B viruses and is widely used for influenza isolation despite its lower 
sensitivity than monkey kidney cultures (Harmon, 1991, 1999; Boon et al., 2001). 
 
Detection of influenza viruses by haemadsorption: 
Influenza viruses usually produce CPE but do so relatively slowly. Their CPE is often 
difficult to identify and to distinguish from non-specific degenerative changes (Leland, 
1999). Detection of viral growth can be improved by haemadsorption. Influenza virus-
specific haemagglutinin is expressed on the plasma membranes of virus-infected cells 
and is responsible for the affinity of viruses for erythrocytes. Haemadsorption can also 
be used as a screening method for haemagglutinating viruses, such as influenza and 
parainfluenza viruses, at times when respiratory viruses are prevalent. CPE may be 
tested for haemadsorption at several intervals during the incubation period, usually at 
intervals of 3-7 days (Minnich and Ray, 1987). If negative, the culture is usually 
washed, refed with fresh medium and reincubated. After 10 days the harvest from that 
tube is usually repassaged into a fresh culture (Leland, 1999). 
 
Detection of influenza viruses by rapid culture confirmation (shell vial technique): 
The shell vial technique is a variation of traditional cell culture in screw-capped tubes 
for rapid culture confirmation. The method usually employs cell cultures on coverslips  
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in shell vials. Clinical material is placed directly on the cell monolayer and the vial is 
centrifuged at low speed (700 x g) for 1 h. Approximately 75-85% of infected cultures 
are positive 18-40 h after incubation (Stokes et al., 1988; Mills et al., 1989). This 
method has been widely adopted to detect influenza viruses during epidemics for a large 
number of samples since it reduces the turnaround time. In addition, it has the 
advantage of allowing the detection of other respiratory pathogens within the same 
sample (Magnard et al., 1999). 
 
IFA has been used routinely in many virus laboratories for the rapid and direct 
confirmation of viral antigens in clinical samples. The sensitivity of IFA is usually 
greater than 80%, and its specificity approaches 100%, compared with standard cell 
culture methods (McQuillin et al., 1970), but problems have been reported. Use of IFA 
requires highly trained staff to prepare and read the smears. Problems may occur due to 
inconsistencies between samples and difficulties in consistently obtaining high quality 
samples containing an adequate amount of infected cells for examination with little or 
no mucus contamination. Further difficulties arise from the lack of objective endpoints 
and the inability to automate the procedure (Figure 1.7a). 
 
Most clinical laboratories confirm the presence of virus by rapid immunoassay 
procedures, such as membrane-filtration EIA, ELISA followed, where possible by later 
characterisation with serological or molecular biological methods. These methods are 
cost-effective, since large numbers of specimens can be handled, and provide a good 
backup for rapid diagnosis by direct antigen detection methods (Boon et al., 2001; 
Amano and Cheng, 2005). 
 
1.7.1.2 Serological methods in influenza diagnosis 
Serological diagnosis of influenza is based upon demonstrating a fourfold or greater 
increase in antibody between an acute-phase serum sample (collected as soon as 
possible after the onset of illness) and a convalescent–phase sample (collected 10-14 
days later). It requires the collection of a pair of serum samples, which is often not 
feasible. Although serological diagnosis is retrospective and, therefore, of limited 
usefulness in many clinical situations, it is more economical than virus isolation and 
often establishes a diagnosis when isolation attempts fail. Its main value is for 
epidemiological investigations or other research studies (Stamboulian et al., 2000). 
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Figure 1.7c: ELISA. 
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Traditional methods for serological diagnosis are haemagglutination-inhibition (HI), 
complement fixation (CF), neutralisation, single-radial-haemolysis (SRH) and EIA. 
 
Haemagglutination-Inhibition (HI): 
The HI test is simple, inexpensive, and an important viral test that can also be used to 
determine haemagglutinin subtype of haemagglutinating viruses (Julkunen et al., 1985). 
The haemagglutinin protein on the virus surface can agglutinate erythrocytes. The HI 
assay measures antibody to the HA and provides information about immunity to 
infection. In this test, paired sera from patients with influenza infection are treated to 
remove non-specific inhibitors, and a series of dilutions is made. Then each dilution is 
added a standard quantity of intact virus and after incubation chicken cells are added. 
The presence of antibody is indicated by inhibition of haemagglutination, and the 
highest serum dilution that inhibits haemagglutination is recorded as the titre of HI 
antibody in the serum specimen. Several studies showed that HI is a more sensitive 
method than CF for detecting antibody responses to influenza virus A and influenza 
virus B infections (Julkunen et al., 1985). HI detects antibodies to strain-specific 
haemagglutinins, whereas CF mainly detects antibodies to type specific nucleoproteins. 
Haemagglutinins are used as antigens in influenza virus vaccines, making HI the 
method of choice for measuring vaccine-induced antibodies (Julkunen et al., 1985; 
Prince and Leber, 2003). Although the HI assay requires laboratory skill and expertise, 
it remains the test of choice for WHO global influenza surveillance because of its high 
reliability. Subtype identification of type A viruses requires antisera that are prepared in 
chickens, ferrets or other animals (Yamane et al., 1983; Julkunen et al., 1985). 
 
Complement fixation (CF): 
CF has been widely used in the serodiagnosis and for seroepidemiological surveys of 
various virus infections. For influenza viruses, CF test measures antibody to the 
nucleoprotein antigen and is, therefore, useful for type-specific diagnosis but cannot be 
used to distinguish between subtypes. An advantage of the test is that fewer viral test 
antigens are required. However, this advantage is offset by the large number of 
biological reagents requiring standardisation, the occurrence of anticomplementary sera, 
the relative insensitivity of the test and the requirement for skill (Boon et al., 2001). 
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The CF test is based on the use of the complement, a complex of proteins that are 
present in the sera of normal animals. The lack of specificity of the complement allows 
it to react with any antigen-antibody complex. The indicator used in CF is sheep red 
blood cells (RBC). CF is a good test for patients who have received influenza vaccines 
and have high levels of antibody against envelope proteins (Yamane et al., 1983) Figure 
1.7b.  
 
HI is a more sensitive method than CF and detects antibodies to strain-specific 
haemagglutinins, whereas CF mainly detects antibodies to type-specific antigens 
diagnosis (Pyhala and Kleemola, 1976; Madore et al., 1983; Julkunen et al., 1985).  
 
The neutralisation test: 
The neutralisation test measures the level of antibody which prevents infection by 
influenza viruses and generally correlates well with HI results. The test has rarely been 
used because it is too cumbersome, time-consuming and expensive for large numbers of 
samples (Okuno et al., 1990).  
 
Modification of the test to a micro-neutralisation assay has largely overcome these 
drawbacks. The use of continuous cell lines and detection of virus by haemagglutination 
has made the test practical for processing large numbers of sera. Haemagglutination 
indicates the presence of antigen in the virus infected cells and the absence of 
haemagglutination indicates the absence of infectious virus as a result of neutralisation 
by the neutralising antibody. Detection and quantification of the neutralising antibody 
provides a valuable tool for the determination of humoral immune status after exposure 
to influenza virus. The neutralisation values also reflect the immunogenicity of the virus 
strain, according to the dilution of antibody required to neutralise a standard dose of 
infectious virus (Frank et al., 1980). More recent modifications to the micro-
neutralisation immunoassay utilise the enzyme immunochemical techniques to detect 
endpoints and the test is referred to as the neutralisation immunoassay. These tests are 
preformed in 96-well tissue culture plates and an ELISA reader is used to detect the 
neutralisation end point (van de Water et al., 1993). 
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Single-radial-haemolysis (SRH): 
SRH detects and measures antibody to influenza virus haemagglutinin. This method is 
based on the phenomenon of antibody and complement-mediated haemolysis of virus 
sensitised erythrocytes. The sensitised erythrocytes and complement are immobilised by 
combining with agarose and is used for assaying of the anti-haemagglutinin antibody in 
the human serum. Test serum is placed in a central well and allowed to diffuse 
overnight. Zones of lysis surrounding the well correlate with the presence of antibody 
and their area is proportional to antibody concentration. The SRH test is strain-specific 
and is useful for antigenic characterisation of virus isolates but its use is limited to 
research centres (Schild et al., 1975; Sato et al., 1983, 1988). 
 
EIAs or ELISA techniques: 
EIAs are sensitive immunoassays that use an enzyme linked to an antibody or antigen as 
a marker for the detection of a specific antigens or antibodies, respectively. The EIA 
principle is widely used in the point-of care kits are now widely available as commercial 
kits (Linde, 2001). Neutralising antibody tests are more sensitive than CF and at least as 
sensitive as HI tests and offer greater flexibility in measuring antibody to the various 
proteins of influenza (Masihi and Lange, 1980; Murphy et al., 1981). However, they 
cannot be used for HA subtyping. 
 
EIAs are suitable for testing large number of samples and generally require little 
technical expertise to perform. Because the colour change reactions are objectively 
measured by a spectrophotometer, the technologist is not required to make subjective 
assessments (Leland, 1999) Figure 1.7c. 
 
1.7.1.3 Direct detection of virions by electron microscopy  
Electron microscopy (EM) is an important adjunct to other diagnostic virology tests. In 
some cases, it may be the only procedure for detecting viruses because they are 
fastidious or not cultivable or biochemical probes are not readily available. EM showed 
its worth in the 2003 investigation of respiratory samples from patients with severe 
acute respiratory syndrome (SARS), particularly those in Hong Kong and Southern 
China or those travelling from that part of the world. Laboratory investigations by EM 
facilitated the early recognition and subsequent identification of the SARS coronavirus  
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agent, a newly recognised virus of humans that belongs to the family Coronaviridae 
(Curry et al., 2006). 
 
Transmission electron microscopy utilises an electron beam travelling directly through 
the specimen to obtain a two-dimensional image of the specimen. Scanning electron 
microscopy uses modified electron beams to generate a three-dimensional image of the 
specimen but is rarely used for clinical diagnosis. There are three basic means of 
preparing specimens for electron microscopy. Negative staining of the virus with 
phosphotungstic acid is the most widely used technique for virus detection by EM. This 
technique uses the electron scattering power of heavy metal salts to provide contrast to 
viruses so that their detailed structure can be seen. The second means of preparing 
specimens for the electron microscope involves freeze-etching. The specimen is quickly 
frozen in propane and sectioned in a microtome while maintaining the specimen 
temperature between -70oC and -170oC. The third means of preparing specimens 
requires fixation, dehydration and embedding in plastic. The embedded specimen is 
then thin-sectioned. The most commonly used fixatives for EM are glutaraldehyde, 
osmium tetroxide and uranyl acetate (Chapin-Robertosn and Edberg, 1991). The biggest 
limitation of EM as a diagnostic tool is its relatively low sensitivity. A viral count of 
106-107 viral particles per millilitre must be present for detection directly by EM. 
However, the sensitivity of EM can be increased by viral concentration. Viral particles 
are centrifuged into EM grids after aggregating with specific antiserum. This technique 
is known as immunoelectron microscopy (IEM) (Menegus, 1984). IEM uses specific 
antibodies to agglutinate viruses to increase test sensitivity and in some cases 
ultracentrifugation may not be necessary. Viral concentration by ultracentrifugation is a 
necessary procedure in EM examination of viruses, in particular when specific 
antibodies are not available (Li et al., 1995).  
 
1.7.1.4 Molecular methods 
Samples containing viruses that have been stored under non-ideal conditions or 
recovered from partially degraded specimens may not retain their labile antigenic 
determinants or their infectivity. Under these circumstances, methods have been 
developed that are capable of detecting viral nucleic acids rather than protein, because 
both DNA and RNA are considerably more stable than proteins. However, the stability  
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of the DNA and RNA also depends on a number of factors including presence of 
proteases, nucleases and other experimental conditions (Zhang and Evans, 1991). 
 
A number of molecular methods can be employed for the detection of influenza viruses, 
the majority of which are based on PCR methodologies. PCRs can detect and amplify 
influenza viral RNAs and, therefore, have increased sensitivity. In addition, PCR 
permits typing and subtyping and provides amplified DNA suitable for further 
molecular analysis (Zhang and Evans, 1991). 
 
RT-PCR 
By this method, influenza viral RNA is extracted from clinical specimens. 
Complementary DNA (cDNA) to the extracted influenza RNA is then synthesised by 
reverse transcription using specific synthetic oligonucleotide primers. These 
oligonucleotides are designed to anneal with a specific nucleotide sequence on the viral 
genome and the cDNA molecule is synthesised. This step is, however, dependent on the 
enzyme reverse transcriptase (Zhang and Evans, 1991). The cDNA is then amplified 
with specific primers using DNA polymerase. In addition, the specific primers for the 
second amplification process can be designed for the purpose of typing and/or 
subtyping of influenza virus using PCR. RT-PCR has higher sensitivity and specificity 
compared with the other diagnostic methods used for the confirmation of influenza 
virus. However, the specificity of the PCR assay can be further increased by a technique 
known as the nested PCR (Atmar et al., 1996b; Ellis and Zambon, 2002). 
 
Nested PCR uses additional primers to amplify a target sequence within the target 
sequences of the products of the initial PCR assay and within the same reaction mixture. 
As the nested PCR primers are designed to discriminate between the subtypes or strains, 
the presence or absence of nested PCR products provides more information and 
increases the specificity of the reaction (Zhang and Evans, 1991). The drawbacks of the 
technique include cost and the need to use complicated procedures. Despite these 
drawbacks, PCR is a rapid diagnostic method with very high sensitivity. The most 
striking differences between PCR and culture techniques are in the amount of work 
required to obtain results and the speed of the tests.  i.e. 24 h for PCR; 3-10 days for 
culture (Magnard et al., 1999). Despite these advantages the final subtyping of epidemic 
strains in reference laboratories is still done by HI. 
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Real–time RT-PCR 
Most molecular techniques use an enzymatic step to amplify target nucleic acids before 
detection of a specific sequence. Typically, the logarithmic amplification of the target 
sequence results in an amount of DNA product at the end of the PCR reaction, which 
has no correlation with the number of target copies present in the original specimen. For 
Real-time RT-PCR, the detection of amplicon accumulation can be recognised using 
fluorogenic probes or intercalating dyes such as SYBR green 1, rather than by 
conventional end-point analysis. There is no need for post-amplification procedures, 
such as gel electrophoresis, which are required for RT-PCR (Ellis and Zambon, 2002; 
Peters et al., 2004). 
 
Quantitative molecular assays have been used primarily to determine the viral load in 
the diagnosis of HIV, HCV and hepatitis B virus infections (Mellors et al., 1996; Bell et 
al., 1997; Ellis and Zambon, 2002). Although quantitative PCR assays have been 
widely employed in the diagnosis of influenza infections, the development of such 
assays is technically demanding. However, the potential value of such assays for 
monitoring the efficacy of anti-influenza drugs and for the monitoring of the course of 
the disease in immunosuppressed patients has been apparent in recent years (Ellis and 
Zambon, 2002). Real-time measurement of amplicon accumulation also allows the 
determination of reaction efficiency and permits the selection of more sensitive assay 
formats (Peters et al., 2004). 
Table 1.2 shows comparison of methods.  
 
Molecular methods are more sensitive, specific, and rapid for detection of respiratory 
viruses (Kehl et al., 2001; Liolios et al., 2001; van Elden et al., 2002; Weinberg et al., 
2002) and are widely used for the diagnosis of influenza viruses, despite their relative 
complexity and the requirement for highly trained personnel. They are still relatively 
difficult to perform and their use is currently limited to reference or hospital laboratories 
(Ellis and Zambon, 2002; Storch, 2003). In addition, a high percentage of false-
positives can result because of the high sensitivity of the PCR amplification system. 
There is an urgent need to develop novel detection systems with high sensitivity, short 
operation times, together with ease of processing and interpretation (Su et al., 2003). 
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Table 1.2: Comparison of the properties of commonly used diagnostic methods for 
influenza virus detection. 
      Method            Type Time taken Sample required Advantage Disadvantage 
 
Culture 
 
 
Culture method 
 
3-7 days 
Nasopharyngeal 
aspirate, 
Nose and throat 
swab, 
Bronchoalveolar 
aspirate 
Whole infectious  
virus measured; 
Virus 
recoverable for 
typing 
Requires infectious 
virus. 
Highly skilled 
Time required 
 
Shell vial 
centrifugation 
method 
 
 
Culture method 
 
48 h 
Nasopharyngeal 
aspirate, 
Nose and throat 
swab, 
Bronchoalveolar 
aspirate 
Whole infectious 
virus measured; 
Virus 
recoverable for 
typing 
Requires infectious 
virus. 
Highly skilled 
Time required 
 
HI 
 
Serological 
method 
 
2 days 
 
Serum 
 
 
Sensitive and 
specific 
Retrospective 
2-3 weeks after  
infection 
Paired samples needed 
 
 
Antigen ELISA 
 
Immunological 
method 
 
 
1 day 
 
 
Serum 
 
Specific 
 
Less sensitive 
 
RT-PCR 
 
 
Molecular 
method 
 
 
1-2 days 
Nasopharyngeal 
aspirate, 
Nose and throat 
swab, 
Bronchoalveolar 
aspirate 
Sensitive. 
Allows further 
molecular 
analysis. 
Specific 
Cost 
High skills required 
No virus recoverable 
Specialised 
equipment/laboratory 
needed 
Qualitative results 
 
Multiplex PCR 
 
 
Molecular 
method 
1-2 days Nasopharyngeal 
aspirate, 
Nose and throat 
swab 
Bronchoalveolar 
aspirate 
Sensitive and 
specific Tests>1 
target per assay 
Allows further 
product analysis 
Several pathogen 
can be detected 
simultaneously 
Requires extensive 
optimisation to ensure 
no false negatives or 
primer competition. 
May be limited by 
product size. 
No virus recoverable 
 
Real–Time 
PCR 
 
Molecular 
method 
 
4-5 h. Does 
not require 
any post-
PCR 
processing 
 
Nasopharyngeal 
aspirate, 
Nose and throat 
swab 
 
Sensitive and 
specific. 
Can be 
quantitative 
can be 
multiplexed 
 
Requires specialised 
equipment. 
Product analysis not 
always feasible. 
No virus recoverable 
 
(Ellis and Zambon, 2002). 
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1.7.2 Currently available commercial diagnostic test kits for influenza 
Influenza is responsible for winter epidemics of respiratory illness among all age groups 
(Lui and Kendal, 1987). Rates of infection are highest among children although the 
morbidity and mortality are highest among individuals aged >65 years and 
immunocompromised patients (CDC, 1999). Therefore, a rapid virological diagnosis is 
needed to initiate antiviral therapies and reduce times of patient hospitalisation and 
minimise the use of inappropriate antivirals. 
 
The US Food and Drug Administration has urged the marketing rapid influenza 
diagnostic tests that can produce results within 30 min (Amano and Cheng, 2005). 
These tests could directly detect influenza A or B virus-associated antigens or enzymes 
in throat swabs, nasal swabs, or nasal washes. Reported methods generally have greater 
than 70% sensitivity and 90% specificity for viral antigens (Poehling et al., 2002; 
Montalto, 2003). The assays vary in specificity, sensitivity, complexity, time to obtain 
results and cost, depending on the test kit used. The commercial diagnostic kits include 
the BD Directigen Flu A+B, BD Directigen Flu A, FLU OIA, QuickVue Influenza  A/B 
Test, and ZstatFlu®-II tests (Linde, 2001; Montalto, 2003).  
 
1.7.2.1 BD Directigen Flu A+B (Becton Dickinson)  
BD Directigen Flu A+B is an enzyme immunoassay (EIA) membrane test for influenza 
A and B. This kit has moderately sensitivity and high specificity (the nucleoprotein is 
the target antigen), allows rapid diagnosis (less than 15 min) and is technically simple 
(Reina et al., 2002). This test involves extraction of influenza A or B virus antigens 
from patient specimens. A swab is used to obtain a specimen from nasopharyngeal 
washings, aspirates or directly from the nose or throat. However, results may vary, 
depending on the specimen type. Each extracted specimen is expelled through a filter 
assembly into each of two wells of a triangular plastic test device containing a 
membrane surface. Viral antigens, if present in the extracted specimens, are bound to 
the membrane surface. Viral antigen is captured on the membrane by using enzyme-
conjugated monoclonal antibodies specific for influenza A and B virus nucleoprotein. A 
positive test result is indicated by the presence of a purple triangle in a well on the 
plastic device. The absence of a purple triangle (when compared with the positive 
control) indicates a negative test result (Cazacu et al., 2003). Compared with cell 
culture, the assay has an overall sensitivity of 86.2% for influenza A and 80.8% for 
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influenza B; overall specificity is 90.7% for influenza A and 99.5% for influenza B (BD 
Directigen, 2001; Montalto, 2003). 
 
1.7.2.2 BD Directigen Flu A  
The BD Directigen Flu A kit employs the same principle as the BD Directigen Flu A+B 
kit, but only detects influenza A viruses. This enzyme immunoassay performs best 
when nasopharyngeal washings and aspirates are used. The assay takes about 15 min to 
complete. Compared with cell culture, its overall sensitivity is 91% and its specificity 
95% (Montalto, 2003). Figure 1.8. 
 
1.7.2.3 FLU OIA  
The FLU OIA test is an optical immunoassay (Covalcuiuc et al., 1999) that detects 
influenza A and B nucleoproteins but does not distinguish between influenza A and B 
viruses in specimens. The assay is based on alterations to the reflected light path by 
influenza antigen-antibody complexes formed on an optical surface. Antigen binds to an 
antibody-coated silicon wafer, which changes the wafer’s optical thickness and alters 
the path of reflected light. This produces a purple dot indicating a positive result. The 
assay has an overall sensitivity of 64.4% and a specificity of 94.4% (Schultze et al., 
2001). 
 
The Flu OIA assay is easy to perform and is amenable to testing in physician’s offices 
or small laboratories that lack more complex viral diagnostic capabilities. It does not 
require additional equipment and results are available within 20 min. The kit has an 
average shelf life of 6-8 months and is stable at room temperature for up to 12 h 
(Hindiyeh et al., 2000). Comparison of four clinical specimen types (nasopharyngeal 
swabs, throat swabs, nasal aspirates and sputum) for detection of influenza A and B 
viruses by FLU OIA showed that results from sputum and nasal aspirate samples were 
the most predictive of influenza virus infection and throat swabs were the least 
predictive (Covalcuiuc et al., 1999). 
 
1.7.2.4 Quick Vue Influenza A/B Test (A lateral flow immunoassay)  
This assay also uses monoclonal antibodies to detect influenza A and B viral 
nucleoproteins but does not distinguish between them (Poehling et al., 2002). This test 
involves extraction of influenza A or B virus antigens from patient specimens. Each 
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Figure 1.8: BD Directigen Flu A kit. 
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patient’s specimen is placed in a small tube containing an extraction agent, which can 
disrupt the viral particles and so expose the internal viral nucleoproteins. After 
extraction, a test strip is placed in the extraction reagent tube and allowed to react with 
reagents. A specimen that contains influenza virus antigens produces a pink to red test 
line and the appearance of a blue control line indicates a positive result for either 
influenza type. The absence of a pink or red test line and the presence of a control blue 
line indicate a negative test result. The test which takes 10 min to set up and gives 
positive results within 10 min. Data from the manufacturer indicates that QuickVue has 
a specificity of 96–99% and a sensitivity of 73-82%, compared with cell culture 
(Poehling et al., 2002; Quach et al., 2002; Bellei et al.,2003; Cazacu et al., 2003). 
 
1.7.2.5 ZstatFlu®-II test assay   
ZstatFlu®-II is an enzyme-based assay that detects the functional neuraminidase (NA) 
activity of influenza A or B virus. The specimen is incubated for 15 min at room 
temperature with a synthetic NA substrate bound to a chemiluminescent molecule and 
the mixture is then placed in a special imaging device. Liberation of the 
chemiluminescence by activity of influenza NA is detected using polarised high-speed 
detector film. A positive result appears as a ‘+’-shaped white film image, while a 
negative result produces no image in the ZstatFlu®-II test assay. In addition, the 
ZstatFlu®-II test assay has a sensitivity and specificity of 89% and 96% for detection of 
influenza virus, in comparison to cell culture (Hamilton et al., 2002; Achyuthan et al., 
2003a,b). 
Table 1.3 shows comparison of commercial rapid viral tests. 
 
 
 
 
 
 
 
 
 
 
 
 
T. Peduru Hewa     Chapter One: Review of the literature 
 45
 
Table 1.3: Comparison of commercial rapid viral tests. 
 
Features BD 
Directigen 
Flu A+B 
BD Directigen Flu A FLU OIA QuickVue 
Influenza A/B 
Test 
ZstatFlu 
Distinguishes 
between 
influenza A and 
B viruses 
yes no no no no 
Cost per test US$20 - 
U$24 
US$17 - U$20 US$12 - U$17 US$15 - U$18 US$20 
Assay time 15 min 15 min 15 min 10 min 20 min 
Number of 
steps 
9 11 7 3 4 
Preferred 
specimen 
nasopharyn
geal 
aspirate 
nasopharyngeal 
washing or aspirate 
nasopharyngeal 
swab 
nasopharyngeal 
washing or 
aspirate 
throat swab 
Sensitivity (%) 67 - 96 60 - 77 62 - 88 73 - 81 51 - 72 
Specificity (%) 88 - 97 80 - 90 52 - 80 96  - 99 93 - 100 
Shelf life < 1 year Variable 1 year 1 year 3 years 
Storage room 
temperature 
room temperature 4oC - 8oC  room 
temperature 
room 
temperature 
Batching no no no no yes 
Portability yes, with 
medium 
yes, liquid transport 1 h only yes, must be 
refrigerated 
 
> 24 h 
without 
medium 
 
 
(Montalto, 2003). 
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1.8 New developments in biosensor research for influenza detection 
In recent years there has been much research in the development of biosensors for the 
detection of influenza virus. The development of one-step detection methods uses 
biosensors which give only signals that have the capacity to be manipulated and to 
increase sensitivity through digital technology.  
 
1.8.1 Biosensors and immunosensors 
A biosensor is an analytical device that incorporates a biologically active sensing 
material onto a transducer. The biological system (i.e. enzymes, antibodies, antigens) 
provides the specificity and selectivity to the detection system while the transducer (i.e. 
electrodes, optical sensors, and piezoelectric devices) provides signal processing and 
amplification capacity. There are two basic types of biosensors which are biocatalytic or 
bioaffinity-based. Biocatalytic biosensors use an immobilised enzyme as biological 
receptors to catalyse a biochemical reaction. Bioaffinity-based biosensors are designed 
to monitor the binding event itself and use specific binding proteins, lectins, receptors, 
nucleic acids, membranes, whole cells or antibodies for bimolecular recognition (Luppa 
et al., 2001). Biosensors are extensively used as diagnostic tools, predominantly for 
point-of-care testing. Such biosensors which use antibodies are termed immunosensors 
(Eun et al., 2002; Figure 1.9). 
 
Principles of Immunosensors: 
The general design for immunosensors is shown in Figure 1.10. There are four types of 
immunosensor detection device, based on the type of transducer used: electrochemical, 
optical, piezoelectric and thermometric. All types of transducers can either be run as 
direct (nonlabelled) or as indirect (labelled) immunosensors. Direct or nonlabelled 
sensors are able to detect the physical changes during the immune complex formation. 
Indirect or labelled sensors use signal-generating labels which are more sensitive than 
direct sensors (Hock, 1997; Luppa et al., 2001).   
 
1.8.1.1 Electrochemical immunosensors 
Electrochemical transducers are based on the detection of changes in electron transfer 
due to interaction between the antigen and antibody. The types of electrochemical 
sensing devices that are employed include potentiometric and amperometric sensors 
(Ghindilis et al., 1998).  
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Biosensors  
Bioreceptors Transducer 
Antibody DNA optical piezoelectric 
Cell Enzyme Heat 
Electrochemical 
 
(Adapted from Vo-Dinh and Cullum, 2000). 
Figure 1.9: Different categories of biosensor. 
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Figure 1.10: Schematic diagram of a typical immunosensor design.  
(Adapted from Luppa et al., 2001). 
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Potentiometric immunosensors: 
An antibody is a protein whose electric charge is affected by the binding of an antigen 
(Marty et al., 1998). Potentiometric immunosensors are based on the measure of a 
change in potential induced by the binding of free antigen or antibody on its specific 
immobilised antibody or antigen. In this system direct detection leads to small changes 
in potential, so that a poor sensitivity and non-specific effect of binding is obtained 
(Marty et al., 1998; Luppa et al., 2001).  
 
Amperometric immunosensors: 
Amperometric detection is based on the measurement at a fixed potential of the current 
generated when electroactive species are either oxidized or reduced at the electrode. The 
current produced is directly related to the concentration of the electroactive species 
(Marty et al., 1998). Electrochemically active labels are needed for the electrochemical 
reaction of the analyte at the sensing electrode. For example, alkaline phosphatase 
catalyses the hydrolysis of p-nitro phenyl phosphate or p-aminophenyl phosphate (4-
APP) compounds, which results in the production of electrochemically active phenol or 
p-aminophenol (Aizawa, 1994). Horseradish peroxidise (HRP), glucose oxidase, 
glucose-6-phosphate dehydrogenase have also been successfully applied as labels 
(Luppa et al., 2001). 
 
1.8.1.2 Optical immunosensors 
Optical immunosensors are based on measurements of absorption or emission of light 
by immunoreactants. Interactions between light and the reactant can be measured as 
changes in absorbance, fluorescence, luminescence, scatter or refractive index (RI). 
Optical sensing devices in use include total internal reflection spectroscopy (TIRS), 
ellipsometry, optical dielectric waveguides and surface plasmon resonance (SPR) 
sensors (Luppa et al., 2001). 
 
Surface plasmon resonance (SPR):  
The most commonly used optical immunosensors are based on SPR devices. SPR is a 
direct optical sensing technique that measures the refractive index change due to 
biospecific interactions that occur in the vicinity of a thin metal film surface. The most 
common setup of SPR (Kretschmann prism coupling) can be seen in Figure 1.11 
(Homola et al., 1999; Homola, 2003). There are two leading SPR systems on the 
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(Adapted from Homola, 2003). 
This configuration is commonly found in available SPR instrumentation.  
Figure 1.11:   Excitation of surface plasmons using the Kretschmann prism coupling. 
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market: the BIAcore™ system from Biacore (Uppsala, Sweden) and the IAsys™ from 
Fisons Applied Sensor Technology (Cambridge, UK).  
 
SPR based methods are capable of real-time monitoring of the antigen-antibody reaction 
and a wide range of molecules can be detected with lower limits ranging between 109 
and 1013 mol/L (Schofield and Dimmock, 1996; Mullett et al., 2000). SPR has been 
successfully incorporated into an immunosensor format for the simple, rapid, and 
nonlabelled detection of various biochemical analytes. Proteins, complex conjugates, 
toxins, allergens, drugs, and pesticides can all be determined directly using either 
polyclonal or monoclonal antibodies or synthetic receptors with high sensitivity and 
selectivity as the sensing element (Mullett et al., 2000). The applications of SPR to 
virology were first described by Dubs et al., (1991, 1992) who showed that interactions 
between antibodies and a number of animal viruses (vaccinia virus, poliovirus) and 
plant viruses (TMV and cowpea mosaic virus) could be studied in real time. SPR has 
also been used for the detection of influenza viruses and the study of interactions that 
involve viral proteins and receptors. The first use of SPR in influenza detection was 
reported by Schofield and Dimmock, 1996. They used a sensor chip coated with a 
carboxylated dextran polymer matrix, on which a monoclonal antibody (HC10) for 
capture of influenza virus was coupled. Influenza virus was injected into the flow 
system, and its binding affinity with the surface antibody was monitored (Schofield and 
Dimmock, 1996). Detection limits for SPR and QCM are both in the sub-nanogram 
region (Mullett et al., 2000; Eun et al., 2002; Amano and Cheng, 2005). Because the 
molecular weight of the influenza A or B virion is about 2.5 x 106, the detectable 
number of virions is considered to be around 106 (Amano and Cheng, 2005). In both 
QCM and SPR is directly proportional to the concentration of virus. The QCM 
measures mass by detecting the change in vibrational frequency of the quartz crystal. 
The change in frequency of the crystal upon binding is proportional to mass of the 
binding substances. Similarly in SPR, the resulting refractive index change is directly 
proportional to the concentration of analyte (Homola, 2003; Vaughan et al., 2003).  
 
1.8.1.3 Piezoelectric immunosensors 
Piezoelectric immunosensors are based on the measurement of the mass change due to 
antigen-antibody complex formation on the surface of a piezoelectric transducer 
(Ghindilis et al., 1998). Examples of such devices include the QCM and SAW sensor.  
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The theory of piezoelectricity was first postulated in 1880 by Pierre and Jacques Curie 
who described the generation of electrical charges on the surface of a solid caused by 
extension, pressure or torsion. The occurrence of a mechanical deformation arising from 
an external electric field has been called the converse piezoelectric effect (Janshoff et 
al., 2000). Although a large number of crystals, including zinc oxide (ZnO) exhibit 
piezoelectric properties, only quartz (SiO2) provides the unique combination of 
mechanical, electrical, chemical, and thermal properties, which has led to the 
development of commercially available QCM sensors. The converse piezoelectric effect 
provides the fundamental basis for QCM methodology, as an oscillating potential 
difference induces the piezoelectric crystal to oscillate mechanically around its steady-
state position. Owing to the electromechanical coupling within quartz crystals, 
alterations of the mechanical oscillation can be conveniently inferred from electrical 
measurements (Janshoff et al., 2000, Janshoff and Steinem, 2001). 
The schematic diagram in Figure 1.12 shows the general relationships between 
mechanical and electrical variables in piezoelectric phenomena.  
 
Mass Sensitivity: 
Sauerbrey in 1959 described the first mathematical analysis of mass sensitivity for 
quartz oscillation. He developed the relationship between the frequency change and the 
mass of the thin film deposited on the crystal surface and showed that the frequency 
decrease f was proportional to the deposited mass m, if the resonator was operated in air 
or vacuum, according to the equation: 
 
 
Δf   =  -  f2q Mf   =  -   f2q mf
                                  Nρq S             N ρq
 
 
where fq is the fundamental resonant frequency of the quartz, N is the frequency 
constant for the specific crystal cut (NAT = 1.67 x 105 Hz . cm; NBT =  2.5 x 105 Hz . 
cm), ρq =  2.65 kg/dm3 is the quartz density, and S is the surface area of the deposited 
film, the mass of which is Mf. When the deposited film covers the whole sensitive area 
of the quartz crystal it is easier to use the area density, mf = Mf/S (Bunde et al., 1998; 
Vaughan et al., 1999; Mecea, 2005; www.Maxtekinc.com).  
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Figure 1.12:  Relationship between mechanical and electrical variables. 
 
The direct piezoelectric effect is the production of electric displacement by applying a 
mechanical stress. The converse piezoelectric effect results in a strain in the crystal when 
an electrical field is applied to a piezoelectric crystal (Adapted from Janshoff et al., 
2000).  
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When a crystal is placed in a liquid, the oscillating frequency depends on the particular 
liquid used. When the over layer is not equally distributed, the relationship between the 
Δf and ∆m is no longer linear and corrections are necessary. The oscillating surface 
generates plane-laminar flow in the liquid, which causes a decrease in the frequency 
proportional to (ρη)1/2, where ρ and η are the liquid density and the viscosity, according 
to the equation: 
 
∆f =  -fq3/2 ( ρLηL / π pqηq)1/2 
 
where fq is the frequency of oscillation of the unloaded crystal in Hz, ρq  the density of 
quartz kg/m3, ηq shear modules of quartz, ρL the density of the liquid in contact with the 
electrode in kg/m3 and ηL the viscosity of the liquid in contact with the electrode in 
N.sec/m2. This equation represents Kanazawa’s solution for the change in resonant 
frequency of the crystal due to the loading of liquid (www.Maxtekinc.com). 
 
Classification of acoustic wave sensors: 
There are four common types of acoustic sensors, based on their wave propagation 
characteristics.  
a). Thickness-shear-mode sensors (TSM) also known as the quartz–crystal microbalance 
(QCM) technique that used in the current study.  
b). Flexural-plate-wave sensors (FPW). 
c). Surface–acoustic–wave sensors (SAW). 
d). Shear-horizontal-acoustic-plate-mode sensors (SH-APM) (Janshoff et al., 2000). 
Figure 1.13 shows schematic sketches of the four common types of acoustic resonators 
and their wave propagation mode. 
 
The Thickness-shear-mode (TSM) sensor:  
TSM devices generate acoustic waves that travel in a direction perpendicular to the 
plate surfaces. For this to occur, the quartz crystal plate must be cut to a specific 
orientation with respect to the crystal axes. Generally AT-cut crystals are used for TSM 
devices, being cut with an angle of 35.25o to the z-axis. AT-cut quartz crystals exhibit a 
high frequency stability of Δf/f ~10-8, which makes them well suited for many electronic 
devices. Since AT-cut quartz crystals have a temperature coefficient that is almost zero 
between 0 to 50oC, this particular cut is the most suitable one for QCM applications.  
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Figure 1.13:    Schematic sketches of the four common types of acoustic resonators 
and their wave propagation mode.  
(Reproduced from Janshoff et al., 2000). 
The particle displacement is indicated by a black arrow and the direction of the wave 
propagation by an open arrow.  
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TSM devices are typically constructed of circular quartz plates with thin metal 
electrodes deposited on each side (Ebato et al., 1994; O’Sullivan and Guilbault, 1999).  
An AT–cut quartz crystal is shown in Figure 1.14a and Figure 1.14b.  
 
Quartz-crystal microbalance (QCM): 
QCM is based on the measurement of changes of the frequency response resulting from 
adsorption of an antibody or antigen onto a modified piezoelectric crystal surface. The 
relationship between frequency shift and surface mass change for the QCM is given by 
the Sauerbrey equation. The QCM operates at frequencies below 15 MHz (Gizeli and 
Lowe, 1996). It is one of the most popular transducers used in biosensing, because of its 
simplicity, convenience, low cost, rapid and real-time response (Nakanishi et al., 1996; 
Uttenthaler et al., 1998). The QCM has been applied in many fields, such as food 
analysis, clinical analysis, environmental monitoring and gene probe assays (Alder and 
McCallum, 1983; Rogers, 1995; Ito et al., 1996; Morgan et al., 1996; Caruso et al., 
1998).  
Figure 1.15a shows the QCM instrument used in the current study (RQCM, Maxtek 
Inc., USA) and Figure 1.15b shows the type of frequency changes observed after 
addition of antibody to the crystal surface in such a device.  
 
The QCM consists of a thin quartz disk with electrodes plated on it. The application of 
an external electrical potential to a piezoelectric material produces internal mechanical 
stress. As the QCM is piezoelectric, an oscillating electric field applied across the 
device induces an acoustic wave that propagates through the crystal. These acoustic 
waves travel in a direction perpendicular to the plate surfaces (O’Sullivan and 
Guilbault, 1999).  
 
There is considerable interest in developing new sensors for the quick and reliable 
detection of influenza that require minimum sample handling and laboratory skill 
requirements. QCM is just one of the strategies being undertaken to develop single-step, 
direct sensing methods that eliminate separation, incubation or use of any single–
reporting agents. In recent years, non-labelling techniques including SPR and QCM 
have shown promise in sensor research and their application for the detection of viral 
samples (Amano and Cheng, 2005). 
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Figure 1.14a: The assignment of 
axes to a quartz crystal. 
 
 
 
      
Figure 1.14b: AT- quartz crystal. 
 
 
 
(Reproduced from O’Sullivan and Guilbault, 1999). 
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                    Figure 1.15a: Maxtek quartz crystal microbalance. 
 
 
 
(Reproduced from www.Maxtekinc.com). 
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 Figure 1.15b:  Example of the typical real time piezoelectric response for the 
binding of antibodies to a crystal surface. 
 
 
 
  
 
(Reproduced from Vaughan et al., 1999). 
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Surface Acoustic Wave (SAW) Sensors: 
Lord Rayleigh was the first to discover this acoustic mode known as surface acoustic 
waves (SAW) in 1887 (Ballantine et al., 1997). A stress-free boundary of a solid gives 
rise to these surface-confined waves that propagate as coupled longitudinal and 
transversal waves. The operating frequencies of SAW sensors are usually above 
100MHz (Gizeli and Lowe, 1996; Ballantine et al., 1997). SAW microsensors offer 
great potential for chemical sensor applications, but only gas sensing applications have 
been successful to date (Grate, 2000; Freudenberg et al., 2001). Use in liquid-based 
applications has not been very satisfactory due to problems with instability, poor 
reproducibility and external environmental factors, such as temperature fluctuation 
(Bender et al., 2003). Despite these limitations, a small number of publications describe 
the use of a SAW device for biosensing applications, including the detection of 
microorganisms such as Legionella and Escherichia coli (Howe and Harding, 2000).   
 
1.8.2 Clinical applications of immunosensor systems 
Sensing applications that can handle clinical samples remain rare. Despite all of the 
recent advances in sensor technology, there are no immunosensors in practice that can 
test clinical samples. However, the potential applications of clinical interest using these 
novel techniques may become increasingly important in the future (Luppa et al., 2001). 
 
Clinical applications of piezoelectric immunosensors: 
Two strategies have been used for enhancing the sensitivity of piezoelectric 
immunosensors. One is the direct or surface, enhancement technique, which involves 
increasing the effective area of the electrode surface or the improvement of the loading 
of active antibody or antigen molecules at the electrode surface via a suitable 
immobilisation method. The other technique involves indirect or mass amplification, in 
which the mass sensitivity of detection of the analyte is increased by attaching a particle 
(such as a nanoparticle) to the analyte (Luppa et al., 2001). 
 
1.8.2.1 Applications of piezoelectric immunosensors using surface enhancement 
The formation of specific antigen–antibody complexes leads to changes in the mass at 
the surface of the immunosensor. The immobilisation of antibodies and antigens not 
only produces a functionalised sensing interface but also determines the sensitivity as 
well as the regenerative ability of QCM-based immunosensors. The most commonly  
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used immobilisation method is the covalent attachment of antibodies or antigens to an 
intermediate layer on the electrode surface, such as a self-assembled monolayer (Su, et 
al., 1999; Fung and Wong, 2001), polymeric coatings (Chu et al., 1995, 1996; Babacan 
et al., 2000), electro polymerised films (Si et al., 1997) and plasma polymerised films 
(Nakanishi et al., 1996; Wang et al., 2004). Immobilisation may also be implemented 
using the direct adsorption of antibodies or antigens to the electrode surface or the 
intermediate layer and may include the use of the thiolated antibodies or antigens (Park 
and Kim, 1998), layer-by-layer assembly of polyelectrolyte films (Wu et al., 2000) and 
the use of an assembled nanoparticle layer (Wang et al., 2003). The immobilisation 
methods that lead to sensitivity enhancement are characterised by an increased electrode 
surface and an improved loading of antibodies or antigens. However, immobilised 
antibodies or antigens are randomly oriented using these approaches. 
 
A strategy for oriented immobilisation of antibodies or antigens has been shown to 
enhance sensitivity by generating unobstructed recognition sites for the analytes. One 
such approach to oriented immobilisation of antibodies is to utilise immobilised Protein 
A which binds the antibody Fc domain of most classes of IgG with high affinity 
(Guilbault et al., 1992; Minunni et al., 1996; Susmel, et al., 2000; Gerdon et al., 2005). 
 
1.8.2.2 Applications of piezoelectric immunosensors using mass amplification 
Chu et al., 2006 developed QCM immunosensors by the application of antibody-
functionalised gold nanoparticles as the amplifying mass. To further optimise the 
immunosensing performance, the Protein A-based oriented immobilisation of antibodies 
was employed. The sensitivity was substantially improved via an amplification step and 
a detection limit as low as 3.5 ng/mL for human IgG was achieved in the model system 
described (Chu et al., 2006). 
 
1.8.3 Applications of QCM techniques for microbiological analyses 
QCM has already been used successfully for the detection of pathogenic 
microorganisms such as Listeria monocytogenes (Minunni et al., 1996), Chlamydia 
trachomatis (Ben-Dov et al., 1997), Vibrio cholerae (Carter, et al., 1995), Salmonella 
typhimurium (Prusak-Sochaczewski et al., 1990), Staphylococcus epidermidis (Pavey, 
et al., 1999) and Pseudomonas aeruginosa (Bovenizer et al., 1998). Other applications  
include the detection of DNA, the measurement of protein-ligand interactions, and the  
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detection of virus capsids, virus, bacteria, and mammalian cells. The application of 
QCM in influenza research has been limited to the study of virus/receptor interactions. 
Sato et al., (1996) described its use to study the binding of influenza A virus to 
monosialogangliosides (GM3) in membranes and to explore the influence of membrane 
composition on receptor functions of GM3. Other viruses have also been detected using 
QCM techniques. Eun et al., 2002 reported a method for detection of the orchid viruses, 
Cymbidium Mosaic Potex Virus (CymMV) and Odontogossum Ringspot Tobamo Virus 
(ORSV) by pre-coating the QCM crystal with virus specific antibodies.  
 
The QCM detection limit was as low as 1 ng for the detection of two orchid viruses, a 
sensitivity that was comparable with that of ELISA. However, the QCM was much 
more rapid (Eun et al., 2002). The QCM immunosensor technique has a number of 
advantages. It is (a) simple, (b) provides an online detection system, (c) portable, (d) 
less expensive than SPR and (e) the instrument is easy to handle. The coated QCM 
crystal has a relatively long shelf-life of at least 1 month (Eun et al., 2002). 
 
Su et al., 2003 used QCM for detection of dengue virus. They immobilised two 
monoclonal antibodies on a QCM crystal that bound specifically to the dengue virus 
envelope protein (E-protein) and a non-structural protein (NS-1). The reported 
sensitivity for the QCM immunochip was 100-fold greater than the conventional 
sandwich ELISA method.  
 
Zhou et al., 2002 developed a QCM technique for the detection of hepatitis B virus 
(HBV). An HBV nucleic acid probe was immobilised onto a gold electrode coated with 
polyethyleneimine and crosslinked, using a glutaraldehyde (PEI-Glu) or a physical 
adsorption method. The coated crystal prepared by PEI-Glu showed better results than 
the physical adsorption method with respect to sensitivity, reproducibility and stability. 
A linear relationship was observed between the frequency shifts due to probe-viral DNA 
hybridisation and the amount of HBV DNA present in the range 0.02-0.14 μg/mL.  
 
Zuo et al., 2004 developed an immunosensor for SARS, and detected a frequency shift 
that was proportional to the antigen concentration within the range 0.6-4 μg/mL 
 
 
 T. Peduru Hewa       Objectives of the research project 
 
Objectives of the research project: 
 
1. To evaluate currently available diagnostic methods for the detection of influenza 
infections from clinical specimens.  
2. To develop ELISAs for the detection of influenza A and B viruses using antisera 
prepared against purified type-specific antigens as a preliminary to the development of 
a biosensor.  
3. Using reagents standardised by ELISAs, to develop a QCM acoustic device specific 
for influenza A and B viruses. 
4. To optimise parameters that affect the sensitivity of the QCM biosensor in the 
detection of influenza A and B viruses. 
5. To evaluate the suitability of QCM biosensor for the laboratory diagnosis of influenza, 
in comparison with the other currently available diagnostic methods.  
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2.1 Chemicals 
Acetic acid, glacial (AnalaR grade) BDH Chemicals, Poole, UK 
Acetone BDH Chemicals, Poole, UK 
Acrylamide/bisacrylamide (40% w/v) Bio-Rad Laboratories Pty. Ltd., Regents 
Park, NSW, Australia 
Agarose (molecular biology grade) Promega Corporation, Annandale, NSW, 
Australia 
Ammonium persulphate      Sigma-Aldrich, St. Louis, MO, USA 
Amphotericin B (tissue culture grade) Sigma-Aldrich, St. Louis, MO, USA 
Ampicillin CSL Ltd, Parkville, VIC, Australia 
Aprotinin, bovine lung, Crystalline     Calbiochem-Novabiochem Corporation, 
[trypsin inhibition units/mL (TIU/mL)]           San Diego, California, USA                                         
Boric acid     BDH Chemicals, Poole, UK 
Bovine Serum albumin    Thermo Trace Pty. Ltd., Castle Hill,      
                                                                           NSW, Australia 
Bromphenol Blue       Sigma-Aldrich, St. Louis, MO, USA 
Calicum chloride BDH Chemicals, Poole, UK 
Chloroform (AnalaR grade) BDH Chemicals, Poole, UK 
4-chloro-1-naphthol  Sigma-Aldrich, St. Louis, MO, USA 
Citric acid BDH Chemicals, Poole, UK 
Coomassie Brilliant Blue R250®     Sigma-Aldrich, St. Louis, MO, USA 
Coverslips, Glass 12mm Dia    Mirella Research Pty. Ltd., Brunswick,    
                                                                           VIC, Australia 
Dimethylsulphoxide (DMSO; AnalaR) BDH Chemicals, Poole, UK 
D-Glucose (AnalaR grade) BDH Chemicals, Poole, UK 
Dialysis tubing MD25-14 x 100 CLR  Biolab, Mulgrave, VIC, Australia 
(Membrane cell)  
Dithiotreitol   Sigma-Aldrich, St. Louis, MO, USA 
Dulbecco’s modified Eagle’s medium/F12 Invitrogen Corp., Carlsbad, CA, USA 
Deoxynucleotide Mix (dNTP) Promega Corporation, Annandale, NSW, 
Australia 
Eagle’s MEM powder Thermo Trace Pty. Ltd., Clayton, VIC, 
Australia 
Ethanol (99.8% AnalaR grade) BDH Chemicals, Poole, UK 
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Ethidium bromide Sigma-Aldrich, St. Louis, MO, USA 
Ethylenediaminetetraacetic acid (EDTA), BDH Chemicals, Poole, UK 
disodium salt (molecular biology grade)  
Evan’s Blue ICN Biomedicals, Seven Hills, NSW, 
Australia 
Ficoll paque     Sigma-Aldrich, St. Louis, MO, USA 
Fluorescein calibration dye     Bio-Rad Laboratories, Hercules, CA,       
                                                                           USA 
Foetal calf serum Trace Bioscience Pty. Ltd., Castle Hill, 
NSW, Australia 
Formaldehyde Sigma-Aldrich, St. Louis, MO, USA 
Formamide Sigma-Aldrich, St. Louis, MO, USA 
Freund’s adjuvant (complete) Sigma-Aldrich, St. Louis, MO, USA 
Freund’s adjuvant (incomplete)  Sigma-Aldrich, St. Louis, MO, USA 
Glacial acetic acid (AnalaR grade)     BDH Chemicals, Poole, UK 
Glue (craft) UHU Australia Pty. Ltd., Smithfield, 
NSW, Australia 
Glycerol (AnalaR grade) BDH Chemicals, Poole, UK 
Glycine (AnalaR grade) BDH Chemicals, Poole, UK 
Glycogen Roche Diagnostics GmbH, Mannheim, 
Germany 
Gold (111) chloride trihydrate Sigma-Aldrich, St. Louis, MO, USA 
Hydrogen peroxide (30% w/v 100 volume) Merck Pty. Ltd., Kilsyth, VIC, Australia 
HEPES (N-2-Hydroxyethylpiperasine-N-2- BDH Chemicals, Poole, UK 
ethanesulphonic acid) (tissue culture grade)  
Hydrochloric acid (AnalaR grade)     BDH Chemicals, Poole, UK 
Isopropanol  Sigma-Aldrich, St. Louis, MO, USA 
Isoamylalcohol (3-methyl-1-butanol) Sigma-Aldrich, St. Louis, MO, USA 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Promega Corporation, Annandale, NSW, 
Australia 
MES 2-[N-morpholino]ethanesulfonic acid Sigma-Aldrich, St. Louis, MO, USA 
Magnesium chloride (MgCl2.2H2O) BDH Chemicals, Poole, UK 
Magnesium sulphate (MgSO4.H2O) BDH Chemicals, Poole, UK 
β-mercaptoethanol (electrophoresis grade) Sigma-Aldrich, St. Louis, MO, USA 
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Methanol (AnalaR grade) BDH Chemicals, Poole, UK 
N,N,N’,N’-tetramethylethylenediamine Sigma-Aldrich, St. Louis, MO, USA 
Neutral Red (tissue culture grade) Sigma-Aldrich, St. Louis, MO, USA 
Nuclease-free water ICN Biomedicals Inc., St. Louis, MO, 
USA 
Orange G        BDH Chemicals, Poole, UK 
Penicillin G (tissue culture grade) CSL Ltd, Parkville, VIC, Australia 
Phenol Red  Invitrogen Corp., Carlsbad, CA, USA 
Phenol Sigma-Aldrich, St. Louis, MO, USA 
Polyethylene glycol 6000      BDH Chemicals, Poole, UK 
Potassium acetate       BDH Chemicals, Poole, UK 
Potassium chloride (AnalaR grade) BDH Chemicals, Poole, UK 
Potassium dihydrogen orthophosphate  BDH Chemicals, Poole, UK 
(AnalaR grade) 
Proteinase K  Sigma-Aldrich, St. Louis, MO, USA 
Silver nitrate (AnalaR grade) Sigma-Aldrich, St. Louis, MO, USA 
Sodium acetate  BDH Chemicals, Poole, UK 
Sodium bicarbonate (AnalaR grade) BDH Chemicals, Poole, UK 
Sodium chloride (AnalaR grade) BDH Chemicals, Poole, UK 
Sodium carbonate (AnalaR grade) BDH Chemicals, Poole, UK 
Sodium citrate (AnalaR grade)     BDH Chemicals, Poole, UK 
Sodium dihydrogen orthophosphate BDH Chemicals, Poole, UK 
Sodium dodecyl sulphate (SDS) BDH Chemicals, Poole, UK 
Di-sodium hydrogen orthophosphate,  BDH Chemicals, Poole, UK 
anhydrous (AnalaR grade) 
Sodium hydroxide BDH Chemicals, Poole, UK 
Streptomycin (tissue culture grade) CSL Ltd, Parkville, VIC, Australia 
Sucrose (AnalaR grade) BDH Chemicals, Poole, UK 
Sulphuric acid 18M (AnalaR grade) BDH Chemicals, Poole, UK 
SYBR® green 1 nucleic acid gel stain BioScientific Pty. Ltd., Gymea, NSW, 
Australia  
Tetracycline Roche Diagnostics GmbH, Mannheim, 
Germany 
Tris [Tris-(hydroxymethyl) aminomethane] Research Organics Inc., Cleveland, OH,  
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(Tris-HCl)                                                          USA 
Triton N-101 Sigma-Aldrich, St. Louis, MO, USA 
Triton X-100 Sigma-Aldrich, St. Louis, MO, USA 
Trypan Blue ICN Biomedicals, Seven Hills, NSW, 
 Australia 
Trypsin (crystallised bovine pancreas) ICN Biomedicals, Seven Hills, NSW 
 Australia 
Tryptone Oxoid Australia, West Heidelberg, VIC, 
Australia 
Tween 20 (polyethylene glycol sorbitan Sigma-Aldrich, St. Louis, MO, USA 
monolaurate) 
Xylene cyanol Sigma-Aldrich, St. Louis, MO, USA 
Yeast extract Oxoid Australia, West Heidelberg, VIC, 
Australia 
Water (DNase and RNase-Free)   ICN Biomedicals Inc, Aurora, OH, USA 
X-gal Promega Corporation, Annandale, NSW, 
Australia 
  
2.2 Equipment 
Arodisc syringe filter 0.2 μm, 0.45 μm          Gelman Sciences, Ann Arbor, MI, USA 
Analytical balance: Sartorius BP 210S           Sartorius AG, Gottingen, Germany 
Avanti® J-25I  High- performance                 Quantum Scientific Pty. Ltd., Milton, QLD,  
Australia 
Bench top centrifuge: Sigma 3K10  Beckman Coulter, Inc., Fullerton, CA,  
Centrifuge    USA  
Centricon YM-10 Centrifugal Filter Unit      Millipore Australia Pty. Ltd., North Ryde, 
                                                                        NSW, Australia 
CHC-100  Crystal holder  Maxtek Inc.,  Cypress, CA, USA 
CO2 incubator: Sanyo MCO-17A1                Quantum Scientific Pty. Ltd., Milton, QLD, 
Australia 
Dry block heater: Ratek                                 Labquip Technologies, Boronia, VIC,  
Australia 
  Egg Incubator: Multiplo E3                          Multiplo Pty. Ltd., Sydney, NSW, Australia 
  Electrophoresis gel tanks                              Bio-Rad Laboratories, Hercules, CA, USA 
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Electrophoresis power supply                       Bio-Rad Laboratories, Hercules, CA, USA 
Eppendorf centrifuge                                    Quantum Scientific Pty. Ltd., Milton, QLD,  
                                                                       Australia 
FC-550 Flow Cell  Maxtek Inc., Cypress, CA, USA  
                                    Fluorescence microscope (model U-RFL-T    Olympus Corp., Shinjuku-ku, Tokyo, Japan 
                                    with SPOT -RT software V3.1)   
Gene Pulser II system  Bio-Rad Laboratories Pty. Ltd., Regent’s 
Park, NSW, Australia 
Gel Doc 1000 system   Bio-Rad Laboratories Pty. Ltd., Regent’s 
Park, NSW, Australia 
GeneAmp® PCR System 2400   Perkin-Elmer Corporation, Norwalk, CT,     
USA 
Haemocytometer (Improved Neubauer)        Selby Scientific Instruments, Clayton, VIC, 
Australia 
Inverted microscope: Olympus IMT-2          Olympus Corp., Shinjuku-ku, Tokyo,    
Japan 
Microtiter plate (V-bottomed)  Greiner Laboratechnik GmbH,          
Frickenhausen, Germany  
Microtiter plate (U-bottomed)                        Disposable Products Pty. Ltd., Adelaide,  
                                                                        SA, Australia 
Microtiter plate (96 well, flat bottomed)  Nunc Co. Ltd., Roskilde, Denmark 
Model A-99 syringe pump   Extech equipment Pty. Ltd., Boronia, VIC, 
   Australia 
MyiQ Single-Colour Real-Time PCR  Bio-Rad Laboratories, Hercules, CA, 
Detection System  USA 
Nitrocellulose membranes  Bio-Rad Laboratories, Hercules, CA,    
          USA 
OptimaTM L-80 XP Ultracentrifuge  Beckman Coulter, Inc., Fullerton, CA,    
   USA 
Optima TM TLX Ultracentrifuge  Beckman Coulter, Inc., Fullerton, CA,    
   USA 
pH meter                                                         U-Lab Instruments, Eltham, VIC, Australa 
Quartz Crystals (2.54 cm diameter)  Maxtek Inc., Cypress, CA, USA 
RQCM (Research Quartz Crystal  Maxtek Inc., Cypress, CA, USA  
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Microbalance)   
Rheodyne Model 5020 sample   Alltech Associates Australia, Baulkham  
Injector (switching valves)  Hills, NSW, Australia 
Sonicator power supply and probe   Branson sonic Power Company,    
Danbury, CN, USA 
Tissue culture flasks: 25, 75, and 175 cm2     Greiner Labortechnik, Frickenhausen,    
Germany 
Tissue culture plates: 6-, 24- and 96-well      Greiner Labortechnik, Frickenhausen,    
Germany 
 
2.3 Kits 
Ampli Taq® DNA Polymerase Kit (Roche Molecular Systems Inc., Branchburg, NJ,  
USA) 
Contents: Ampli Taq® DNA Polymerase, Gene Amp® 10 x PCR Buffer; 25 mM  
MgCl2.  
 
Bio-Rad Protein Assay Kit (Bio- Rad Laboratories Pty. Ltd., Regent’s Park, NSW,  
Australia). 
Contents: Bovine gamma protein 1.54 mg/mL, Bio-Rad dye reagent concentrate. 
 
pGEM ®- T Vector  System 1 (Promega Corporation, Annandale, NSW, Australia) 
Contents: pGEM ®- T Easy Vector, Control insert DNA, T4 DNA ligase, 2 x Rapid 
Ligation Buffer.  
 
BD Directigen™ Flu A kit  (Becton, Dickinson and Company, Maryland, USA) 
Contents: ColorPAC Devices, Reagent A, Reagent 1-8, Control + and  Control -.  
 
QIAamp  Viral RNA Mini Kit ® (QIAGEN Pty. Ltd., Gmbh, Clifton Hill, VIC,  
Australia)  
Contents: Buffer AVL containing carrier RNA, Buffer AW1, Buffer AW2, QIAamp  
spin columns. 
 
QIA quick® PCR Purification Kit (QIAGEN Pty. Ltd., Gmbh, Clifton Hill, VIC,  
Australia) 
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Contents: QIA Quick Spin columns, Buffer PB, Buffer EB, Buffer PE. 
 
TMB Microwell Peroxidase System (Kirkegaard and Perry Laboratories Inc., 
Gaithersburg, MD, USA) 
Contents: TMB peroxidase substrate, peroxidase solution B (0.02% H2O2 in a citric  
acid buffer). 
Titan One Tube RT-PCR system (Roche Diagnostics GmbH, Mannheim, Germany) 
Contents:  Enzyme mix, RT-PCR reaction buffer, MgCl2 stock solution, DTT solution. 
 
Wizard® Plus SV Minipreps DNA purification System (Promega Corporation,  
Annandale, NSW, Australia) 
Contents: Wizard® Plus SV Cell Resuspension solution, Wizard® Plus SV Cell Lysis  
Solution, Wizard® Plus SV Neutralisation Solution, Wizard® Plus SV Column Wash  
Solution, Wizard® SV minicolumns, alkaline protease solution. 
 
2.4 Restriction enzyme and buffers 
The following restriction enzymes were obtained from the Promega Corporation,  
Annandale, NSW, Australia: 
Restriction enzyme  Cleavage sequence 
BamH1            G    GATC 
EcoR1     G    AATT 
Nsi1     TGCA    T 
Pst1     TGCA    G 
Sca1     AGT     ACT 
 
2.4.1 Modifying enzymes 
Enzyme      Supplier 
BigDye®  Terminator v3.1 Cycle Sequencing kit Perkin-Elmer Applied Biosystems, 
                                        FosterCity, CA, USA 
Alkaline phosphatase, calf intestinal            Promega Corporation, Annandale, 
NSW, Australia 
RNase A  Roche Diagnostics GmbH, 
Mannheim, Germany 
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 RQ1 RNase-free DNase  Promega Corporation, Annandale, 
NSW, Australia 
SP6 RNA polymerase  Roche Diagnostics GmbH, 
Mannheim, Germany 
T3 RNA polymerase                            Promega Corporation, Annandale, 
NSW, Australia 
T4 DNA ligase  Promega Corporation, Annandale, 
NSW, Australia 
T7 RNA polymerase  Promega Corporation, Annandale, 
NSW, Australia 
        Taq DNA polymerase, recombinant  Invitrogen Corporation, Carlsbad, 
CA, USA 
 
2.5 Anaesthetics 
Ketamine® Troy Laboratories Pty. Ltd., Smithfield, 
(ketamine hydrochloride; 100mg/mL)  NSW, Australia 
Xylazil®      Troy Laboratories Pty. Ltd., Smithfield,  
(xylazine hydrochloride; 20 mg/mL)   NSW, Australia 
A mixture of Ketamine (16.7 mg/mL) and Xylazine (10 mg/mL) was used at a dosage 
of 0.5 mL/kg body weight.  
 
2.6 Antibodies 
2.6.1 Unconjugated monoclonal antibodies 
Mouse monoclonal antibody to influenza A matrix protein, Biodesign International, 
Saco, Me, USA. 
Mouse monoclonal Antibody to influenza B virus matrix protein, Biodesign 
International, Me, USA. 
Mouse monoclonal antibody to Influenza A nucleoprotein (NP), Centers for Disease 
Control and Prevention, Atlanta, GA, USA. 
Mouse monoclonal antibody to Influenza B nucleoprotein (NP), Centers for Disease 
Control and Prevention, Atlanta, GA, USA. 
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2.6.2 Conjugated antibodies 
Goat anti-mouse IgG FITC Conjugated affinity-purified antibody, Chemicon 
International Inc., Temecula, CA, USA 
Goat anti-mouse IgG FITC Conjugated affinity-purified antibody, Jackson Immuno 
Research Laboratories, Inc, West Grove, PA, USA  
Rabbit anti-chicken IgG horseradish peroxidise (HRP) -conjugated affinity-
purified secondary antibody, Chemicon International Inc., Temecula, CA, USA 
Goat anti-mouse IgG/IgM horseradish peroxidase (HRP) -conjugated affinity-
purified secondary antibody, Chemicon International Inc., Temecula, CA, USA 
Rabbit anti-Goat IgG HRP-conjugate, Chemicon International Inc., Temecula, CA, 
USA 
 
2.7 Molecular weight markers 
2.7.1 DNA markers 
The molecular sizes of plasmid DNA, PCR products and DNA fragments were 
determined according to their mobility relative to the markers in a commercial DNA 
ladder (1 kb Plus, Invitrogen, Carlsbad, CA, USA). The ladder contained DNA 
fragments of size 0.1-100 kb.  
  
2.7.2 Protein markers 
The relative molecular mass of proteins (Mr) was estimated according to their mobility  
in comparison  with  pre-stained broad range molecular mass marker (SeeBlue®plus2  
pre-stained standard, Invitrogen Corp., Carlsbad, CA, USA). These markers had 10 pre- 
stained proteins in the range 4-250 kDa. 
 
2.8 Biologicals 
2.8.1 Continuous mammalian cell lines 
MDCK: Madin Darby canine kidney cultures were obtained from CSL Ltd, Parkville, 
VIC, Australia. 
 
2.8.2 JM 109 Competent cells: Promega Corporation, Madison, WI, USA.  
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2.8.3 Virus stocks 
Influenza A strains:  The following strains were obtained from Professor G. Tannock, 
Department of Biotechnology and Environmental Biology, RMIT University, 
Bundoora, VIC, Australia: 
A/Puerto Rico (PR)/8/34 (PR), A/Sydney/5/97, A/Victoria/3/85, A/Panama/2007/99 
A/Shearwater/Australia/1/72, A/New Caledonia/20/90. 
Influenza B strains: CSL Ltd, Parkville, VIC, Australia: 
B/Victoria/504/2000, B/Panama/45/90, B/Lee/40. 
 
2.8.4 Red blood cells 
Chicken red blood cells (RBCs) were provided Process Development Department at 
CSL Ltd., Parkville, VIC, Australia. Guinea pig RBCs were provided by Mr Rob Shaw 
of the WHO Collaborating Centre for Reference and Research on Influenza, Parkville, 
VIC, Australia. 
 
2.8.5 Non specific-pathogen-free eggs  
Non-specific pathogen-free (NSPF) eggs were purchased from the Research Poultry 
Farm, Research, VIC, Australia. 
 
2.9 General solutions, buffers and stock solutions 
All solutions and buffers were prepared using Milli-Q® water unless otherwise 
specified. 
Phosphate Buffered Saline (PBS):  1.43 mM NaCl, 30 mM KCl, 14.7 mM KH2PO4 (pH 
7.2), 82.1 mM Na2HPO4.12H2O (pH 7.4). 
TE buffer: 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0. 
 
2.9.1 M1 protein purification solutions 
TNE Buffer: 0.15 M NaCl, 1mM EDTA, 0.05 Tris-HCl pH7.4. 
 
2.9.2 Immunofluorescence reagents 
Cell Fixation Solution: 80% (v/v) acetone in PBS. 
Evans Blue: 1% Evan’s Blue in PBS. 
Glycerol: 80% glycerol in PBS solution. 
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2.9.3 Quantal assay solutions 
Fixative: 80% acetone in PBS – freshly prepared. 
Wash Buffer: 0.05% Tween 20 in PBS. 
Blocking Buffer: 5% skim milk, 0.1% Tween 20 in PBS. 
 
2.9.4 ELISA solutions 
Coating Buffer: 0.1 M Na2CO3 pH 9.6. 
10 x PBST: PBS with 1% Tween-20 
Washing Buffer: 1 x PBST (PBS with 0.1% Tween-20).  
Blotto: 5% (w/v) skim milk in 1 x PBST. 
Stop Solution: 2 M H2SO4. 
96-well Microtiter plates: Flat-bottomed Dynatech, Immulon-2- plates, Dynatech, 
Chantilly, VA, USA. 
 
2.9.5 Molecular biology solutions 
DNA Loading Buffer (6 x ): 0.25% (w/v) Bromphenol Blue, 0.25% (w/v) xylene 
cyanol, 30% (v/v) glycerol. 
DNA Loading Buffer (10 x ) :10% Ficoll; 50% glycerol, 0.5% Orange G, 1.0%SDS, 
10 mM EDTA, 50 mM Tris-HCl pH 8.0. 
Miniprep Solution I: 50 mM glucose, 10 mM EDTA, 25 mM Tris-HCl pH 8.0.  
Miniprep Solution II: 1% (w/v) SDS in 0.2 N NaOH. 
Miniprep Solution III: 5 M potassium acetate, 11% (v/v) glacial acetic acid. 
TAE: 40 mM Tris acetate, 10 mM EDTA pH7.6. 
 
2.9.6 SDS-PAGE buffers and solutions 
SDS-PAGE Resolving Gel Buffer: 1.5 M Tris-HCl pH 8.8, filtered through a 0.45 μM 
filter and stored at 4oC. 
SDS-PAGE Stacking Gel Buffer: 0.5 M Tris-HCl pH 6.8, filtered through a 0.45 μM  
filter and stored at 4oC. 
SDS-PAGE Gel Mix (Resolving): 10-15% (v/v) acrylamide, 0.375 M Tris-HCl pH 8.8, 
0.1% (w/v) SDS, 0.05% (w/v) ammonium persulphate, 0.1% (v/v) TEMED. 
SDS-PAGE Gel Mix (Stacking): 4% (v/v) acrylamide, 0.125 M Tris-HCl pH 6.8, 
0.125 % (w/v) SDS, 0.05% (w/v) ammonium persulphate, 0.1% (v/v) TEMED. 
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SDS-PAGE Running Buffer: 25 mM Tris-HCl, 192 mM glycine, 0.1% (w/v) SDS pH 
8.0. 
5 x Sample Buffer: 60 mM Tris-HCl pH 6.8 containing 25% glycerol, 2% SDS, 0.1% 
Bromphenol Blue with or without 14.4 mM 2-β mercaptoethanol. 
SDS-PAGE staining solutions: 
Coomassie Blue Staining Solution: 0.1% (w/v) Coomassie Brilliant Blue R250®, 50% 
(v/v) methanol, 10% (v/v) glacial acetic acid. 
Coomassie Blue Destaining Solution: 10% (v/v) ethanol, 10% (v/v) glacial acetic acid. 
 
2.9.7 Western blot solutions and buffers 
Western Blot Transfer Buffer: 15.6 mM Tris-HCl, 120 mM glycine. Before use 
methanol was added to 20%. 
Tris Buffered Saline (TBS): 10 mM Tris-HCl, 150mM NaCl, adjusted to pH 7.4. 
Immunoblot Substrate Solution: 83% (v/v) TBS, 17% (v/v) 3mg/ml 4-chloro-1-
naphthol in methanol, 0.05% (v/v) H2O2.  
 
2.9.8 Silver staining solutions 
Solution A: 0.8g silver nitrate in 10 mL distilled H2O. 
Solution B: 189 μL of 10N NaOH and 1.4 mL 30% (14.8 M) ammonium hydroxide in 
50 mL distilled H2O. 
Solution C: Solution A was added dropwise to solution B, constantly stirring until the 
brown precipitate had cleared. Then H2O was added to 100 mL. It was used within 15 
min. 
Solution D: A volume of 0.5 mL of 1% citric acid was mixed with 35 μL of 38% 
formaldehyde. This freshly prepared mixture was then diluted to 100 mL.  
 
2.9.9 Antibody-colloidal gold conjugate buffers and solutions 
Tris–Buffered Saline (TBS): 20 mM Tris-HCl and 150mM NaCl adjusted pH to 8.0 
with concentrated HCl. 
TBS containing 0.1% BSA (TBS-BSA): TBS containing 0.1% (w/v) BSA. 
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2.10 Cell culture 
2.10.1 Mammalian cell culture media 
MEM Growth Medium: Eagle’s Minimal Essential Medium (MEM) containing 10 
mM HEPES pH 6.8, 0.14% (w/v) sodium bicarbonate, 100 U/mL penicillin G, 100 μg/L 
streptomycin, 1 μg/L amphotericin B and supplemented with foetal calf serum to 5% 
(pH 7.2). 
MEM Maintenance Medium: MEM Growth Medium but with no foetal calf serum. 
Maintenance Medium used for influenza virus assays also contained 1 μg/mL (w/v) 
crystalline trypsin. 
Cell Freezing Medium (CFM): 
MEM with 15% (v/v) FCS, 10% (v/v) DMSO, 0.1% (w/v) sodium bicarbonate, 100 
U/mL penicillin, 100 μg/mL streptomycin and  1 μg /mL amphotericin B. 
2 x  Leibovitz L-15 Maintenance Medium:  
Leibovitz L-15 Medium (with L-glutamine), 20 M HEPES buffer, 0.28% (w/v) sodium 
bicarbonate, 200 U/mL penicillin  G, 200 μg/L streptomycin, 2 μg/L amphotericin B. 
 
Agarose Overlay:   
Equal volumes of 2 x Leibovitz L15 Maintenance Medium and 1.8% agarose maintained 
at 46oC were mixed together. Crystalline trypsin was added to a final concentration of 1 
μg/mL just prior to use. 
Neutral Red Overlay: 
Agarose Overlay maintained at 46oC containing 0.1% (w/v) Neutral Red. 
Trypsinising Solution  (trypsin/versene):  
0.1% (w/v) trypsin, 0.5 mM EDTA prepared in PBS and sterilised by filtration. 
Citrate Saline: 0.1 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, 10 mM 
D-glucose, 3.0 mM sodium citrate. 
 
2.10.2  Bacterial culture media 
Luria Bertani Agar (LBA): 10 g of tryptone, 5 g of yeast extract, 10 g of sodium 
chloride and 6 g of bacteriological agar were added to 1 litre of deionised water and the 
mixture autoclaved at 121oC for 15 min. After cooling to 50oC, the agar was poured into 
Petri dishes and allowed to set. 
Luria Bertani Broth (LBB): LBA but without agar. 
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SOB Broth: Tryptone 2%, yeast extract 0.5%, NaCl 10mM, KCl 2.5mM, MgSO4.7H2O 
10mM. The broth was sterilised by autoclaving at 121oC for 15 min.  
SOC Broth: SOB Broth containing 20 mM glucose.  
X-gal Plates: X-gal plates were prepared by spreading 40 μl of X-gal (20 mg/mL) and 
100 μL of 100mM IPTG evenly across the surface of LBA plates containing appropriate 
antibiotics. X-gal agar plates were dried before use. The plates were stored in the dark. 
Ampicillin: Stock concentrate was added to LB broth at a final concentration of 50 
μg/mL 
Ampicillin plates: LBA with 50 μg/mL, 60 μg/mL and 100 μg/mL of Ampicillin plates 
were prepared. 
 
2.11 Oligonucleotide primers for PCR 
PCR primers were used to amplify the selected areas of the influenza genome as 
described by Poddar (2002). Primers were resuspended in nuclease free water. 
 
2.12 Oligonucleotides 
A summary of all oligonucleotides used in these studies is presented in Tables 2.1 and 
2.2. Oligonucleotides were purchased as desalted preparations of approximately 40 
nmoL, unless otherwise stated. 
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Table 2.1: Primers for influenza virus type A, type B and subtype-specific target gene amplification by multiplex RT-PCR 
(Poddar, 2002). 
Gene target Sense primer (5’- 3’) Antisense primer (5’-3’) Amplicon size 
(bp) 
Type A/Matrix  
Type/B/NS 
H1    
H3 
NI  
N2   
 
 
CCG AGA TCG CAC AGA GAC TTG AAG AT 
ACA AAT TGA GGT GGG TCC G 
AAT TTG CTA TGG CTG ACG GA 
GCA AGC TTA CAG CAA CTG TT 
AAG GGG TTT TCA TAC AGG TAT GGT 
GGA AAT CGT TCA TAT TAG CCC ATT G 
 
GGC AAG TGC ACC AGC AGA ATA ACT 
ACC AGG GTA GTC AAG GGC T 
CTA CAG AGA CAT AAG CAT TTC 
ATA GTC ACG TTC AGC GCT G 
TCT GTC CAT CCA TTA GGA TCC 
AGC ACA CAT AAC TGG AAA CAA TGC 
 
311 
108 
164 
232 
106 
173 
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Gene target Sense primer (5’- 3’) Antisense primer (5’-3’) Amplicon size 
(bp) 
 
A/Matrix full gene 
 
 
B/NS  full gene  
 
 
SP6 primer 
 
T7 primer 
 
 
 
CTT CTA ACC GAG GTC GAA ACG 
 
AGG ATT TAT TTA GTC ACT CGC AAA C 
 
 
ATT TAG GTG ACA CTA TAG AAT AC 
 
GTA ATA CGA CTC ACT ATA GGG  
 
 
 
TTA CTC CAG CTC TAT GCT GA 
 
TTC ATA AGC ACT GCC TGC TGT AC 
 
 
 
           976 
 
           1056 
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Table 2.2: Oligonucleotides used for cloning. 
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2.13 Cell culture preparation 
2.13.1 Viable cell counts 
Cells in suspension were counted by the method of Absher (1973). Cells grown in tissue 
culture flasks were first trypsinised and resuspended in MEM Maintenance Medium. 
Suspensions were diluted 1:10 and 1:100 in 0.4% (w/v) Trypan Blue and the cell 
concentration determined using a Neubauer haemocytometer. The cell concentration of 
the suspension was determined from the number of unstained viable cells in each of 5 
main squares, according to the following formula: cell count = average cells per square 
x dilution factor (either 10 or 100) x 104 cell mL-1
 
2.13.2 Maintenance of continuous cell cultures 
All continuous lines were grown in either 75 cm2 or 175 cm2 tissue culture flasks in 
MEM Growth Medium in a 37oC, 5% CO2 incubator until confluent. They were 
passaged after washing twice with PBS and dispersing with sufficient trypsin-versene to 
cover the cells. Flasks were then returned to the 37oC incubator until the cells had 
detached from the surface. They were then diluted in MEM Growth Medium and seeded 
to new flasks or tissue culture plates. As a general precaution to minimise mycoplasma 
contamination, cells were only sub-cultured 40-50 times, after which new ampoules 
were retrieved from liquid nitrogen for subsequent culture. For long-term storage, low-
passaged cells were suspended in Cell Freezing Medium at a concentration of 2 x 106 
cells mL-1 and aliquots added to 1 mL cryovials, which were frozen slowly at –80oC in 
foam racks. On following day, the vials were transferred to liquid nitrogen for long-term 
storage. 
 
Cells were recovered from liquid nitrogen storage by quickly thawing a vial at 37oC, 
transferring the contents to a 25 cm2 tissue culture flask containing MEM Growth 
Medium and incubating for 6-16 h at 37oC in a 5% CO2 incubator. The medium was 
then replaced with fresh MEM Growth Medium in order to minimise the toxic effects of 
the DMSO in the Cell Freezing Medium. 
 
2.14 Propagation of viruses 
2.14.1 Growth of influenza virus in eggs 
Ten-to-eleven day old non-specific pathogen-free (NSPF) eggs were swabbed with 70% 
ethanol. Then 100 μL of a 1:1000 dilution of an allantoic preparation of virus were 
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inoculated to the allantoic cavity using a 19 g needle. The egg was sealed with a drop of 
PVA glue and eggs were incubated at 34oC for 2- 3 days in a humidified egg incubator. 
Allantoic fluid was then harvested and clarified by centrifugation at 5,000 x g for 10 
min at 4oC. One-millilitre aliquots of each virus preparation were stored at –80oC. 
 
2.14.2 Cell culture 
Influenza virus was grown in MDCK cell cultures. Cells were grown to 70-80% 
confluence, washed twice with PBS and inoculated with virus. After adsorption for 30 
min at RT with constant rocking, MEM Maintenance Medium (supplemented with 0.1 
μg/L crystalline -trypsin for MDCK cultures) was added and the cultures incubated for 
2-4 days at 37oC in a 5% CO2 incubator until extensive CPE was visible. The infected 
cultures were then subjected to one freeze-thaw cycle and clarified by centrifugation at 
5,000 x g for 5 min and the supernatant dispensed into aliquots and stored at –80oC until 
required.  
 
2.15 Virus titrations 
2.15.1 Influenza virus 
2.15.1.1 Plaque assays 
Plaque assays were performed in 6-well tissue culture dishes with confluent MDCK 
monolayers. Viruses were serially diluted tenfold and 200 μL dilutions were inoculated 
to monolayers, leaving one well as a negative control (inoculated with 200 μL of PBS). 
The monolayers were allowed to adsorb for 30 min at RT with constant rocking. Three 
millilitres of solution containing equal volumes of a 2 x L-15 medium, 1.8% (w/v) 
agarose and 0.1% trypsin was added to each well. Plates were incubated at 34oC for 4 
days. Plates were then stained by adding 2 mL of a staining overlay containing 2 x L-15 
medium, 1.8% (w/v) agarose and 0.008% (w/v) Neutral Red to each well. The plates 
were incubated overnight to allow the stain to penetrate and plaques were counted 
following day (Tannock et al., 1984). 
 
2.15.1.2 Haemagglutination (HA) assays 
Allantoic fluid was tested for the presence of influenza virus by assaying for 
haemagglutinin activity (Anonymous, 1982). Fifty microlitres of harvested allantoic 
fluid were serially diluted two-fold in PBS in Microtiter plates. Then fifty microlitres of 
0.5% (v/v) chicken RBC were added in a V-bottomed microtitre plate and the contents 
T. Peduru Hewa  Chapter Two: Materials and methods 
 
 82
mixed by gently tapping the plate. The plate was incubated at room temperature for 30 
min at RT. The HA titre was determined from the well containing the highest dilution of 
virus that showed complete haemagglutination (streaming of RBCs that occurred when 
the plate was tilted at 45o. 
 
2.15.1.3 Quantal assays of influenza viruses 
MDCK cells were grown to 80% confluence in 96-well culture plates. The monolayers 
were then washed twice with PBS and ten-fold dilutions of 100 μL virus (to 10-10) 
added to wells, using 4 wells for each dilution. Virus was allowed to adsorb for 1 h at 
RT with constant rocking. One hundred microlitres of Maintenance Medium were 
added per well and the plates were incubated at 34oC in a 5% CO2 incubator overnight. 
Medium was then removed from each well by aspiration and the cells gently washed 
twice with PBS and 100 μL/well of cold fixative added. The plate was incubated at RT 
for 10 min and fixative removed and then air-dried before performing an ELISA. The 
plates were washed with three times with Wash Buffer. Then 100 μL of primary 
antibody (anti-Influenza A/B NP monoclonal antibody diluted 1:4000 in Blocking 
Buffer) were added to each well and the plates incubated for 1 h at RT. Plates were 
washed four times with Wash Buffer and 100 μL of secondary antibody (goat anti–
mouse IgG HRP conjugate diluted 1:2000 in Blocking Buffer) added per well and the 
plate held for 1 h at RT. After washing 5 times in Wash Buffer and once in PBS, the 
colour in each well was developed using a TMB substrate reagent kit (TMB Microwell 
Peroxidase System, USA). The optical density of each well at 450 nm was determined 
in an ELISA plate reader. The mean and standard deviation for the 4 uninfected control 
wells were calculated, and the cut-off for positive cells was the mean minus 3 standard 
deviations. Titres were expressed as 50% tissue culture infectious doses (TCID50) 
according to the method of Reed and Muench (1938). 
 
2.16 Haemadsorption 
Confluent MDCK cells were washed twice with PBS and 100 μL of fresh samples were 
inoculated into MDCK cells, and then 1 mL MEM Maintenance Medium (containing 2 
μg/mL of crystalline -trypsin) was added to each well. After 3, 7, 10 and 14 days of 
incubation, plates were examined under the inverted microscope and checked for the 
presence of a CPE.  The supernatant fluid was checked for HA titre. The plates was 
washed twice with PBS and then 2 mL of 0.4% guinea pig RBC or 0.05% chicken RBC 
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added to each well. The plate was incubated 4oC for 30 min irrespective of whether or 
not a CPE was present. Each plate was washed with ice-cold PBS and observed under 
the inverted microscope and the cell sheet examined for adherent RBCs. 
 
2.17 Indirect immunofluorescence assay using the shell vial method 
Cells were grown on the surface of round coverslips (12 mm) in shell vials. When cells 
were confluent, they were washed twice with PBS and then 50 μL of fresh samples 
were added to the coverslips. The shell vials were centrifuged at 700 x g for 60 min and 
after adding 1 mL of Maintenance Medium (containing 1 μg/mL concentration of 
crystalline trypsin) were incubated for 48 h at 34oC in a 5% CO2 incubator. Then cells 
in the vials were washed twice with PBS and fixed by adding 1 mL of chilled 80% 
acetone in PBS mixture for 15 min at 4oC. Then the shell vials were washed twice with 
PBS and 100 μl of primary antibody (influenza A and B mouse monoclonal antibody 
diluted 1:200 in PBS) were added and incubated for 30 min at 37oC in a humidified 
chamber. After washing twice with PBS and 100 μL of FITC-conjugated antibody 
[fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG diluted) 1:200 in 1% 
Evans Blue] were added and incubated for 30 min at 37oC in humidified chamber. The 
shell vials were again washed twice with PBS and once with MilliQ water and the 
coverslips mounted on microscope slides in a drop of 80 % (v/v) glycerol for viewing in 
a fluorescence microscope (Bartholoma and Forbes, 1989). 
 
2.18 Directigen® FLU-A Enzyme immunoassay 
The Directigen® Flu A in vitro enzyme immunoassay membrane test was used for the 
rapid detection of influenza A antigen from nasal washings, according to the 
manufacturer’s instructions. 
 
2.19 Antibody production in Chickens 
Three doses of protein antigen (100 μg/mL) were administered at 3 week intervals.  
Blood samples were collected by the wing vein 1 week after the first two injections. For 
the final bleed chickens were bled from the heart using 19½ gauge needles with 60 mL 
syringes and blood was collected into 50 mL tubes and distributed into 8 mL Vacuette 
tubes. All bloods and a pre-injection sample was incubated at 4oC overnight. The serum 
was separated by centrifugation at 2,500 x g for 10 min and the sera stored at –70oC.   
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2.20 Virus purification 
Allantoic virus was clarified at 3,000 x g for 5 min. The supernatant was then 
centrifuged at 160,0030 x g for 60 min at 4oC using an SW41 Ti rotor in a Beckman 
OptimaTM L-80 XP Ultracentrifuge. The virus pellet was resuspended in a 500 μL of 
TNE buffer. Concentrated virus was centrifuged to a 60% sucrose cushion through a 
30% sucrose interface at 160,030 x g for 90 min using an SW41 Ti rotor in a Beckman 
OptimaTM L-80 XP Ultracentrifuge. Virus was collected by aspiration of 1-2 mL of the 
interface, which was then diluted 1:5 in TNE buffer and pelleted by centrifugation at 
160,030 x g for 60 min using an SW41Ti rotor. It was then resuspended in 0.5-1.0 mL 
of TNE buffer and centrifuged through a 15-60% sucrose gradient at 160,030 x g for 12 
h at 4oC using an SW41Ti rotor in a Beckman OptimaTM L-80 XP Ultracentrifuge. The 
virus band was collected diluted 1:5 in TNE buffer and centrifuged at 160,030 x g for 
60 min at 4oC using an SW41Ti rotor. The pellet was resuspended in a small volume of 
TNE buffer and stored at –70oC (Anonymous, 1982). 
 
2.21 Protein determination 
2.21.1 Bradford assay 
A standard albumin solution (1mg/mL) was used to make protein standards of 0-5 
μg/mL. Forty microlitres of Bradford reagent were added to each well and the contents 
diluted with sterile Milli-Q water up to 200 μL. Results were read on a Dynatech MR 
7000 ELISA reader at 600nm. 
 
2.22 Acid-dependent extraction of M1 protein with non-ionic detergent  
Influenza A (A/PR8/34) and B (B/Lee/40) M1 (matrix) proteins were separated by acid-
dependent extraction with nonionic detergent, as described by Zhirnov (1990; 1992) and 
Zhirnov and Klenk (1997). Allantoic-grown preparations of influenza A and B viruses 
were clarified at 3,000 x g for 5 min. The supernatant was then centrifuged at 160,030 x 
g for 60 min at 4oC using an SW41 Ti rotor. The virus pellet was resuspended in a 0.5-
1.0 mL of TNE buffer. Concentrated virus was purified by sucrose-gradient 
centrifugation. A volume of 0.5 mg/mL virus in TNE buffer was loaded over a two-
layered glycerol gradient containing: 4.45 mL of 15% glycerol (w/w) prepared in 
distilled water (interlayer) and 4.3 mL of 25% glycerol (w/w) (bottom layer) containing 
1% Triton N-101 (TN-101), 5 units of aprotinin, 150 mM NaCl, 5 mM MES 
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(morpholinoethanesulphonic acid) adjusted to pH 7.0 using 1 M Tris –(hydroxymethyl) 
aminomethane. The gradient was centrifuged at 12oC for 2.5 h at 59,764 x g in an SW41 
Ti rotor. Supernatants were carefully removed and the pellets containing virus subunits 
were resuspended in 5% glycerol containing 0.2% Triton N-101, 2.5 units of aprotinin, 
50 mM NaCl and 0.2 M Na2HPO4 adjusted to pH 4.5 using 1M citric acid. The 
suspensions were loaded onto 9.5 mL of 20% glycerol prepared in distilled water and 
centrifuged at 12oC for 1 h and 45 min at 59,764 x g in an SW41 Ti rotor. After 
centrifugation, the top layer containing soluble M1 proteins was decanted. Then the M1 
protein preparation was clarified by centrifuging in 1.0 mL Eppendorf tubes at 12,000 x 
g for 20 min. Finally the M1 protein was concentrated using a Centricon-10,000 MW 
filters. The recovered M1 protein was visualised by electrophoresis in a 12.5% 
polyacrylamide gel followed by Coomassie R-250 gel staining. M1 protein was further 
purified using dialysed against 100 volumes of ice–cold PBS at 4oC for 24 to 48 h with 
one change. The recovery of dialysed protein was checked by Bradford assay and the 
integrity of the dialysed protein determined by electrophoresis on a 12.5% SDS-PAGE 
gel. 
 
2.23 ELISA experiments 
2.23.1 General procedure 
Ninety six well flat-bottomed plates were used to determine antibody titres of chicken 
antisera. The wells were coated with 100 μL of purified M1 protein in Coating Buffer 
and incubated overnight at 4oC. Plates were then washed in PBST and PBS before 
blocking with 200 μL/well of Blotto. Plates were incubated for 1 h at RT, and then 
washed 5 times with PBST and once with PBS. Appropriate serial dilutions of chicken 
antisera in 100 μL of PBST were added and incubated for 1 h at RT. After washing 5 
times in PBST and once with PBS, 100 μL of rabbit anti-chicken IgY (IgG) HRP 
conjugate diluted in Blotto were added to each well and incubated for 1 h at RT. After 
washing plates 5 times in PBST and once with PBS, the plate was developed using 
TMB substrate reagent kit according to the manufacturer’s instructions. Briefly, 
substrate reagent A and B were warmed to RT, mixed 1:1 and then 50 μL/well  were 
added and the plate allowed to develop in the dark for 10 min. Reactions were stopped 
by the addition of 50 μL/well of 2M H2SO4. The plates were read at 450 nm on a 
Dynatech MR 7000 ELISA reader with titres defined as the highest to reach on OD of 
T. Peduru Hewa  Chapter Two: Materials and methods 
 
 86
0.2, which was about 3 times the background level. A row without M1-protein was used 
as negative control in order to eliminate non-specific activity due to residual conjugate. 
 
2.23.2 Sandwich ELISA protocol 
Fifty microlitres of a 1:1,000 dilution of chicken antiserum in Coating Buffer were 
added to each well of a 96-well ELISA plate, which was then held overnight at 37oC in 
a moist chamber. Plates were then washed in PBST and PBS before blocking with 200 
μL/well of Blotto. The plates was washed three times with PBST and then tapped on 
absorbent paper to drain. A 50 μL of amount of each patient’s sample and positive and 
negative control antigens were added to individual wells and the plates incubated at RT 
for 1 h. They were then washed three times with PBST and once with PBS and 50 μL of 
mouse monoclonal antibody to M1 protein of influenza in PBST were added per well 
and the plate held at RT for 1 h. After washing three times with PBST and once with 
PBS, 50 μL of 1:2000 dilution of goat anti-mouse HRP conjugate in ELISA  Diluent 
were added per well and the plate incubated at RT for 1 h. It was then washed three 
times with PBST and once with distilled water and 50 μL of TMB substrate reagent 
added per well and the plate left RT for 10 min to achieve maximum colour 
development. Reactions were stopped with 50 μL of 2 M H2SO4 by gently mixing and 
absorbance was read using a microtiter plate ELISA reader (Dynatech MR 7000) at 450 
nm (Crowther, 1995). 
 
2.24 SDS-PAGE staining 
Once electrophoresis was completed, the gel was removed from its glass plates and 
immersed in Coomassie Blue Staining Solution and shaken for 30 min. Destaining was 
performed in Destaining Solution on a shaker for 30 min or overnight (SDS-PAGE 
buffers and solutions are described in the Section 2.9.6). 
 
2.25 Western blot analysis 
Western blotting was used to transfer proteins to a nitrocellulose membrane (0.2 μm). 
After electrophoresis was complete, the SDS-PAGE gel was removed from its glass 
plates and the stacking gel removed. The resolving gel, nitrocellulose membrane, four 
sheets of Whatman chromatography paper and Scotchbrite pads were soaked in Transfer 
Buffer and placed in the apparatus. The transfer was performed in Transfer Buffer 
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cooled with ice at 70V for 1 h, or 15V overnight. After transfer, the membrane was 
probed by immunoblotting (Bollag et al., 1996). 
 
2.26 Immunoblotting 
After retrieval from the trans-blot unit, the nitrocellulose membrane was blocked in 5% 
(w/v) skim milk in TBS for 1 h. All incubations and washes during immunoblotting 
were performed on a shaker at RT. Sheets were washed twice for 2 min in TBS and 
were then incubated in chicken influenza M1 antiserum, diluted in Blocking Buffer, for 
1 h. The sheets were then washed in TBS for 10 min and incubated with rabbit anti-
chicken IgY (IgG) HRP conjugate diluted in Blocking Buffer for 1 h. After rinsing 
twice in TBS for 2 min, the sheets were developed in a freshly prepared substrate 
solution. The sheets were rinsed in distilled H2O to stop the reaction. 
 
2.27 Silver staining Method 
If the SDS-PAGE gel was stained with Coomassie Brilliant Blue 250, it was rinsed with 
50% methanol overnight with at least two changes of water. Otherwise, it was fixed in 
50% methanol, 10% acetic acid for at least 1 h with 2-3 changes and rinsed for 30 min 
in H2O with at least 3 changes. Solution A, B and C were prepared. The gel was 
removed, placed in a clean container and stained in Solution C for 15 min with gentle 
agitation. Finally the gel was rinsed three times gently with H2O. The gel was placed in 
a clean container and developed in a fresh preparation of Solution D. Finally, the gel 
was removed into 1% acetic acid to stop staining and was washed three times with H2O 
(Bollag et al., 1996).  
 
2.28 Extraction of viral RNA 
2.28.1 Method 1 
Viral RNA was extracted from cell culture supernatants, allantoic fluids and nasal wash 
samples using a QIAamp® Viral RNA Mini Kit according to the manufacturer’s 
instructions. 
 
2.28.1 Method 2 
RNA was extracted by consisted of a modified acid guanidinium thiocyanate-phenol-
chloroform procedure (Sambrook et al., 2001). One hundred microlitres of allantoic 
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fluid containing virus was mixed with 340 μL of denaturing solution consisting of 0.1M 
2- mercaptoethanol in guanidinium thiocyanate buffer. Phenol/chloroform extraction 
was then performed using 5 parts TE-saturated phenol and 1 part chloroform. The 
extracted RNA was then precipitated in isopropanol containing 20 g/L glycogen. 
Following centrifugation at 12,000 x g for 15 min, the RNA was washed with 80% 
ethanol. The ethanol was removed and the pellet allowed to dry. RNA was then 
resuspended in 20 μL of nuclease-free water. 
 
2.29 Reverse transcription-polymerase chain reaction and cycling 
conditions 
RT-PCR was performed using the Titan™ One Tube RT-PCR system according to the 
manufacturer’s instructions. The reaction mixture contained 0.2 mM of each dNTP, 0.4 
μM of each primer, 5 mM DTT solution, 10 μL of 5 x RT-PCR buffer, 1.5 mM MgCl2, 
1 μL of enzyme mix and nuclease–free water to a final volume of 50 μL. The reaction 
was carried out in a GeneAmp PCR 2400 system using the following cycling 
conditions:  reactants were heated to 50oC for 30 min (for cDNA synthesis), followed 
by 94oC for 2 min to denaturation. PCR amplification was carried out over 35 cycles 
with each cycle consisting of a denaturation step at 94oC for 30 s, an annealing step at 
56o C for 30 s, followed by extension at 72oC for 5-10 min. A final extension time at 
72oC for 10 min was applied and the sample was stored at 4oC until required. 
 
2.30 Polymerase chain reaction and cycling conditions 
PCR amplification of DNA targets was carried out using Taq DNA polymerase 
according to the manufacturer’s instructions. PCR was carried out in 50 μL reaction 
volumes with approximately 500 ng of template DNA and in the presence of 1 U of Taq 
DNA polymerase, 0.2 μm of each primer, 0.4 μM of each dNTP and 1.5-4.0 μM MgCl2. 
Reactions were performed using a Gene Amp PCR System 2400. Reactions were 
conducted at 94oC for 2 min, followed by 35 cycles of denaturation at 94oC for 30 s, 
annealing at 50-60oC for 30 s and extension at 72oC for 5-10 min. A final extension 
time at 72oC for 5 min completed the reaction.   
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2.31 Electro-competent cell preparation E. coli (JM109) 
One litre of LBB was inoculated with 1/100 volume of a fresh overnight culture of E. 
coli (JM109) grown in LBB. Cells were grown at 37oC with vigorous shaking to an 
ABS600 of 0.5 to 0.8 (~ 3-4 h). Cells were harvested by chilling the flask on ice for 15-
30 min and centrifuging in a cold rotor at 4000 x g for 15 min. The supernatant was 
removed and cells resuspended to a total volume of 1 L cold water. Cells were 
centrifuged as before and resuspended in 500 mL ice cold water. Centrifugation was 
repeated and the cells resuspended to a final volume of 2-3 mL in 10% (v/v) glycerol at 
a concentration of about 1-3 x 1010 cells/mL. The cell suspension was then frozen in 
aliquots in liquid nitrogen and stored at -70oC. The frozen cells were stored for a 
maximum of 6 months (Sambrook et al., 2001). 
 
2.32 Extraction of plasmid DNA by alkaline lysis  
Plasmid DNA was extracted by alkaline lysis, as described by Sambrook, et al. (2001). 
Individual colonies were inoculated to 2 mL of LB containing ampicillin which was 
incubated overnight at 37oC with constant shaking. Cells in a 1 mL sample were then 
pelleted by centrifugation at 18,000 x g for 1 min and resuspended in 250 μL of chilled 
Miniprep Solution I. Cells were then lysed by the addition of 250 μL of Miniprep 
Solution II and mixed by inversion. Chilled Miniprep Solution III (250 μL) was then 
added and again the samples mixed by inversion and placed on ice for 2 min. The 
samples were then centrifuged at 18,000 x g for 10 min and the supernatant collected. 
Two hundred and fifty microlitres of isopropanol were then added and the samples 
again mixed by inversion. They were incubated at RT for 10 min and then centrifuged at 
18,000 x g for 20 min. The DNA pellets were washed with 400 μL of 70% (v/v) 
ethanol, dried and resuspended in 20 μL of nuclease–free water. 
 
2.33 Plasmid DNA purification 
Small–scale plasmid purification was performed by inoculating broth cultures 
consisting of 5-10 mL of LB containing ampicillin. Cultures were incubated overnight 
at 37oC with constant shaking. Plasmid DNA was purified from 3-5 mL of culture using 
Wizard® Plus SV Miniprep DNA purification system according to the manufacturer’s 
instructions. 
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For large-scale plasmid purification, 2 mL of LB containing ampicillin were inoculated 
and incubated for 8 h at 37oC with constant shaking. Fifty microlitres of the starter 
culture were then used to inoculate a 50 mL culture of LB containing the appropriate 
antibiotic and the culture incubated overnight with constant rotation at 37oC. Plasmid 
DNA was then purified using a QIA filter midi kit, according to the manufacturer’s 
instructions. 
 
2.34 Cloning of viral genes into pGEM-T Easy 
2.34.1 PCR product purification  
 PCR products were purified using a QIAquick® PCR Purification Kit, according to the 
manufacturer’s instructions. 
 
2.34.2 Ligation of DNA 
 Purified PCR products were ligated by the pGEM®-T Easy system (Section 2.3) 
according to the manufacturer’s instructions, using a 1:3 molar ratio of vector DNA to 
insert DNA. Ligations were allowed to proceed for 1-2 h at RT or overnight at 4oC. 
 
2.34.3 Electroporation 
Forty microlitres of a competent cell suspension were mixed with 1-2 μg of DNA in a 
cold 1.5 mL polypropylene tube and stored on ice for 1 min before transferring to a cold 
0.1 cm electroporation cuvette. The Gene Pulser II system was set at 25 μF and 1.25 kV 
with the pulser controller set at 800 Ω. The mixture was pulsed once at these settings 
and then 1 mL of SOC was added. The mixture was then transferred to a 1.5 mL 
polypropylene tube and incubated at 37oC for 1 h. After the incubation, the cell 
suspension was centrifuged 13,000 x g for 2 min and the pellet was resuspended in 100 
μL of fresh SOC medium. Aliquots of 5 μL, 10 μL and 25 μL were spread on the 
culture plates with appropriate antibiotics and incubated at 37oC overnight for analysis 
(Sambrook et al., 2001). 
 
2.34.4 Confirmation of cloning 
Two methods were employed to determine whether inserts had been successfully ligated 
into the vector in selected clones. Plasmid DNA from the miniprep was cut using the 
restriction enzyme EcoR1 and the product electrophoresed on a 1% gel to observe the 
size of the bands. Alternatively, individual white colonies were picked using a toothpick 
T. Peduru Hewa  Chapter Two: Materials and methods 
 
 91
and transferred into the 50 μL of nuclease-free water in an Eppendorf tube after 
duplicating each colony on separate culture plates. Then the cells were boiled in an 
Eppendorf tube for 5 min and PCR was performed to confirm the presence of the insert. 
 
2.35 Nucleotide sequencing 
DNA was purified for sequencing using the QIAquick® PCR purification kit to remove 
salts and other impurities, which may hinder the incorporation of dye terminators. The 
purified DNA was amplified using the BigDye®  Terminator v3.1 Cycle Sequencing kit. 
The amplified DNA was then precipitated using ethanol and sodium acetate, as 
described in the manufacturer’s instructions, and was sequenced using the ABI Prism 
377 DNA Sequencer with XL Upgrade at Monash University, VIC, Australia. 
 
2.36 Pre-treatment of QCM crystals  
To remove impurities and contaminants from the crystal surface, the piezoelectric 
quartz crystal was immersed in 1.2 N NaOH for 30 min, then washed with distilled 
water, air dried and placed for 5 min in 1.2 N HCl. It was then washed with distilled 
water and ethanol and dried in a stream of nitrogen gas (Park and Kim, 1998). 
 
2.37 Antibody immobilisation on a quartz crystal  
One hundred microlitres of 8 μg/mL of mouse monoclonal antibody to M1 protein of 
influenza A in PBS were added onto the surface of the crystal. The crystal was then 
incubated for 37oC for 1 h in humid environment and washed with PBS, rinsed with 
distilled water and dried in a stream of nitrogen gas. 
 
2.38 Antibody immobilisation on a quartz crystal using Protein A 
One hundred microlitres of protein A solution (2 mg/mL in PBS) were added to the 2.54 
cm diameter quartz crystals and incubated at RT in a humid environment for 2 h or 
overnight to immobilise Protein A onto quartz crystals. The crystal was rinsed with 
distilled water and 100 μL of 8 μg/mL of mouse monoclonal antibody to M1 protein of 
influenza in PBS was added onto the surface of the crystal. The crystal was then 
incubated for 37oC for 1 h in humid environment and washed with PBS, rinsed with 
distilled water and dried in a stream of nitrogen gas. 
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2.39 Preparation of colloidal gold 
All glassware used in this preparation were thoroughly cleaned in aqua regia 
(HCl:HNO3 3:1), rinsed in distilled water and oven-dried prior to use. Gold 
nanoparticles were prepared using a method previously reported (Grabar et al., 1995) 
with slight modification. A volume of 190 mL of 5 x 10-3 M of gold (III) chloride 
trihydrate (HAuCl4.3H2O) in distilled water was brought to the boil with vigorous 
stirring in a 500 mL round-bottomed flask. Then 10 mL of 0.5% mL (w/v) of trisodium 
citrate were added. The solution turned deep blue within 20 s and the final colour 
changed to a red colour 60 s later. Boiling the suspension was continued for an 
additional 10 min and the heat source removed and the colloid suspension stirred for a 
further 15 min. The colloidal solution was stored in dark bottles at 4oC.   
 
2.40 Preparation of the antibody-colloidal gold conjugate 
The antibody-colloidal gold conjugate was prepared by the addition of 30 μg of mouse 
monoclonal antibody to M1 protein of influenza virus to 1 mL of colloidal gold (pH 
9.0) solution, followed by incubation at RT with gentle mixing for 1 h. Then 200 μl of 
5% BSA (w/v) in PBS were added into the mixture to stabilise the colloidal gold 
solution and the mixture was incubated for an additional 30 min. The antibody-colloidal 
gold conjugate was centrifuged at 10,000 × g for 10 min. The supernatant fluid 
containing unbound antibody was discarded whilst the red-coloured antibody-colloidal 
gold conjugate pellet was gently resuspended in 1 mL of TBS-BSA. Finally, after a 
second centrifugation step at 10,000 × g for 10 min, the supernatant fluid was removed 
and the antibody-colloidal gold conjugate pellet was resuspended in 100 μL of TBS-
BSA and stored at 4oC (Chu et al., 2006).  
 
 
 
 
 
  
 
 
 
 
CHAPTER THREE 
EVALUATION OF DIFFERENT METHODS FOR THE 
DETECTION OF INFLUENZA VIRUSES 
 
The aim of this thesis was to develop a biosensor method for the rapid diagnosis of the 
influenza viruses and, as a basis for comparison, the suitability and limitations of the 
currently available diagnostic methods were examined. Five widely used methods for 
the diagnosis of influenza, including the standard cell culture method, the shell vial 
method, a conventional and real-time PCR and the Directigen Flu A test, were evaluated, 
using standard egg-grown preparations of A/PR/8/34 and B/Lee/40. Each of these 
methods was evaluated, in comparison with the viral genome copy number (using the 
M1 gene of A/PR/8/34 and the NS gene of B/Lee/40) when measured by real-time PCR.  
 
The standard cell culture method shown to be the most sensitive for A/PR/8/34 and 
B/Lee/40 compared with the other available methods such as the shell vial method, the 
conventional PCR and the BD Directigen Flu A test subsequently. 
 
In the current study, the time for diagnosis by the BD Directigen Flu A kit was 20 min, 
by real-time RT-PCR 10 h, by conventional RT-PCR 24 h, by the shell vial method 48 h 
and by the standard cell culture method 72 h. Overall, when considered for use in rapid 
diagnosis, each of these tests had limitations. 
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3.1 Introduction  
Sensitive and rapid diagnostic methods are required for effective disease management 
and surveillance programmes. In particular, rapid and accurate diagnosis of influenza 
infections is important for clinicians in deciding whether to initiate anti-viral drugs in 
patients at high risk of severe respiratory illness.  
 
Several existing and widely using influenza viral diagnostic methods were evaluated in 
this part of the study. These included a standard reverse transcriptase polymerase chain 
reaction (PCR), which was used for reference (the gold standard for clinical samples in 
Chapter 6), shell vial and standard cell culture isolation methods and the BD Directigen 
Flu A kit. Real-time RT-PCR was also used to estimate the viral RNA copy number in 
samples as an absolute measure of sensitivity but does not measure infectious virus. The 
sensitivities of these methods were determined using serial dilutions of standard 
preparations of egg-grown A/PR/8/34 and B/Lee/40 viruses. Sensitivity is one of the 
main factors to be considered in selecting a diagnostic screening test. Other 
considerations are the simplicity of the method, which contributes to its applicability in 
small decentralised laboratories. 
 
The shell vial and standard cell culture isolation methods are able to detect infectious 
virus. Real-time PCR can, therefore, be used to estimate the RNA copy number in a 
viral population in comparison with the infectious virus titre. In addition, virological 
techniques used in the other parts of the thesis were also used to evaluate the properties 
of egg-grown viruses in this chapter.   
 
The simplest and most commonly used method for detecting influenza virus is the 
haemagglutination (HA) assay, which can be used to quantify virus particles, 
irrespective of whether or not they are infectious. Another commonly used method for 
measuring influenza virus concentration is the plaque assay, a quantitative assay that 
measures infectivity.  
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The HA unit (HAU) is a useful unit for comparative purposes and for most laboratory 
strains of influenza virus, the following relationship has been determined: 
1 HAU = 2 x 105 p.f.u = 107 physical particles, as determined by electron microscopy 
counting (Barrett and Inglis, 1985). 
 
Viruses that cannot produce plaques in cultured cells but cause some detectable CPE 
can be assayed using a quantal endpoint method, in which the dilution that results an 
infection at 50% of replicate hosts is calculated and titres are expressed as 50% 
infectious doses (ID50). 
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3.2 Results 
3.2.1 Evaluation of different diagnostic tests using standard preparations of 
influenza A and B virus 
Titre of virus stocks: 
Preparations of A/PR/8/34 and B/Lee/40 were grown in the embryonated chicken eggs 
using the method given in the Section 2.14.1 and aliquots were stored at -80oC. The titre 
of the preparation of egg-grown influenza A/PR/8/34 was 3.75 x 109 pfu/mL, 1280 
HAU/mL and 10 9.14/mL TCID50. For influenza B/Lee/40 the corresponding titres were 
2.25 x 107 pfu/mL, 640 HAU/mL, 107..25/mL TCID50. 
 
3.2.2 Evaluation of the sensitivity of the RT-PCR 
A series of 10-fold dilutions of egg-grown preparations of A /PR/8/34  (titre 3.75 x 109 
pfu/mL) and B/Lee/40 (2.25 x 107 pfu/mL) were prepared to evaluate the sensitivity of 
the PCR, which was used as the reference or gold standard for subsequent work on 
clinical samples (see Chapter 6). Figure 3.1a and b shows the cDNA amplification 
patterns of RNAs obtained from both viruses. DNA fragments of 311 and 108 bp 
indicate the presence of the influenza A M1 gene and the influenza B NS gene, 
respectively. PCR yields decreased proportionately with increasing dilutions of the virus 
in the initial extraction mixture. The results in Figure 3.1a and b indicate that the M1 
gene of the A/PR/8/34 preparation could be detected at a dilution of 10−7; the 
corresponding dilution for the NS gene of the B/Lee/40 preparation was 10−5. Both 
dilutions had infectious titres of approximately 102 pfu/mL (Section 3.2.4). 
(All experimental figures are shown at the end of this chapter). 
 
3.2.3 Evaluation of the specificity of the RT-PCR 
The specificity of PCRs for influenza A/PR/8/34 and B/Lee/40 were tested separately 
using primers specific for each virus. Extracted RNA of each was tested in a multiplex 
PCR mixture containing two sets of primers. The specificity of each PCR was assessed 
by testing the following reference strains: A/PR/8/34 (H1N1), A/New Caledonia/20/90 
(H1N1), A/Sydney/5/97 (H3N2), A/Panama/2007/99 (H3N2), A/Victoria/3/85 (H3N2), 
B/Lee/40, B/Panama/45/90 and B/Victoria/504/2000. In each test a preparation of 
respiratory syncytial virus was included as a negative control (Figure 3.2). 
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3.2.3.1 Other methods 
The shell vial and standard cell culture methods are well established procedures for the 
detection of influenza viruses in clinical specimens. In the following chapter the 
sensitivity of these and other previously described techniques were evaluated as a basis 
for comparison with QCM methods specific for influenza viruses that are described in 
Chapter 5. Sensitivities of 87.5-90.9%, have been reported for the shell vial technique 
using polyclonal antibody for the detection of antigens, in comparison with standard cell 
culture methods (Batholoma and Forbes, 1989). For the Directigen Flu A kit 
sensitivities of 64.2-84.7% and specificities of from 90-100% have been reported 
(Mercante et al., 1996; Quach et al., 2002).  
 
3.2.4 Evaluation of the sensitivity of the shell vial method 
Ten-fold dilutions of egg-grown viral preparations of A/PR/8/34 (titre 3.75 x 109 
pfu/mL) and B/Lee/40 (2.25 x 107 pfu/mL) were evaluated by the shell vial method 
(Sections 2.17 and 3.2). The detection limit for A/PR/8/34 was a concentration of 
infectious virus of 101 pfu/mL and, for B/Lee/40, 102 pfu/mL (Figure 3.3). 
 
3.2.5 Evaluation of the sensitivity by the standard cell culture method 
The sensitivity of the standard cell culture method using MDCK cultures, as described 
in Section 2.16, was carried out using 10-fold dilutions of the same preparations of 
A/PR/8/34 and B/Lee/40. End-points were determined from the presence of 
haemadsorption. The presence of influenza virus in any haemadsorption- positive 
sample was confirmed by immunofluorescence. From the experiment the detection limit 
was 101 pfu/mL for both virus preparations. 
 
3.2.6 Evaluation of the sensitivity of the Directigen Flu A kit 
Ten-fold serial dilutions of an egg-grown viral sample of influenza A/PR/8/34 (3.75 x 
109 pfu/mL) was used to evaluate the sensitivity of the commercially available 
Directigen Flu A kit, according to the manufacturer’s instructions. The influenza 
B/Lee/40 preparation was undetectable by the Directigen Flu A kit and was used as a 
negative control. The detection limit for A/PR/8/34 was 105 pfu/mL. 
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Table 3.1: Comparison of PCR, the shell vial method, the standard cell culture method 
and the DirectigenFlu A kit for the detection of A/PR/8/34 and B/Lee/40 
 
Lowest infectious titre (log10 pfu/mL) at which virus could be 
detected  
 
Virus 
 
PCR 
    (24 h) 
Shell vial 
method  
(48 h) 
Standard cell 
culture method 
(72 h) 
DirectigenFlu 
A kit  
(20 min) 
 A/PR/8/ 34 2 1 1 5 
B/Lee/40 2 2 1 ND 
 
ND, not done; used as a negative control 
 
These studies indicate that the shell vial method was as sensitive as the standard cell 
culture method for egg-grown A/PR/8/34 but 10-fold less sensitive for B/Lee/40.  The 
PCR method was 10-fold less sensitive for A/PR/8/34 than either the shell vial or 
standard cell culture methods. For B/Lee/40 the PCR was equally sensitive as the shell 
vial but 10-fold less sensitive than the standard cell culture method. The DirectigenFlu 
A kit had the lowest sensitivity, being 10,000-fold less sensitive than the shell vial and 
standard cell culture methods for A/PR/8/34.  
 
3.2.7 Development of real-time PCR assay systems for influenza A and B 
Quantitative real-time PCR assay systems were developed to evaluate the actual copy 
number of the two standard egg-grown preparations of A/PR/8/34 and B/Lee/40 in 
relation to their infectious titre, as determined by the plaque technique. The actual copy 
number is usually higher than the infectious titre because of the presence of non- 
infectious virions and other cellular intermediates of replication that may be released 
when the sample is subjected to freezing and thawing. 
 
The viral titres in samples from patients are not usually evaluated in the routine 
diagnosis of influenza. However, in the current study the sensitivity of the selected 
methods was further evaluated by measuring the influenza viral genome copy number at 
the lowest detectable limit for a particular method.  
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Real-time PCRs were developed for both A/PR/8/34 and B/Lee/40 which were capable 
of detecting the total number of M1 and NS genes from both infectious and non-
infectious particles. Plaque assays are capable of detecting only that portion of the viral 
population that is infectious. 
 
The results obtained by the real-time PCR were compared to other methods described 
above. The relative sensitivity of a particular method was defined in terms of the lowest 
concentration of infectious virus (expressed as pfu/mL) that was detectable by a 
particular test.  
 
cDNA copies of the M1 gene of A/PR/8/34 (956 bp) and the NS gene of B/Lee/40 
(1056 bp) were prepared using primers described in Table 2.2 by RT-PCR.  
These products were cloned into pGEM-T vectors using a TA cloning kit, as described 
in Section 2.34. Recombinant clones were selected after analysing restriction maps of 
clones of pGEM-M1 (Figures 3.4a and b) and pGEM- NS (Figures 3.5a and b). The 
recombinant vectors were then linearised using Sca 1 enzymes of their recombinant 
clones. The M1 and NS genes were transcribed in separate reaction mixtures according 
to the manufacturer’s instructions, using the Riboprobe in vitro transcription system 
with T7 primers (Table 2.2). After transcription, DNA was removed by RQ1 RNase-
Free DNase for 15 min at 37oC digestion. The remaining RNA was quantified by UV-
spectroscopy at 260 nm. The number of RNA copies/mL was calculated by the 
following formula: 
  
6.023 x 1023 [copies mol-1 ;  Avogadro’s number] x concentration g/mL] 
                                                Molecular weight [g/mol] 
= copies /mL 
(Broberg et al., 2003). 
 
An RNA concentration of 1.5 x 1011 copies/5μL was obtained for the M1 gene and 3.75 
x 109 copies/5μL for the NS gene and both were adjusted to 109 copies /5 μL. 
A ten-fold dilution series (dilutions, 1 x 10-1 - 1 x 10-9) was prepared from each RNA 
sample for RT-PCR amplification. Standard curves resulting from this amplification of 
M1 gene RNA and NS gene RNA are shown in Figure 3.6b. 
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3.2.8 Evaluation of the relationship between pfu/mL determined by plaque assays 
and the actual RNA copy number 
Serial 10-fold dilutions of the egg-grown viruses, A/PR/8/34 and B/Lee/40, were used 
to estimate the relationship between viral load, as determined by plaque and the real-
time PCR assays. The results (Figure 3.7) indicate that the real-time RT-PCR was much 
more sensitive than the plaque assay for either virus. It was shown that a concentration 
of 4.54 log10 copies/mL was equivalent to 1 log10 pfu/mL for the A/PR/8/34 preparation 
and 4.46 log10 copies/mL for B/Lee/40. The infectious titre of the lowest detectable 
limits and the actual viral copy numbers for each method are shown in Figure 3.8a and b.  
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             undil    10-1  10-2 10-3 10-4 10-5   10-6 10-7  10-8   10-9  -ve 
 
Figure 3.1a: Serial 10-fold dilutions of total nucleic acids from egg-grown A/PR/8/34 virus 
using single-step PCR. 
Figure 3.1b: Serial 10-fold dilution of total nucleic acids from egg-grown B/Lee/40 virus 
using single-step PCR. 
The dilutions of the samples are indicated. The end lanes are 1 Kb molecular size markers.  
 
            10-2    10-3 10-4    10-5    10-6  10-7    10-8   10-9  -ve 
The dilutions of the samples are indicated. The end lanes are 1 Kb molecular size markers.  
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1.1Kb DNA ladder molecular size marker; 2. A/Sydney/5/97, 3. B/Victoria/504/2000, 4. 
A/Sydney/5/97, 5. A/Victoria/3/85, 6. A/PR/8/34, 7. A/Shearwater/Australia/1/72, 8. 
A/New Caledonia/20/90, 9. A/New Caledonia/20/90, 10. A/Panama/2007/99, 11. 
B/Panama/45/90, 12. B/Lee/40, 13. A/PR/8/34, 14 -15 – ve controls. 
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Figure 3.2: Agarose gel electrophoresis analysis of RT-PCR of different strains of 
 influenza viruses for their type-specific amplified target DNA product(s). 
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Figure 3.3: Sensitivity of the Shell vial method compared with the Directigen Flu A kit test using 
egg-grown A/PR/8/34. 
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                Figure 3.4b: Agarose gel electrophoresis analysis of   influenza A  
recombinant clones. 
1 & 13 1Kb DNA marker,  2-11 A1, A2, A3, A4, A5, A6, A7, A8, A9, A10 
recombinant clones, 12. pGEM-T vector. 
Unlike the M1 gene, the pGEM vector does not contain the BamH 1 cleavage site. A2, 
A8 and A9 were selected as recombinant clones.  
 
Figure 3.4a: Recombinant map of the M1 gene. 
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Figure 3.5a: Recombinant map of NS gene.  
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Figure 3.5b: Agarose gel electrophoresis analysis of influenza B                 
recombinant clones. 
1 & 11 1Kb DNA marker, 2-9. B1, B6, B7, B12, B16, B2, B3, B4 recombinant clones, 
10. pGEM-T vector.  
One Sca 1 restriction site is present in the pGEM vector but not in the NS gene. 
Therefore B7 and B16 were selected as recombinant clones. 
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Figure 3.6a: Amplification plots of the A/PR/8/34 real-time PCR assay obtained with 10-
fold serial dilutions of plasmid standards (10-1-10-9 copies per reaction).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6c: The melting curves of RT-PCR products of A/PR/8/34. 
A single peak of influenza A strain indicates that the real-time RT-PCR product was specific. 
Figure 3.6b: Linearity and efficiency of the RT-PCR assay for A/PR/8/34. 
A Serial 10 fold dilutions of influenza A RNA standard. The linear relationship between log 
concentration and cycle number for 1 x 109 -  1 x 10 1 molecules is shown. The slope of the 
curve of −1.863 indicates maximum efficiency for the PCR reaction.  
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Figure 3.7: Relationship between infectious titre and gene copy number for the 
standard preparations of A/PR/8/34 and B/Lee/40. 
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Figure 3.8a: The relationship between the lowest detectable infectious titre and corresponding 
copy number in the standard preparation of A/PR/8/34, using different tests. 
Figure 3.8b: The relationship between the lowest detectable infectious titre and corresponding 
copy number in the standard preparation of B/Lee/40, using different tests.  
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There is a correlation between the infectious titre and actual copy number for each virus. The 
infectious titre of the lowest detectable limits and the actual viral copy numbers for each method are 
shown in Figures 3.8a and b. The viral genome copy number is always higher than the infectious titre 
of a sample because of the presence of non-infectious particles and other intermediates in replication. 
The limit for detection of the BD kit was 105 pfu/mL.
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3.3 Discussion 
Respiratory viral infections are characterised by a short incubation period (commonly 3-
6 days) in which the peak viral load in nasopharyngeal washes is 103–107 TCID50/mL 
(Nicholson et al., 2003). In samples taken 3-4 days after the onset of symptoms, the 
viral load drops sharply (Nicholson et al., 2003). However, for influenza infections of 
immunocompromised patients (i.e. those infected with HIV or receiving 
immunosuppressive therapy or the frail elderly) such a drop may not occur (Nicholson 
et al., 2003). Rapid diagnostic methods are required at the symptomatic stage of an 
influenza infection for the institution of antiviral drug therapy that is specific for 
influenza viruses. Many respiratory viruses, including parainfluenza viruses, respiratory 
syncytial virus, adeno- and coxsackieviruses, produce clinical symptoms that are 
indistinguishable from influenza (Abed and Boivin, 2006). Rapid diagnostic methods, 
such as the BD Directigen Flu A kit, are simple to use and are widely used as point-of-
care tests in disease management, despite their lower sensitivity compared with other 
tests. The use of cell culture, and especially the shell vial procedure, had been 
recognised for many years as the gold standard for the diagnosis of influenza but is 
relatively labour intensive and requires at least 24-48 h to obtain a result. However, 
infectious virus obtained from such tests can be used for later characterisation.  
 
In Chapter 3 the sensitivity and rapidity of five currently available methods for the 
diagnosis of influenza were evaluated using egg-grown preparations of A/PR/8/34 and 
B/Lee/40. For most tests, differences in sensitivity and specificity have been reported 
between different laboratories. Some of these differences may be due to the quality of 
the sample, which is dependent on conditions of storage and transport for the specimens 
(Batholoma and Forbes, 1989).  
 
Real-time RT-PCR can be used for the quantitative estimation of the viral loads in 
influenza samples, although it provides no information as to the infectivity of the 
sample. Real-time RT-PCR is not widely used in routine diagnosis of influenza but 
could used for the evaluating the effectiveness of antiviral therapy against influenza 
infections (Falsey et al., 2007). 
 
An infectious titre of 102 pfu/mL of the A/PR/8/34 and B/Lee/40 egg-grown reference 
viruses was the lowest that could be detected by conventional RT-PCR (Figure 3.1a and 
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b). For the shell vial assay the lowest detectable infectious titre was 101 for A/PR/8/34 
and 102 pfu/mL for B/Lee/40.  For the standard cell culture method, a titre of 101 
pfu/mL was the lowest that could be detected for both.  A titre of 105 pfu/mL was 
required for A/PR/8/34 using the BD Directiogen Flu A kit. 
 
The lower detectable limit for B/Lee/40, compared with A/PR/8/34, observed in shell 
vial method may have been due to its slower rate of replication. However, after growth 
for 72 h, the standard cell culture method was shown to be equally sensitive for both 
A/PR/8/34 and B/Lee/40 (detection limit 101 pfu/mL). The slower rate of growth of 
B/Lee/40, together with the shorter incubation times used in the shell vial method (48 h), 
may have been responsible for the observed difference in sensitivity. 
 
The viral genome copy number is always higher than the infectious titre of a sample 
because of the presence of non-infectious particles and other intermediates in replication. 
In Figure 3.7 the viral genome copy number and the infectious titre of both A/PR/8/34 
and B/Lee/40 were determined (Figure 3.7). There was little difference in sensitivity for 
either preparation when tests were carried out by different diagnostic methods (Figure 
3.8). Using real-time RT-PCR the lowest viral load that could be detected for A/PR/8/34 
was 4.54 log10 copies/mL (101 pfu/mL) and, for B/Lee/40, 4.46 log10 copies/mL (101 
pfu/mL) (Figure3.7). Under fully optimised conditions a PCR should be sufficiently 
sensitive to detect a single copy of template viral RNA. However, in the current 
evaluation, a much lower sensitivity for PCR than the expected value was observed. 
Possible reasons for this include the presence of PCR inhibitors, proteases or RNases in 
the allantoic fluid of chicken embryos which may have reduced the RNA detection 
threshold (Magnard et al., 1999). Naturally occurring RNases degrade free RNA copies 
in the allantoic extracts and reaction mixtures. Naturally occurring proteases also 
degrade the reverse transcriptase and Taq polymerase enzymes in the reaction mixture, 
which can reduce the yield of the PCR product(s). In addition, the sensitivity of a PCR 
is reduced by the need for a concentration of at least 100 ng of DNA in order to 
visualise a DNA on an agarose gel in the reading of the test.  
 
Real-time RT-PCR allows the detection of amplicon accumulation since it is performed 
using the fluorogenic dye or a DNA intercalating dye, such as SYBR Green 1, rather 
than by conventional end-point analysis. As there is no need for a post-amplification 
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procedure, such as gel electrophoresis, the test can be completed rapidly (Ramaakers et 
al., 2003). In the present study real-time RT-PCR was 4000-fold more sensitive than 
infectivity-based diagnostic methods (Figure 3.7). 
 
The rapidity of these diagnostic methods was also evaluated, as the time for completion 
has been identified as a major limiting factor for their suitability for use in screening 
influenza infections (Magnard et al., 1999). In the current study, using egg-grown 
viruses, the time for the diagnosis by the BD Directigen Flu A kit was shown to be 20 
min, 10 h for real-time RT-PCR, 24 h for conventional RT-PCR, 48 h for shell vial 
assay and 72 h for standard cell culture method. Therefore, neither the standard cell 
culture or shell vial methods are suitable for screening purposes but can be used as 
confirmatory methods. The processing times for the BD Directigen Flu A, conventional 
RT-PCR and real-time RT-PCR methods are much more rapid but each has major 
limitations. For example, the BD Directigen Flu A kit method has low sensitivity. The 
use of conventional RT-PCR is limited because of the presence of inhibitors in samples 
and the need for high technical skills and an expensive instrument. Real-time RT-PCR 
also needs high technical skill and an expensive instrument. Therefore, an ideal 
diagnostic method for the rapid diagnosis of influenza is not currently available.   
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CHAPTER FOUR  
DEVELOPMENT OF ELISAS FOR THE DETECTION OF 
INFLUENZA A AND B VIRUSES USING MABS AND ANTISERA 
PREPARED AGAINST PURIFIED M1 PROTEINS 
 
In this chapter antigen ELISAs were developed to provide an indication of the 
suitability of reagents for use in the development of a QCM biosensor. ELISAs were 
developed to allow detection of all influenza A or B viruses, respective of changes to 
their HA and NA surface antigens, and for their eventual application to clinical 
specimens.  
 
The current study was initiated using type-specific and conserved viral M1 proteins of 
both A/PR/8/34 and B/Lee/40 viruses which do not vary between subtypes. The M1 
proteins of A/PR/8/34 and B/Lee/40 were separated from other viral proteins and their 
specificity and biological activity were confirmed. Polyclonal antisera prepared in 
chickens induced antibody titres of 1:12,900 for A/PR/8/34 M1 and 1: 78,000 for 
B/Lee/40 M1. There were no cross-reactions between the antisera and M1 proteins of 
A/PR/8/34 and B/Lee/40.   
 
The sensitivity and the specificity of the M1-specific MAbs and polyclonal antisera 
prepared against A/PR/8/34 and B/Lee/40 were analysed and compared for their 
suitability to detect influenza viruses. The sensitivity of the ELISA for the detection of 
purified A/PR/8/34 and B/Lee/40 viruses was 20 μg/mL and 14  μg/mL for polyclonal 
antibody and 30 μg/mL and 20 μg/mL for MAbs, respectively. The limit of detection 
for each virus was 104 pfu/mL, irrespective of whether antisera or MAbs were used for 
capture. Non-purified cell culture grown preparations of either virus could be detected 
at 103 pfu/mL. 
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4.1 Introduction 
The objective of the work described in this chapter was the development of a type-
specific antigen ELISA for the detection of influenza A and B viruses. Two antigens 
were considered for the ELISA, the M1 and NP proteins, both of which have highly 
conserved type-specific amino acid sequences between influenza A and B sub-types and 
are not subject to the continuous antigenic variation seen with the HA and NA surface 
glycoproteins (Bucher et al.,1987; Bucher et al., 1991). Reagents developed for the 
ELISA were standardised for use in the development of a QCM biosensor to be 
described in Chapter 5.  
 
The influenza M1 protein is an important type-specific antigen for the detection of 
influenza viruses by immunochemical techniques. It is a major structural antigen of the 
virion and provides significant antigenic mass for use in the preparation of high titre 
polyclonal antisera (Bucher et al., 1987). The M1 protein comprises 35-45% of the total 
viral protein (approximately 3000 molecules) while the other type-specific antigen, the 
NP protein, is less abundant (approximately 1000 molecules) and less antigenic (Bucher 
et al., 1987; Lamb and Krug, 2001). Because of these properties, Ml was considered as 
a suitable antigen for use in the development of biosensor for the detection of infection 
and for the discrimination between influenza A and B viruses.  
 
The M1 protein of A/PR/8/34 and B/Lee/40 sequences were selected from the National 
Centre for Biotechnology Information http://www.ncbi.nlm.nih.gov/
Accession numbers:  A/PR/8/34 - CY009445.1; B/Lee/40 - DQ792900.1     
The multiple protein alignment was done with CLUSTAL W (1.8), a software available 
from the Internet (http://bioweb.pasteur.fr/seqanal/interfaces/clustalw. html). 
According to alignments with the sequence of A/PR/8/34 and B/Lee/40 M1 proteins, 
overall identity was 28.46% (Figure 4.1).    
 
4.1.1 M1 protein  
The M1 protein is highly hydrophobic and poorly soluble in water. Treatment of 
influenza viruses with non-ionic detergents, such as Triton x-100 and Nonidet-P40, in 
low salt concentrations at low pH effectively increases the solubilisation of the M1 
protein (Zhirnov, 1990; Ruigrok et al., 2001). M1-RNP linkages are sensitive to acidic 
pH and it is important in M1 purification that these linkages do not form (Zhirnov, 
1992). Treatment with detergent under acidic conditions was used to isolate the M1 
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protein from the other viral proteins, using methods described by Zhirnov (1990; 1992), 
who showed that the M1 protein isolated under these conditions retained its biological 
properties.  
 
4.1.2 Structure of the M1 protein 
The M1 protein has two protein domains, an N-terminal domain containing amino acid 
residues 1-164 and a C-terminal domain containing amino acid residues 165-252. M1 
also has a basic amino acid cluster at position 101-105 and a zinc-finger motif at 
position 148-162. The basic amino acid has been shown to bind viral RNA (Ruigrok et 
al., 2001; Ye et al., 2001). The N-terminal domain has two bundles of four α−helices 
packed together to form a hydrophobic interface. Crystals formed at low pH consist of 
two monomers of M1 packed as a dimer with antiparallel orientation. The crystal 
structure of the stable M1 fragment consists of nine α−helices (H1–H9), eight loop 
regions (L1–L8) but no β helix. H1, H2, H3 and H4 comprise the first domain (amino 
acids 2–67) and H6, H7, H8 and H9 the second (amino acids 91–158). The first and 
second domains are linked by a coil which contains a short helix (H5) (Sha and Luo, 
1997; Harris et al., 2001).  
Fig. 4.2 shows the crystalline structure of the M1 protein. 
 
4.1.3 Immunological interactions 
Interactions between antibodies with antigens form the basis of all immunological 
techniques. Immunoassays are quantitative techniques that depend on the reactions 
between analytes (antigens) and detector molecules (antibodies). The high affinity and 
specificity of an antibody for an antigen is conferred by molecular complementarity. 
There are five different classes of mammalian immunoglobulins (G, A, M, D, and E), 
but the majority of immunoassays are performed with immunoglobulin G (IgG). The 
regions responsible for the binding are the epitope in the antigen and the paratope of the 
antibody. The properties of the antibody-antigen interactions can be characterised by 
their structure, their strength (affinity) and their stability (avidity).  
 
All IgGs are bivalent, but their ability to bind bivalently to the surface of a virus particle 
depends mainly on cognate epitopes and the angle of the FAb arm attached to the virus 
surface. This is a concentration-dependent process and aggregation is lost at high IgG 
concentrations when epitopes become saturated (Dimmock and Hardy, 2004) 
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In the current study, type-specific polyclonal as well as monoclonal antibodies were 
tested for their sensitivities when used in ELISAs for the detection of influenza A and B 
viruses. Anti-influenza M1 polyclonal antibodies were prepared by injection of the 
isolated influenza M1 protein to chickens. Monoclonal antibodies were purchased 
commercially. In chickens and lower vertebrates the antibody corresponding to IgG is 
IgY. The IgY molecule has the same general structure as mammalian IgG but lacks the 
Fc domain and cannot fix complement or bind to Protein-A or -G (West, et al., 2004). 
In the following studies SPF chickens were used to raise polyclonal antibodies against 
the M1 protein of influenza A and B viruses. SPF chickens have been used in other 
studies to prepare antisera to influenza antigens (Tamm, 1968) and are relatively cheap 
and readily available. A theoretical advantage of their use is that antibodies to 
contaminating egg-derived proteins from egg-grown viruses are not produced in 
chickens. In this chapter, antigen ELISAs were developed and optimised using 
monoclonal and polyclonal antibodies against the M1 antigen. These parameters were 
used as a basis for optimising the QCM (Chapter 5).  
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  APR834          MSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEVLMEWLKTRPILSPLTKGIL 
  BLee40          MSLFGDTIAYLLSLIEDGEGKAELAEKLHCWFGGKEFDLDSALEWIKNKRCLTDIQKALI 
                  ***: :. :*:**:* .*  ***:*::*.  *.**: **:  :**:*.:  *: : *.:: 
 
  APR834          GFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLYR-KLKREITFHGAKEISLSY 
  BLee40          GASICFLKPKDQ-ERKRRFITEPLSGMGTTATKKKGLILAERKMRRCVSFHEAFEIAEGH 
                  *  : :  *.::  ::***: :.*.* * . . .*.: * . *::* ::** * **: .: 
 
  APR834          SAGALASCMGLIYNRMGAVTTEVAFGLVCATCEQIADSQHRSHRQMVXTTNPLIRHENRM 
  BLee40          ESSALLYCLMVMYLNPENYSMQVKLGTLCALCEKQASHSHRAHSRAARSSVPGVRREMQM 
                  .:.**  *: ::* .    : :* :* :** **: *. .**:* : . :: * :*:* :* 
 
  APR834          VLASTTAKAMEQMAGSSEQAAEAMEVAIRARQMVQAMRTIGTHPSSSAGLKNDLLENLQA 
  BLee40          VSAMNTAKTMNGMG----KGEDVQRLAEELQNNIGVLRSLGASQKNGEGIAKDVMEVLKQ 
                  * * .***:*: *.    :. :. .:* . :: : .:*::*:  ... *: :*::* *:  
 
  APR834          YQKRMGVQMQRFK 
  BLee40          SSMGNSALVRKYL 
                  .   .. ::::  
 
 
             Figure 4.1: Clustal W alignment  of  M1 protein sequences of A/PR/8/34 and B/Lee/40. 
 
 
The overall identity was 28.46% 
Identical (*) 
Conserved substitution (:) 
Semi-conserved substitution (.) 
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Figure 4.2: The structure of an M1 monomer at neutral pH (blue) superimposed 
on an M1 monomer at acidic pH (gold). 
 
 
Helices are labelled H1-H9 and N- and C-terminals are indicated.  
(Adapted from Harris et al., 2001).  
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4.2 Results 
4.2.1 Isolation of influenza A and B matrix proteins 
 The M1 proteins from A/PR/8/34 and B/Lee/40 were separated from other viral 
proteins by an acid-dependent extraction method using nonionic detergent, as described 
in Section 2.22. Electrophoresis of 4-5 μg of purified M1 proteins from each virus was 
performed under nonreducing conditions on SDS-polyacrylamide gels (see Section 
2.24). The M1 protein of A/PR/8/34 was visualised by Coomassie Blue staining in 
Figure 4.3a. The results indicate the presence of a single band with an Rm of 27.8 kDa, 
as described by Zhirnov (1991, 1992). Further analysis using the more sensitive silver 
staining method also indicated the presence of a single protein with an Rm of 27.8 kDa 
(Figure 4.3b). (All experimental figures are shown at the end of this chapter). 
 
4.2.2 Development of an ELISA for the detection of M1 protein 
4.2.2.1 Determination of optimal M1 protein concentration    
Chequerboard titrations were carried out using both MAbs against different 
concentrations of purified M1 proteins. From data obtained for the M1 protein of 
A/PR/8/34 (Figure 4.4a) a concentration of 0.025 mg/mL, which produced the highest 
signal and lowest background, was chosen for use in subsequent tests. For the M1 
protein of B/Lee/40 (Figure 4.4b), a concentration of 0.00625 mg/mL was used. In 
Figure 4.5 a and b, the binding characteristics of both antisera and MAbs were tested 
against different concentrations of corresponding M1 preparations. Figures 4.5 a and b 
clearly show that greater binding of M1 proteins of influenza A/PR/8/34 and B/Lee/40 
occurred with polyclonal antisera than with either of the MAbs.   
 
4.2.2.2 Determination of the optimal conjugate dilution for use in the ELISA 
The optimal dilution of enzyme-conjugated anti-IgG for maximum specific activity 
(signal) and minimum non-specific binding (background) was determined. A 
chequerboard titration was performed using various dilutions of polyclonal or 
monoclonal antibody and conjugate (HRP) dilutions. A 1:1,000 dilution of the rabbit 
anti-chicken IgY (IgG) HRP conjugate was optimal for polyclonal antibody (Figure 
4.6a) and the same dilution was also optimal for monoclonal antibody, using goat anti-
mouse HRP conjugate (Figure 4.6b). All monoclonal antibody dilutions were in the 
range used for M1 detection and a dilution of the conjugate of 1:1,000 was selected for 
use in subsequent ELISA studies.  
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4.2.3 Preparation of antisera 
Purified M1 proteins of A/PR/8/34 and B/Lee/40 were used to prepare polyclonal 
antisera in chickens. Each antigen was injected to three chickens, as described in 
Section 2.19. A blood sample was collected from each chicken prior to injection. The 
activity and specificity of the antisera obtained were measured by an indirect ELISA, 
using the purified M1 protein as the antigen (Section 2.23.1). Figures 4.7 and 4.8 show 
the titre increase following the first, second and third dose for each chicken injected 
with purified M1 proteins of A/PR/8/34 or B/Lee/40.   
 
Data analysis for antibody titration: 
Analysis of the data was prepared using the program Prism 4.0 (GraphPad software Inc, 
San Diego, USA) and curves were generated by non-linear regression analysis. The IC50 
value for each antibody preparation was determined by analysis of the sigmoid dose-
response curve, using the following equation:  
Y = bottom + (top – bottom)/ (1+ 10^ (Log IC50 –X)), 
where X is the logarithm of concentration and Y the response. Y starts at the bottom and 
goes to the top following a sigmoid curve. 
The mid or inflexion point (IC50) is the analyte concentration that reduces the maximum 
absorbance by 50%.  
 
 Table 4.1: Serum titres against purified M1 proteins prepared from A/PR/8/34 
and B/Lee/40: 
Dose Virus Chicken 
1a 2a 3a
A1 359 29,854 12,955 
A2 20 954 1,444 
 
A/PR/8/34 
A3 319 6,931 8,085 
B1 14 251 65,815 
B2 4 1,300 10,934 
 
B/Lee/40 
B3 100 4,737 78,223 
 
a   Antibody titres were determined as IC50 values (see Figures 4.7 and 4.8).   
Sera from A1 and B3 had the highest titres and were used in subsequent experiments. 
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4.2.4 Specificity of chicken antisera for M1 protein 
Chicken antisera were tested for their specificity by a spot immunoassay using the 
protocol described in Section 2.26. Small spots containing 3-4 μg of purified M1 
proteins from A/PR/8/34 and B/Lee/40 were applied to nitrocellulose membranes. The 
results in Figure 4.9a show that specific reactions occurred between both antisera and 
their purified M1 proteins. No reactions occurred when the tests were carried out in 
reverse (Figures 4.9 b and c).   
 
The specificity of antisera for M1 proteins was confirmed by Western blot analysis.  
Figure 4.10 shows the presence of a single band that was specific for the A/PR/8/34 M1 
antiserum (A1 chicken serum) and similar findings were obtained for the B/Lee/40 M1 
antiserum (B3; results not shown).    
  
4.2.5 Binding characteristics of polyclonal antisera prepared against A/PR/8/34 
and B/Lee/40 compared with MAbs specific for influenza A and B viruses  
The following studies were carried out to provide an indication of the most suitable 
conditions for virus capture in the QCM (see Chapter 5). Chequerboard titrations were 
carried out using different virus and antibody concentrations to determine conditions for 
maximum specific activity (signal) with minimum non-specific binding (background) 
by an indirect ELISA. 
 
4.2.5.1 Binding kinetics of antisera prepared in chickens against the M1 proteins of 
A/PR/8/34 and B/Lee/40 
Dilutions of serum from chicken A1 (with the highest titre) were tested against different 
concentrations of purified A/PR/8/34. Figure 4.11a shows that optimum binding (i.e. 
high signal and low background) was achieved at a serum dilution of 1:800 (1:100 – 1: 
6,400) and a virus concentration of 20 μg/mL. For B/Lee/40, similar binding was 
achieved at a serum dilution of 1:400 (1:200 – 1: 6,400) (using chicken B3) and a virus 
concentration of 14 μg/mL (Figure 4.11b). 
.  
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4.2.5.2 Binding kinetics of MAbs against the M1 proteins of A/PR/8/34 and 
B/Lee/40  
Dilutions of monoclonal antibody were tested against different concentrations of 
purified A/PR/8/34. Figure 4.12a shows that optimum binding was achieved at an 
antibody concentration of 8 μg/mL (dilutions 1: 16 μg/mL – 1: 0.125 μg/mL) and a 
virus concentration of 30 μg/mL. For B/Lee/40 similar binding was observed at an 
antibody concentration of 4 μg/mL (dilutions 1: 4 μg/mL – 1: 0.0625 μg/mL) and a 
virus concentration 20 μg/mL (Figure 4.12b). 
 
Antisera prepared against the M1 protein of A/PR/8/34 and B/Lee/40 at dilutions of 
1:100 - 1: 25,600 produced absorbances that were 20% higher than MAbs for both 
viruses over the same dilution range from an initial concentration of 8 μg/mL (see 
Figure 4.5 a and b). 
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Figure 4.3a:  Isolation of M1 protein of A/PR/8/34 by electrophoresis in a 12.5% 
polyacrylamide gel followed by Coomassie Blue R-250 staining. 
Lanes 1- 4: purified M1 protein; Lane 5: protein marker; Lane 6: virus proteins from whole 
purified A/PR/8/34 
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Figure 4.3b: Isolation of M1 protein of A/PR/8/34 by electrophoresis in a 12.5% 
polyacrylamide gel followed by silver gel staining. 
Lane1 – 4: purified M1 protein; Lane 5: protein marker; Lane 6: virus proteins from whole purified 
A/PR/8/34 
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                             Figure 4.4a: Titration curves of M1 protein at different concentrations of 
 influenza A M1 MAb  
Each line is derived from data obtained from the same dilution of influenza A M1 antigen using different 
concentrations of  M1 MAb (8 μg/mL - 0.015 μg/mL at 2-fold dilutions from 1: 125). 
Figure 4.4b: Titration curves of M1 protein at different concentrations of 
 influenza B M1 MAb. 
Each line is derived from data obtained from the same dilution of influenza B M1 antigen using 
different concentrations of M1 MAb (8 μg/mL – 0.063 μg/mL at 2- fold dilutions from 1: 125). 
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Figure 4.5a: Reactions between polyclonal antibody and MAb and purified influenza A/PR/8/34 
M1 protein.  
Each line shows data obtained from the same concentration of influenza A M1 antigen (0.025 mg/mL)  
and different concentrations of  M1 MAb (8 μg/mL - 0.015 μg/mL at 2- fold dilutions) and polyclonal 
antibody (1: 100 – 1: 25,600). 
Figure 4.5b: Reactions between polyclonal antibody and MAb and purified influenza 
B/Lee/40 M1 protein. 
Each line shows data obtained from  the same concentration of influenza B M1 antigen (0.00625 
mg/mL) and different concentrations of  influenza B MAb (8 μg/mL – 0.003 μg/mL at 2-fold 
dilutions) and polyclonal antibody (1: 100 – 1: 25,600).
 124
T. Peduru Hewa  Chapter Four: Development of ELISAs  
 
2.00 2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.00 4.25 4.50 4.75 5.00
0.0
0.5
1.0
1.5
2.0 1:500 dilution
1:1000 dilution
1:2000 dilution
1:4000 dilution
1:8000 dilution
-ve contro l
-Log10 [Chicken serum]
A
bs
or
ba
nc
e 
nm
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
0.0
0.5
1.0
1.5
2.0
2.5
1:500 dilution
1:1000 dilution
1:2000 dilution
1:4000 dilution
1:8000 dilution
-ve control
-Log10 [MAb]
A
bs
or
ba
nc
e 
nm
 
 
 
 
 
Figure 4.6a: Titration curves for rabbit anti-chicken HRP conjugate and dilutions of chicken 
serum. 
Each line shows data obtained from the same concentration of rabbit anti-chicken HRP conjugate, 
using different concentrations of chicken A antiserum (1: 200 – 1: 256, 000 at 2-fold dilutions). 
Figure 4.6b: Titration curves for goat anti-mouse HRP conjugate and dilutions of mouse 
MAb. 
Each line shows data obtained from the same concentration of goat anti-mouse HRP conjugate, 
using different concentrations of mouse MAb (16 μg/mL – 0.125 μg/mL at 2-fold dilutions). 
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Figure 4.7a: Antibody responses to influenza A  
M1 protein in chicken A1 after different doses. 
  Figure 4.7b: Antibody responses to influenza A  
  M1 protein in chicken A2 after different doses. 
 
 
 
 
      Figure 4.7c: Antibody responses to influenza A  
M1 protein in chicken A3 after different doses. 
Chicken antisera A were diluted two-fold (1: 32 – 1: 65,536) and against M1 antigen  
(0.025 mg/mL). 
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Figure 4.8a: Antibody responses to influenza B 
M1 protein in chicken B1 after different doses. 
 
 
 
 
Figure 4.8b: Antibody responses to influenza B 
M1 protein in chicken B2 after different doses.
Figure 4.8c: Antibody responses to influenza B 
M1 protein in chicken B3 after different doses. 
Chicken antisera B were diluted two-fold (1: 32 – 1: 65,536) and against M1 
antigen (0.00625 mg/mL).  
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Figure 4.9a: Spot immunoassay for influenza A and B M1 proteins. 
A - Reaction between chicken influenza A M1 antiserum and purified influenza A M1 protein. 
B  - Reaction between chicken influenza B M1 antiserum and purified influenza B M1 protein.  
Figure 4.9b: Spot immunoassay for influenza A M1 protein. 
Absence of specificity for M1 protein of A/PR/8/34 and antiserum prepared against B/Lee/40. 
Figure 4.9c: Spot immunoassay for influenza B M1 protein. 
Absence of specificity for M1 protein of B/Lee/40 and antiserum prepared against A/PR/8/34. 
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Figure 4.10: Western blot analysis of influenza M1 protein, after electrophoresis under 
nonreducing conditions and transfer. 
The nitrocellulose strip was incubated with influenza A M1 antiserum raised in chickens. 
Lane 1:  protein marker; Lanes 2, 3 4 and 5: M1 protein from A/PR/8/ 34. 
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Figure 4.11a: Titration curves for purified influenza A/PR/8/34 virus against different dilutions 
of influenza A M1 antiserum. 
Each line represents results for the same dilution of M1 antiserum and different concentrations of 
A/PR/8/34 (400 μg/mL – 0.4 μg/mL). 
 
 
 
 
 
 
 
 
 
Figure 4.11b: Titration curves for purified influenza B/Lee/40 virus against different 
dilutions of influenza B M1 antiserum. 
Each line represents results for the same dilution of M1 antiserum and different 
concentrations of B/Lee/40 (400 μg/mL – 0.4 μg/mL). 
 
 
 130
T. Peduru Hewa  Chapter Four: Development of ELISAs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12b: Titration curves for purified influenza B/Lee/40 virus against 
different concentrations of influenza B M1 MAb. 
Each line represents results for each concentration of M1 MAb against a range of 
influenza B/Lee/40 (400 μg/mL – 0.4 μg/mL). 
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Figure 4.12a: Titration curves for purified influenza A/PR/8/34 virus against different 
concentrations of influenza A M1 MAb. 
Each line represents results for each concentration of M1 MAb against a range of influenza 
A/PR/8/34 (400 μg/mL – 0.4 μg/mL).  
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4.3 Discussion 
In this chapter antigen ELISAs were developed to provide an indication of the 
suitability of reagents for use in the development of a QCM biosensor (see Chapter 5). 
Both the ELISAs and the QCM were developed to allow detection of all influenza A or 
B viruses, respective of changes to their HA and NA surface antigens, and for their 
eventual application to clinical specimens.  
 
The rationale for use of the type-specific M1 proteins of A/PR/8/34 and B/Lee/40 has 
been outlined in the Introduction. Both were prepared from purified egg-grown allantoic 
virus preparations by methods described by Zhirnov (1990, 1992) and each was shown 
to contain a single band of Rm 27.8 kDa when analysed by PAGE (Figure 4.3 a and b), 
which was confirmed by Western blots (Figure 4.10). Western blots also indicated that 
the capacity of isolated M1 protein to bind specific antibody was unchanged by the 
extraction procedure (Figure 4.10). Purified preparations of both M1 proteins induced 
high levels of antibody to each M1 in chickens after 3 injections to produce titres of 
1:12 900 for A/PR/8/34 M1 and 1: 78000 for B/Lee/40 M1 (Table 4.1). These antisera 
were tested for their specificity using a spot test on a nitrocellulose membrane (Figure 
4.9). No cross-reactions were detected between antisera prepared against the M1 
proteins of A/PR/8/34 and B/Lee/40.   
 
The sensitivity and the specificity of the M1 specific MAbs and polyclonal antisera of 
A/PR/8/34 and B/Lee/40 were analysed by chequerboard titrations (Figures 4.4 and 4.5). 
Polyclonal antisera were shown to bind M1 antigens to a greater extent than the 
corresponding MAbs (Figure 4.5). Such a result is not unexpected since MAbs target 
only a very small number of epitopes (commonly one), whereas polyclonal antibodies 
have the capacity to bind many epitopes and, therefore, higher levels of binding could 
be expected. Polyclonal antisera prepared against HA were shown to have a greater 
capacity to bind the HAs of influenza A and B viruses than MAbs prepared against the 
same antigens (Phillips, et al., 1982; Walls et al., 1986).   
 
Reactions between the M1 antigens of A/PR/8/34 and B/Lee/40 and specific antisera are 
shown in Figures 4.7 and 4.8. Typical sigmoid binding curves can be seen, with the 
linear parts of each curve representing the conditions of equivalence in the interaction 
between antibody and antigen (Bishai and Galli, 1978; Edevag et al., 1986). The mid-
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point of this part of the curve (the inflexion point) was used to estimate the antibody 
titre of each serum.  
 
Other chequerboard titrations were carried out to determine optimum conditions for the 
capture of influenza A/PR/8/34 and B/Lee/40 using polyclonal antisera and MAbs 
specific for M1 antigens. This experiment was undertaken in an attempt to provide an 
indication of the most suitable conditions for virus capture in the QCM (see Chapter 5). 
In Figure 4.11a the inflexion point at an antiserum dilution of 1:800 was an A/PR/8/34 
concentration of 20 μg/mL. For B/Lee/40, the inflexion point at a serum dilution of 
1:400 was 14 μg/mL (Figure 4.11b). The inflexion points using optimum MAb 
concentrations were 30 μg/mL for A/PR/8/34 and 20 μg/mL for B/Lee/40 (Figures 4.12 
a and b). Previous reports have shown that the lowest limits of detection by ELISA for 
purified influenza A/PR/8/34, A/Taiwan/1/86, A/Philippines/2/82 and B/Lee/40 using 
M1 and NP MAb for capture were 7-10 μg/mL, respectively (Walls et al., 1986; 
Coonrod et al., 1988; Glikmann, 1995 a and b).  
 
When tested by the plaque technique, the limit for detection of both A/PR/8/34 and 
B/Lee/40 was 104 pfu/mL, irrespective of whether antisera or MAbs were used for 
capture (data not presented). In a separate experiment non-purified cell culture-grown 
preparations of either virus could be detected to a level of 103 pfu/mL (data not 
presented). The difference in sensitivity is due to the presence of non-infectious virus 
and other viral components in unpurified viral preparations, in addition to infectious 
virus. 
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CHAPTER FIVE 
THE DEVELOPMENT OF A QCM-BASED BIOSENSOR FOR THE 
DETECTION OF INFLUENZA VIRUSES 
 
This chapter describes the development of a QCM-based biosensor for the detection of 
influenza A and B viruses. The QCM was developed, utilising the same reagents used 
for the development of the ELISA methods described in Chapter 4. A number of 
parameters were then further optimised during the development of this sensor to 
improve the sensitivity of detection. The parameters addressed included blocking of 
non-specific binding, the flow cell compression effect, carrier buffer pH, flow rate, 
antibody concentration and the use of Protein A on the crystal surface.  
 
The lowest virus concentration that could be detected under these conditions was 104 
pfu/mL for egg-grown preparations of both A/PR/8/34 and B/Lee/40. Conjugation of 13 
nm gold nanoparticles to the second (detect) antibody resulted in a 10-fold increase in 
sensitivity with a measurable detection limit of 103 pfu/mL. The sensitivity obtained 
with this sensor was sufficient to allow its evaluation with clinical samples from 
patients infected with influenza viruses. 
. 
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5.1 Introduction 
Biosensors based on an immunological interaction at the surface of a transducer that 
results in an electrical signal, have recently received much attention. Piezoelectric 
immunoassay procedures employing the quartz crystal microbalance (QCM) have been 
used in a wide range of applications in the food industry and for use in environmental 
monitoring and clinical diagnostics (Kurosawa et al., 2006; Pejcic et al., 2006). 
 
The QCM technique offers a number of advantages including small size and minimal 
electronic requirements of the equipment used, which is also inexpensive, simple to 
operate, with results being easy to interpret and read in real-time using automated 
monitoring equipment (Lee and Chang, 2005). Once the detection system has been 
optimised, minimal sample preparation and a very short time for data acquisition is 
required compared with most other immunoassay techniques (Eun et al., 2002). ELISA 
and QCM immunosensors are analytical methods that incorporate either an antibody or 
an antigen immobilised on a solid phase for the purpose of selectively detecting an 
analyte. The ELISA technique involves the use of a labelled antibody for detection and 
multiple steps are required in the procedure. By contrast, the QCM technique does not 
require a labelled antibody for detection of the molecular interaction on the QCM 
crystal surface (Park et al., 2003). 
 
5.1.1 The QCM sensor 
The QCM sensor system is a mass sensing device with the ability to measure very small 
mass changes on a quartz crystal sensor in real-time. These devices use acoustic waves 
to detect changes. Central to the QCM system is a thin AT-cut quartz crystal with a gold 
electrode on each side. 
 
The design of the QCM and the 25 mm crystal used in these studies is shown in Figure 
5.1. The top electrode has a 12.7 mm diameter sensing electrode with an extended 
electrode that wraps around the edge of the crystal. The bottom electrode has a 6.4 mm 
diameter contact electrode. This configuration enables both electrical contacts to be 
made on the underside of the crystal allowing measurement in conductive liquids. The 
exposed area of the front electrode is 137 mm2.  
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Figure 5.1: Top and side views of a QCM sensor crystal. 
 
 
When a mass is added to the surface of the piezoelectric crystal, the resulting decreases 
in oscillation frequency can be quantitatively interpreted using the well–known 
Sauerbrey equation (Mecea, 2005; Baltus et al., 2007). 
 
When a buffer solution is passed through the QCM sensor, compressional waves are 
generated in the fluid above the quartz crystal which are reflected at the crystal surface 
and form a standing wave as shown in Figure 5.2. Accordingly, both the resonance 
frequency and the damping resistance vary periodically with the distance of any 
reflector surface from the resonator (Schneider et al., 1995; Janshoff et al., 2000). 
 
 
b a 
 
 
 
 
 
 
Figure 5.2: a. Compressional waves generated in the fluid above the quartz crystal. 
        b. Velocity profile of the particle movement on the quartz surface. 
(Reproduced from Schneider et al., 1995; Janshoff et al., 2000). 
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5.1.2 Operating conditions for the QCM system 
The resonance frequency shift of QCM sensor is influenced by many factors, such as 
mass, viscosity, conductivity and dielectric constant of the solution on the QCM 
resonate, electrode surface morphology, density and temperature of the liquid and ionic 
status of the crystal/electrode interface to a buffer (Park et al., 2000). 
 
The resonant frequency of the crystal is also strongly influenced by the surface 
roughness of the quartz crystal. It has been reported that alteration of hydrophilicity 
after adsorption can lead to large changes in the resonant frequency response. Rough 
hydrophilic surfaces entrap liquids in small cavities, contributing to the overall mass 
detected by the device (Beck et al., 1992; Martin et al., 1993). Hydrophobic cavities, 
however, are often not wetted by the liquid, resulting in the inclusion of air or vacuum 
(Martin et al., 1993) and leading to smaller energy losses than on hydrophilic surfaces. 
Therefore, smooth surfaces are required when operating in fluids to avoid frequency 
shifts arising from such changes and care needs to be taken in preparing the receptor 
layer (Janshoff et al., 2000; Janshoff and Steinem, 2001). 
 
In this study, a QCM was used as a transducer for the development of a flow-type 
antibody sensor to detect influenza A and B viruses using specific polyclonal sera and 
MAbs. To further enhance the sensitivity of this influenza sensor, the effects of pre-
coating the crystal with Protein A to orientate the antibodies through their Fc regions for 
maximal detection and binding of antigen was explored. Furthermore, conjugation of 
the influenza MAbs to gold nanoparticles prior to sensing on the QCM sensor was 
attempted to enhance mass sensitivity of the QCM sensor for the detection of influenza 
viruses.  
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5.2 Results  
5.2.1 Experimental setup of the QCM 
5.2.1.1 Assembly of the QCM sensor 
The measurement system consisted of a commercial QCM sensor coupled to a flow 
injection system. The QCM sensor included a quartz crystal (Maxtek 9 MHz, 25 mm 
diameter crystals), a crystal holder (Maxtek CHC-100), an electronic circuit which 
drove the crystal (oscillator) and an oscillator/frequency counter which collected the 
output signal of the oscillator and outputs measured data which consisted of frequency 
changes (Δf ), resistance change and changes in mass. 
 
The flow injection system consisted of a fluid circuit with a flow-through cell (FC-550 
Flow Cell), sample injection switching valve (Rheodyne Model 5020) and a syringe 
pump (Extech Model A-99). The flow cell had two inlet and outlet tubes with a 1.175 
mm I.D. x 1.55 mm O.D. compatible with 1.55 mm I.D. tubing. The crystal retainer was 
replaced with the flow cell resulting in a flow chamber with a volume of 0.1 mL, which 
was connected to the syringe pump through the Rheodyne switching valve. All 
experiments on this system were carried out at room temperature. A schematic diagram 
of the apparatus used in this work is shown in Figure.5.3 a. The QCM sensor and 
accessory equipment used in these studies are shown in Figure 5.3 b.  
(All experimental figures are shown at the end of this chapter). 
 
The stages involved in the analysis of a sample containing influenza virus using this 
instrument include:  
1. Immobilisation of the influenza-specific chicken polyclonal antibody on the crystal 
surface. 
2. Blocking the unreacted binding sites on the gold surface with 1% (w/v) BSA in PBS. 
3. Delivery of the viral suspension in PBS.  
It is shown in Figure 5.4 
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1. Immobilisation of the influenza-specific chicken polyclonal antibody on the crystal 
surface. 
3. Delivery of the viral suspension in PBS.  
2. Blocking the unreacted binding sites on the gold surface with 1% (w/v) BSA. 
Figure 5.4: Schematic diagram of the sequence of steps of antigen-antibody 
recognition events.  
 
 
 
 
 
5.2.1.2 Immobilisation of the antibody onto gold electrodes 
In this study, four different antibodies were used - chicken polyclonal antibodies or 
mouse monoclonal antibodies specific for the detection of influenza A (A/PR/8/34) or B 
(B/Lee/40) viruses. These antibodies were immobilised onto the gold surface of the 
crystal, as described in the Section 2.37, prior to use. The antibody immobilised crystal 
was shown to be stable for 1 month when stored at 4oC in a humid environment (results 
not shown). 
 
5.2.1.3 Virus strains used in the optimisation of the QCM 
Both influenza A (A/PR/8/34) and B (B/Lee/40) viruses were purified using the method 
described in Section 2.20 and titres were determined by plaque and HA assays. The 
plaque titre of the initial preparation of the purified A/PR/8/34 was 9.5 x 1011 pfu/mL 
and the HA titre 1.024 x 105 HAU/mL. The influenza B/Lee/40 plaque titre was 7.5 x 
108 pfu/mL and its HA titre was 5.12 x 104 HAU/mL. Using the Bradford protein assay, 
the protein concentration of purified A/PR/8/34 was 4.5 mg/mL and B/Lee/40 1.6 
mg/mL.   
 
5.2.2 Stabilisation of the QCM sensor   
5.2.2.1 Stabilisation of crystal with PBS 
A characteristic frequency change profile was observed following injection of carrier 
solution (PBS, pH 7.4) prior to introducing the viral sample suspended in PBS to the  
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antibody-coated crystal. As shown in Figure 5.5, there was a delayed response 
following injection of PBS of approximately 5 min due to the volume of the flow path 
from the injection port to the crystal surface. Once the PBS met the crystal surface, 
there was a significant frequency change of approximately 1000 Hz. The resonant 
frequency of the crystal was recorded until a steady baseline was obtained. 
 
5.2.2.2 Determination of the effect of bovine serum albumin (BSA) as a blocking 
agent on the sensitivity of the QCM 
A solution of 1% (w/v) BSA in PBS which was filtered using a 0.45 μm Arodisc 
syringe filter (to remove particulate, insoluble particles or to minimise possible 
contamination), was used as a blocking reagent to minimise non-specific binding 
interactions on the surface of the immunosensor. A frequency change of less than 5 Hz 
was observed over 30 min (Figure 5.5). 
 
5.2.2.3 Changes in the frequency profile following the introduction of virus 
After stabilisation of the frequency response with PBS on the crystal, a 2 mL sample of 
diluted A/PR/8/34 (100 μg/mL) was injected onto the sensor surface over a 1 h period at 
a constant flow rate of 2 mL/h. A typical profile of observed frequency response 
changes is shown in Figure 5.6. The resonant frequency dropped further with the 
introduction of the viral sample from its previous stabilisation point that was reached by 
PBS alone. The data obtained suggests that at least 60-80 min was required to saturate 
the immobilised antibody layer sensor surface with viral particles (Figure 5.6). A rapid 
drop in the frequency was obtained for the first 20 min (Figure 5.6) following the 
introduction of a sample of the A/PR/8/34 virus (100 μg/mL). The reaction rate then 
reached a steady state approximately 60 min after injection of influenza sample.  
 
5.2.3 Improving the sensitivity of the QCM immunosensor 
As shown in Figure 5.6, addition of 100 μg/mL A/PR/8/34 virus to the sensor generated 
a frequency change of 120 Hz. In order to improve the sensitivity of the QCM sensor 
for the detection of influenza, a number of parameters were addressed. 
 
Several factors influence the frequency response of a QCM sensor, including 
compression effects, mass, viscosity, surface roughness of the sensor surface, pH of the  
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buffer, flow rate and type and concentration of antibody used (Park and Kim, 1998; 
Park et al., 2000; Kim et al., 2004; Mecea, 2005). 
 
5.2.3.1 Adjustment of the compression effect of the sensor 
It has been previously reported that the compression effect influences the sensitivity of 
the QCM sensor (Dong, 2005). The compressional effect resulted from compressional 
waves and is depend on the distance between the reflector and the crystal surface 
(Figure 5.2a and b; Janshoff et al., 2000). The data presented in Figure 5.7a show 
different frequency changes following the addition of PBS to the sensor at four different 
positions (1, 2, 3 and 4) of the flow cell retainer cover (Figure 5.8). These data show 
that the greatest frequency change was observed when the crystal retainer cover was set 
at Position 1. A similar set of data was obtained when 100 μg/mL influenza virus in 
PBS was passed through the sensor (Figure 5.7b). Based on these results, the retainer 
cover was set at Position 1 (Figure 5.8) for all subsequent studies. Frequency responses 
are summarised in Figure 5.9. 
 
Pogo contacts 
       Retainer cover 
           Crystal retainer 
Crystal 
        Female BNC  
      (or SMB jack) 
       Holder housing 
 Maximum sensitivity was shown when 
the retainer cover was rotated to Position 
4 
3 
2 
1
 
 
 
 
 
 
 
 
 
1, 2, 3 and 4 – Four different positions of the retainer cover. 
Figure 5.8: Schematic representation of the rotation of the retainer cover.  
 
(Adapted from www.Maxtekinc.com). 
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5.2.3.2 Optimisation of buffer pH for the QCM 
The dependence of pH on the sensitivity of the immunosensor was studied by varying 
the pH of the carrier buffer (PBS) within the range 6 - 8. A 1:800 dilution of chicken 
A/PR/8/34 antiserum was selected, based on results obtained from the ELISA studies 
(Chapter 4.2.5.1) to prepare the immunoreceptor layer over the gold electrode of the 
crystal. Following blocking of the sensor with 1% (w/v) BSA in PBS, 100 μg/mL of 
A/PR/8/34 in PBS was adjusted to 5 different pH values over the range 6 - 8 and 
injected at a constant rate of 2 mL/h. The QCM responses obtained at different pHs 
within this range are shown in Figure 5.10 a and b. Analysis of the results obtained from 
this study showed that maximum sensitivity was obtained at pH 7.4. 
 
5.2.3.3 Optimisation of the flow rate of the QCM system 
The flow rate used is dependent upon the nature of the receptor-ligand interaction and 
the instrument employed (Kim et al., 2004). In this study, 4 different flow rates between 
2 mL/h and 4mL/h were evaluated using A/PR/8/34 virus (100 μg/mL) over a crystal 
coated with a 1:800 dilution of A/PR/8/34 antiserum. The frequency change was 
recorded over 60 min for each sample. Data presented in Figures 5.11 a and b show that 
the optimum flow rate for maximum sensitivity in this system was 3 mL/h, which was 
used in subsequent experiments. 
 
5.2.3.4 Optimisation of A/PR/8/34 and B/Lee/40 antiserum concentration 
The sensitivity of the immunosensor is also dependent upon both the concentration of 
antigen and the concentration of antibody immobilised on the sensor surface. 
Chequerboard ELISA titration data (Chapter 4 in Figures 4.11 a and b) indicate that the 
optimum A/PR/8/34 virus concentration was 20 μg/mL (IC50 inflexion point) for 1:800  
dilution of A/PR/8/34 antiserum and 14 μg/mL (IC50 inflexion point) for 1:400 dilution 
of B/Lee/40 antiserum. However, very low (<15 Hz) frequency changes were observed 
when these concentrations of A/PR/8/34 and B/Lee/40 (20 and 14 μg/mL) were used. A 
higher concentration of virus (100 μg/mL) was used to compensate for the dynamic 
forces associated using a flow system, compared with the static ELISA method. The 
results from these studies for both A/PR/8/34 and B/Lee/40 antisera were tested on the 
QCM sensor within range 1:200 - 1: 3,200 are shown in Figures 5.12 and 5.13. The 
results suggest that the optimal dilutions were 1:800 and 1:400 for A/PR/8/34 and 
B/Lee/40 antisera, respectively. 
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5.2.3.5 Optimisation of influenza A and B MAb concentration 
Similarly, optimal concentrations of MAbs were determined after varying the MAb 
immobilised on the crystal surface. The chequerboard ELISA titration data (Chapter 4, 
Figures 4.12 a and b) indicate that the optimum A/PR/8/34 virus concentration was 30 
μg/mL (IC50 inflexion point) at a MAb concentration of 8 μg/mL. The corresponding 
figure for B/Lee/40 was 4 μg/mL. However, low (<15 Hz) frequency changes were 
observed at concentrations of A/PR/8/34 and B/Lee/40 of 30 and 20 μg/mL. A higher 
concentration (150 μg/mL) was used to compensate for the dynamic forces associated 
with the flow system, compared with the static ELISA method. The results from the 
QCM studies using the MAbs are shown in Figure 5.14 (A/PR/8/34) and 5.15 
(B/Lee/40). These results suggest that the optimal MAb concentrations were 8 μg/mL 
and 4 μg/mL for A/PR/8/34 and B/Lee/40, respectively. 
 
5.2.4 Immobilisation of antibody on a Protein A-coated gold electrodes 
Previous studies (Guilbault et al., 1992) have shown that orientation of the antibody 
layer on the gold surface improves the sensitivity of the sensor. This can be achieved by 
pre-coating the gold electrode with 2 mg/mL of Protein A in PBS prior to addition of 
the mouse MAb, which binds specifically to Protein A through the Fc region of IgG 
molecule (Figure 5.16; Konig and Gratzel, 1994). The antibody immobilised on to the 
Protein A-coated crystal was shown to be stable for 1 month when stored at 4oC in a 
humid environment (results not shown).  
 
1 
2 
3 
Protein A 
layer 
 
 
 
 
 
 
 
 
 
 
 
3. Delivery of the viral suspension in PBS.  
2. Blocking the unreacted binding sites on the gold surface with 1% (w/v) BSA. 
1. Immobilisation of the influenza-specific MAb on the Protein A- coated crystal surface. 
Figure 5.16: Schematic diagram of the antigen-antibody recognition event with Protein 
A. 
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Three different antibodies were used to evaluate the effect of Protein A on the frequency 
change response of the QCM sensor using influenza A virus antigen. These were:  
a) A/PR/8/34 antiserum without Protein A  
b) Influenza A MAb without Protein A 
c) Influenza A MAb with Protein A  
As shown in Figure 5.17 a and b, increased frequency changes were observed  
following the injection of 100 μg/mL of A/PR/8/34 virus to MAb immobilised with 
Protein A bound to the crystal surface, compared with  antibody bound to the surface 
without Protein A. 
 
Table 5.1: Frequency changes following the binding of purified influenza viruses to 
influenza antibody-modified crystal surfaces: 
(Results are expressed as mean values; + standard deviation; n=3) 
Immobilization method Frequency change (Hz)  after 60 
min post-injection 
Protein A-coated gold electrode plus influenza 
A MAb  
191+ 7.6 
 
Influenza A MAb alone  79 + 4.5 
A/PR/8/34  antiserum  152 + 6.8 
 
The results presented in Figure 5.17 a and b and summarised in Table 5.1, show an 
increased frequency change of 112 Hz over a period of 60 min for viral samples (100 
μg/mL) reacted with MAb and immobilised on a coating of Protein A. Therefore, the 
orientation of the MAb using Protein A improved the frequency change by 141%. In 
addition, the binding of influenza A on influenza A MAb immobilised on Protein A 
resulted in higher frequency changes compared with the results obtained when the 
A/PR/8/34 antiserum, alone, was used.  
 
5.2.5 Determination of the sensitivity of the QCM for the detection of A/PR/8/34 
and B/Lee/40 viruses 
A number of parameters examined in Sections 5.2.3.1 to 5.2.3.5 and 5.2.4 included  the 
efficiency of the blocking buffer, the pH of the reaction buffer, the flow rate, the 
concentration of antibody and the orientation of the antibody using Protein A. Using 
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optimal  conditions, the limits of detection were determined for A/PR/8/34 and 
B/Lee/40 viruses.    
 
One hundred microlitres of monoclonal antibodies (see Section 5.2.3.5; 80 μg/mL 
specific for A/PR/8/34 and 40 μg/mL specific for B/Lee/40 viruses) were immobilised 
onto Protein A on two crystals in separate experiments. Diluted samples of A/PR/8/34 
and B/Lee/40 (1 x 108 - 1 x 103 pfu/mL) in PBS buffer were injected at the optimised 
flow rate of 3 mL/h (Section 5.2.3.3). The results obtained are summarised in Table 5.2. 
The data represent the frequency changes (ΔHz) observed after introducing the virus 
samples to the sensor surface 60 min after injection. 
 
Table 5.2: Frequency responses of the flow type antibody sensor using different 
concentrations of A/PR/8/34 and B/Lee/40 and specific MAbs  
 
Virus -ve 
control 
103 a 104 105  106 107 108 
Influenza A 
Frequency shift (Hz) 
15 b 
+2 
15 
+4.5 
30 
+ 5 
52 
+ 7.6 
144 
+10.4 
303 
+20.2 
493 
+ 20.8 
Influenza B 
 
Frequency shift (Hz) 
15 
+2.5 
16 
+3.2 
37 
+6.5 
66 
+5 
212 
+12.5 
298 
+12.5 
410 
+10 
a  pfu/mL 
 b  Results are expressed as mean values;  + standard deviation;  n=3 
 
Typical recordings of frequency changes observed with the binding of A/PR/8/34 to 
influenza A specific MAb-coated crystal are shown in Figure 5.18a. The data suggest 
that the effective minimum detection limit for influenza A and B was 1 × 104 pfu /mL. 
In order to enhance the mass sensitivity of the immunosensor, the use of gold 
nanoparticle antibody conjugates was evaluated. 
 
 
 
 
 145
T. Peduru Hewa                   Chapter Five: The development of a QCM-based biosensor 
 
5.2.6 Use of nanoparticles to amplify the sensitivity of the biosensor 
In these studies, gold nanoparticles conjugated with antibodies were used to increase the 
sensitivity of the QCM for the detection of influenza viruses. The basis of the technique 
used in these studies is summarised in Figure 5.19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
2 
3 
Protein A 
layer 
13 nm gold nano particle 
3. Delivery of the viral suspension in PBS. 
2. Blocking the unreacted binding sites on the gold surface with 1% (w/v) BSA. 
1. Immobilisation of the influenza-specific MAb on the Protein A- coated crystal surface. 
antibody-functionalised gold nanoparticles. 
Figure 5.19: Schematic diagram of the antigen-antibody recognition event using 
 
The 13 nm gold nanoparticles were prepared according to the method described in 
Section 2.38. Their size was confirmed by TEM analysis as shown in Figure 5.20a. 
Nanoparticles and antibody-nanoparticle conjugates containing either influenza A or 
influenza B  MAb were prepared according to the method described in Section 2.39.  
 
Gold nanoparticle amplification for the sensing of influenza A and B was further 
confirmed by the visible absorption measurements. Analysis of the visible absorption 
spectrum of the nanoparticle revealed an absorption peak (λmax) at 520 nm. Following 
incubation of the nanoparticles with antibody (Section 2.40), the absorption peak shifted 
to 527 nm (Figure.5.21b). This 6-7 nm shift indicates that protein was bound to the 
surface of the nanoparticles which increased the primary gold plasmon peak (Nath and 
Chilkoti, 2002). 
 
 146
T. Peduru Hewa                   Chapter Five: The development of a QCM-based biosensor 
 
5.2.6.1 Frequency change with antibody-gold nanoparticle conjugate 
Influenza A and B MAbs (80 μg/mL for influenza A; 40 μg/mL for influenza B) were 
immobilised to Protein A on QCM crystals in two separate experiments. As a negative 
control, the frequency change due to the gold nanoparticles alone was measured by 
adding a suspension of gold nanoparticles conjugated with either influenza A or 
influenza B MAbs. Since there was no bound antigen on the crystal surface, the 
frequency changes observed were due to non-specific (background) interactions 
between the nanoparticles and the MAbs. The average frequency change for gold 
nanoparticles conjugated with either MAb was 65+10 Hz and this value was used as the 
value of the negative control. 
 
Purified A/PR/8/34 and B/Lee/40 preparations (1 x 108- 1 x 103 pfu/mL) in PBS were 
injected at the optimised flow rate of 3 mL/h for 30 min in each run.  Then PBS was 
added for 15 min to remove any unbound antigen followed by injection of influenza A 
or B MAb conjugated to nanoparticles. Frequency changes due to binding of the 
antibody-nanoparticle conjugates to the bound antigen were recorded over 60 min. A 
series of virus dilutions in the range 1 x 108- 1 x 103 pfu/mL were tested prior to the 
addition of influenza A or B MAb-conjugated gold nanoparticles separately, and the 
percentage of elevated frequency changes was compared with controls without 
nanoparticles. The results are given in the Table 5.3 to 5.5. The typical sensor profile of 
A/PR/8/34 virus is shown in Figure 5.21. 
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Table 5.3: Frequency responses of the flow type antibody sensor using different 
concentrations of A/PR/8/34 and B/Lee/40 and detection with antibody-gold 
nanoparticle conjugates.  
 
 
Virus 
(with nanoparticles) 
103 a  104 
 
105
 
106 
 
107 
 
-ve 
control 
Influenza A 
Frequency shift (Hz) 
102  b
+ 11 
191 
+ 14 
227 
+ 8 
326 
+ 9 
370 
+ 9.5 
65 
+10 
Influenza B 
 
Frequency shift (Hz) 
115 
+5 
214 
+ 5.2 
233 
+10.4 
313 
+ 12.5 
345 
+5 
65 
+7.5 
a  pfu/mL 
 b  Results are expressed as mean values; + standard deviation; n=3 
 
As shown in Figures 5.22 a and b the addition of influenza specific MAb conjugated to 
nanoparticles increased the sensitivity of the assay (580% at 103pfu/mL for A/PR/8/34) 
although at higher titres, the differences in sensitivity were less (22% increase in 
response at 107pfu/mL for A/PR/8/34). (Tables 5. 4 and 5.5).  
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Table 5. 4: Detection of A/PR/8/34 with and without nanoparticles. 
 Virus 
Frequency shift (Hz) 
-ve 
control
103 a 104 
 
105
 
106 
 
107 
 
15  b   15 
+4.5 
30 
+ 5 
52 
+ 7.6 
144 
+10.4 
303 
+20.2 
Influenza A 
+2 (without nanopartcles) 
Influenza A 
(with nanoparticles) 
65 
+10 
102 
+ 11 
191 
+ 14 
227 
+ 8 
326 
+ 9 
370 
+ 9.5 
Amplified frequency (Hz) 50 87 161 175 182 67 
Percentage increase 333 580 536.6 336 126 22 
 
a  pfu/mL 
 b  Results are expressed as mean values; + standard deviation; n=3 
 
Table 5. 5: Detection of B/Lee/40 with and without nanoparticles. 
Virus 
Frequency shift (Hz) 
-ve 
control
103 a 104 
 
105
 
106 
 
107 
 
15  b   
+2.5 
15 
+4.5 
37 
+6.5 
66 
+5 
212 
+12.5 
298 
+12.5 
Influenza B 
(without nanopartcles) 
Influenza B 
 
(with nanoparticles) 
65 
+7.5 
115 
+5 
214 
+ 5.2 
233 
+10.4 
313+ 
12.5 
345 + 5
Amplified frequency (Hz) 50 100 177 167 101 47 
Percentage increase 333 666 478 253 47 15 
a  pfu/mL 
 b  Results are expressed as mean values; + standard deviation; n=3 
The relationships between frequency change and concentration of viruses are shown in 
Fig. 5.22a and b.  
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5.2.7 Relationship between infectious titre and observed frequency change  
The relationships between the infectious titre of A/PR/8/34 and B/Lee/40 observed from 
frequency changes in the presence and absence of nanoparticles are plotted on a semi-
logarithmic scale (Figure 5.23 a and b).  
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 Figure 5.3a: Schematic diagram of the apparatus for continuous 
        flow antibody sensing for QCM analysis. 
 
 
 
 
The flow type antibody sensor system was constructed with a peristaltic pump (1), an 
injector (2), the flow cell installed with the crystal (3), an oscillator circuit (4) and a personal 
computer installed with QCM software (5).  
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Figure 5.3b: QCM assembly used in these studies.   
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Figure 5.5: Observed frequency change with PBS and 1% BSA  
   after incubation with APR/8/34 antiserum. 
 
 
Add 1% BSA Add PBS 
Add PBS
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Figure 5.6: Typical frequency change profile of the flow-type antibody 
sensor during one cycle of measurement. 
Purified A/PR/8/34 virus suspension (100 μg/mL) was injected at t=60 min at the 
rate of 2 mL/h. 
X-Y -  induction time-time of entry of virus sample to the flow cell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction time  
Induction time  
X     Y 
Influenza A virus injection 
Buffer stream
X 
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              Time vs Delta Frequency 1 (Position 1)  
              Time vs Delta Frequency 2 (Position 2) 
              Time vs Delta Frequency 3 (Position 3) 
Time vs Delta Frequency 4 (Position 4)
   Figure 5.7a: Corresponding frequency changes with PBS for four different degrees of 
rotation of the retainer cover. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 5.7b: Corresponding frequency changes with antigen (100 μg/mL) for four 
different degrees of rotation of the retainer cover. 
              Time vs Delta Frequency 1 (Position 1) 
              Time vs Delta Frequency 2 (Position 2)  
              Time vs Delta Frequency 3 (Position 3)  
              Time vs Delta Frequency 4 (Position 4)
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Figure 5.9: Frequency changes with PBS and virus for  
four different rotations of the retainer cover. 
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Figure 5.10a: Typical response profiles of the antibody-immobilised sensor 
at different pHs. 
Figure 5.10b: Effect of buffer pH on the frequency change with  
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   A/PR/8/34 and polyclonal antibody. 
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Figure 5.11b: Effect of the flow rate on the frequency change of the antibody-
immobilised A/PR/8/34 (100 μg/mL) sensor at 60 min. 
Figure 5.11a: Typical response profiles of the antibody-immobilised 
sensor at different flow rates. 
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Figure 5.12a: Frequency change with different dilutions of  
A/PR/8/34 antiserum. 
        Figure 5.12b: Frequency change with different dilutions of A/PR/8/34 antiserum. 
  1: 200 dilution 
1: 400 dilution 
1: 800 dilution 
1: 1,600 dilution 
1: 3,200 dilution 
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Figure 5.13a: Typical response profiles of the different dilutions  
of B/Lee/40 antiserum. 
1: 200 dilution 
1: 400 dilution 
1:800 dilution 
1:1,600 dilution 
1: 3,200 dilution 
 
 
Figure 5.13b: Frequency change with different dilutions of B/Lee/40 antiserum.   
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     Figure 5.14a: Typical response profiles with different concentrations  
of influenza A MAb.
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Figure 5.14b: Frequency changes with different concentrations  
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Figure 5.15a: Typical response profiles with different  
    concentrations of influenza B MAb.  
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Figure 5.15b: Frequency changes with different concentrations of 
influenza B MAb. 
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Figure 5.17a: Typical response profiles due to binding of A/PR/8/34 to antibody 
 immobilised to the crystal surface with and without Protein A.  
Figure 5.17b: Frequency changes due to binding of A/PR/8/34 to  
     antibody immobilised to the crystal surface. 
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B/Lee/40 virus at different concentrations. 
Figure 5.18b:  Frequency changes of the immunosensor as a function of time using  
107 pfu/mL 
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Figure 5.18a:  Frequency changes of the immunosensor as a function of time using 
A/PR/8/34 virus at different concentrations. 
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Figure 5.20a: TEM images (100,000×) of gold nanoparticle suspension (13nm). 
100 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20b: UV-visible absorption spectrum of the gold nanoparticle system.  
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Figure 5.21: Observed frequency changes of the immunosensor following addition of gold-
labelled influenza A MAb to different concentrations of bound A/PR/8/34. 
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Figure 5.22a: Percentage increase in A/PR/8/34 frequency. 
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Figure 5.22b: Percentage increase in B/Lee/40 frequency. 
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Figure 5.23a: Comparison of frequency changes with increasing 
concentration of A/PR/8/34 in the presence and absence of nanoparticles. 
Without nanoparticles 
With nanoparticles 
Figure 5.23b: Comparison of frequency changes with increasing 
concentration of B/Lee/40 in the presence and absence of nanoparticles. 
Without nanoparticles 
With nanoparticles 
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5.3 Discussion  
In Chapter 4, ELISAs were developed for the detection of influenza A and B viruses. 
The aim of this study was to develop a QCM-based biosensor for the detection for 
influenza A and B viruses in clinical samples. 
 
The resonance frequency shift of a QCM sensor is influenced by many factors (Section 
5.2.3).  In the initial experiments, addition of PBS to the type-specific antibody coated 
crystal surface resulted in a significant frequency shift (approximately 1000 Hz), 
followed by the development of a steady baseline (Figure 5.5). The overall resonance 
frequency shift of the QCM in contact with solution was described by Dong, (2005) 
using the following equation: 
 
Δf   =  Δf m +Δf ρ +Δfη +Δ fr                           (1) 
 
where the subscripts m, p, η, indicate mass, compression, viscosity of the solution on the 
QCM and r the roughness of the resonating surface. When PBS was passed over the 
crystal surface, Δfp and Δfr remain constant. Therefore, the frequency shift is due to the 
variation in the mass or viscosity of the solution on the QCM sensor. However, Daikhin 
et al., (2000) attributed the shift to viscosity changes on the surface of the sensor 
(Daikhin et al., 2000; Dong, 2005).  
 
Non-specific binding sites on the crystal surface can be blocked by addition of 1% (w/v) 
BSA prior to the loading of antigen to the immobilised antibody. This step resulted in a 
less than 5 Hz frequency shift over a 30 min period (Figure 5.5). Caruso et al., (1997) 
showed that BSA readily adsorbs to solid surfaces but results in small frequency 
changes (Δf <5 Hz) similar to those observed in this study (Caruso et al., 1997; 
Pastorino et al., 2006). 
 
Following the immobilisation of influenza type-specific antibody (either polyclonal or 
MAb specific for A/PR/8/34 or B/Lee/40) to the gold surface, the binding of antigen 
was shown to be highly specific. Figure 5.6 shows a typical resonant frequency shift 
that was observed during the binding of influenza A virus to the immobilised antibody 
layer. As the virus bound to the coated surface, there was an increase in mass at the 
interface, leading to a decrease in the oscillation frequency. The observed frequency  
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shift was proportional to the increase in mass and could be correlated with the amount 
of analyte binding (Vaughan et al., 1999; Lee and Chang, 2005; Mecea, 2005). In the 
first 20 min after injection of virus to the QCM sensor, there was a rapid change in the 
frequency response due to the binding between antibody and antigen. As shown in 
Figure 5.6, a steady state was observed after this period, suggesting that there was no 
further mass deposition or net increase in reaction between antigen and the antibody. 
 
As described by Dong, (2005) using the equation (1), the magnitude of the overall 
frequency shift observed when the QCM sensor surface in contact with the solution was 
also dependent on the compression effect. The results presented in Figures 5.7 a and b 
confirmed the relationship between frequency shift and compression effect. In this 
experiment, the retaining cover was rotated over 4 different positions (Figure 5.8) 
leading to 4 different compressional effects, while Δf mΔfp and Δfr remained constant. 
The maximum frequency shift was obtained at Position 1 when using either PBS or 
virus when applied on to antibody-coated crystal sensor surfaces. Therefore, a constant 
compression effect was applied in all experiments by setting the retaining cover at 
Position 1 in the cover assembly of the QCM sensor. 
 
It is well known that specific antibody and antigen interactions are dependent upon a 
number of factors, including pH and the ionic strength of the buffer. In this work, PBS 
was used as the buffer. Previous studies have shown that salt concentration and ionic 
strength can influence the response of the QCM sensor (Kim et al., 2004). Given the 
importance of pH in antibody-antigen interactions, it was decided to investigate the 
effect of pH of the PBS on the sensitivity of the QCM. The optimum pH for maximum 
sensitivity was 7.4 (Figure 5.10). The sensitivity of the QCM rapidly declined when the 
pH exceeded 7.4 (Figure 5.10). Park et al., (2000) observed a similar pH-dependent 
response in their studies on the use of a QCM sensor for antibody-based detection of 
Salmonella  and determined that the optimal pH for this sensor was pH 7.2. 
 
Flow rate is one of the key factors which affect the frequency change. The flow rate is 
directly proportional to the pressure created in the flow cell, but sufficient reaction time 
is required to ensure binding between the immobilised antibody and the antigen (Kim et 
al., 2004). The results presented in Figure 5.11, confirmed that the responses observed 
using a flow rate 3 mL/h resulted in a maximum change in frequency shift. The 
sensitivity of the QCM sensor rapidly declined when the flow rate of the running buffer 
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exceeded 3mL/h (Figure 5.11). Taking into account the requirements of rapidity and 
stability for the system, a flow rate of 3 mL/h was selected (Figure 5.11) for use in 
subsequent experiments. Under these conditions, the influenza biosensor response 
occurred approximately 5 min after injection of the virus suspension, leading to 
frequency changes in the system for a period of 60-80 min. After this period, the 
biosensor system was ready for the regeneration procedure. Using a flow rate of 3 mL/h, 
this influenza sensor system only required 60-80 min for one cycle of measurement, 
including the time required for regeneration and baseline stabilisation. 
 
Factors such as surface roughness of the crystal surface, the conductivity and the 
dielectric constant of the running buffer also influence the sensitivity of the QCM 
sensor (Janshoff et al., 2000; Janshoff and Steinem, 2001). The electrode surface 
roughness can cause large mass loadings due to liquid that is trapped within the pores at 
the crystal surface. However, in the current study, the influence of these factors were 
minimised by using the same type of quartz crystal surface and using PBS buffer (pH 
7.4) for all of the experimental studies. Only crystals produced by Maxtek (Maxtek, 
Inc., USA) were used in this study. These crystals were optically polished to 50 Å 
average surface roughness to minimise mass loading effects. The dielectric constant was 
kept constant by using PBS as the running buffer for all experiments. In addition, PBS 
was also used to suspend the antigen sample and to dissolve the antibody before coating 
over the gold electrode.  
 
One of the most important factors that affects the sensitivity of the QCM sensor is the 
optimal concentration of antibody immobilised on the crystal surface that leads to 
improved reaction kinetics, but also avoids unfavourable effects such as minimal non-
specific binding (Luppa et al., 2001; Jin-Cherng et al., 2002). In this study the optimum 
polyclonal antibody concentration for maximum sensitivity of the QCM sensor was 
found to be 1:800 for A/PR/8/34 (Figure 5.12) and 1:400 for B/Lee/40 virus (Figure 
5.13). The optimum MAb concentration immobilised on the QCM for maximum 
sensitivity was found to be 8 μg/mL for A/PR/8/34 (Figure 5.14) and 4 μg/mL for 
B/Lee/40 (Figure 5.15). These results are consistent with values obtained for ELISA 
assays (Chapter 4). Once the optimal antibody concentration was determined, the  
antigen concentration was varied to determine the optimal antigen:antibody to maximise 
the sensitivity of the sensor.  
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The data presented in Figure 5.17 and summarised in Table 5.1 show that the polyclonal 
antibody was more sensitive than MAb for the detection of A/PR/8/34 virus. These 
results are consistent with the results obtained in the ELISA that indicate polyclonal 
antibodies are capable of binding to several different epitopes on any given antigen 
compared with MAbs, which usually bind to a single epitope (Joassin et al., 1987; 
Haurum, 2006).  The same data (Figure 5.17; Table 5.1) showed that when MAb was 
immobilised to Protein A, there was a significant improvement in sensitivity for the 
detection of A/PR/8/34. These results suggest that orientation of the immobilised 
antibody using Protein A improved the sensitivity of the sensor. Immobilised Protein A 
binds to the Fc region of IgG molecules providing with an orientation of the IgG and its 
antigen-binding sites, resulting in maximal binding of virus (Babacan et al., 2000). 
However, chicken polyclonal antibodies belong to the IgY class of immunoglobulins 
which cannot bind to either protein A or G, due to the absence of the Fc region in their 
structure (West, et al., 2004). Previous reports have also shown that antibody 
immobilised on a Protein A layer in a QCM sensor led to increase frequency shifts 
compared with results obtained without a Protein A layer (Konig and Gratzel, 1994; 
Babacan et al., 2000; Wang et al., 2005; Chu et al., 2006). Therefore, all subsequent 
studies were carried out using mouse MAb bound to a Protein A layer.  
 
The results presented in Section 5.2.5 show that the titre of the virus in the sample was 
directly proportional to the mass accumulation on the monolayer, which was then 
proportional to the rate of the frequency shift. Results obtained with different virus 
concentrations, (Figure 5.18, Table 5.2 and Table 5.3) showed that the lowest detectable 
viral infective titre of purified A/PR/8/34 and B/Lee/40 was 104 pfu/mL (25 μg/mL). 
Using a similar approach with Protein A-immobilised anti-virus antibodies, Konig and 
Gratzel (1994) obtained detection limits to 5 x 104 pfu/mL for the detection of human 
herpes viruses. However, Zuo et al., 2004 were able to detect as little as 0.6-4 μg/mL of 
SARS-associated coronavirus (SARS-CoV) in sputum in a gas phase using QCM sensor 
coated with Protein A and polyclonal antibody. 
 
More recently Chu et al., 2006 have described a new approach to improving the 
sensitivity of the QCM biosensor by the use of antibody-functionalised gold 
nanoparticles as a novel mass amplification probe for a QCM sensor with significant 
enhancement of its sensitivity. In this study, influenza A and B MAbs were bound to 13 
nm gold nanoparticles (Figure 20a and b) and used to improve the mass sensitivity of 
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the sensor for influenza detection. As shown in Figure 5.21 and summarised in Table 
5.4 and Table 5.5, the lowest detectable viral infective titre of purified A/PR/8/34 and 
B/Lee/40 was 103 pfu/mL (10 μg/mL) for the QCM sensor using gold nanoparticle-
bound influenza A and B MAbs. The use of antibody conjugated gold nanoparticles 
improved in a 10-fold increase in sensitivity as shown by the decrease in detection 
limits from 104 pfu/mL to 103  pfu/mL (10 μg/mL). This step clearly increases the 
potential of the biosensor for the detection of clinical samples. 
 
However, Figure 5.22a and b and the data summarised in Table 5.4 and 5.5 indicate that 
the nanoparticles did not proportionally increase the sensitivity of the QCM sensor for 
the detection of influenza viruses with high infectious titres. Maximum enhancement of 
the sensitivity was observed only in the range 103-104 pfu/mL suggesting that the 
adsorption of excess antibody–colloidal gold conjugate on the electrode surface leads to 
steric hindrance (Chu et al., 2006). 
 
In order to quantitate the viral titres detected by the QCM sensor, calibration curves 
were established (Figure 23 a and b). These curves describe the relationship between the 
frequency shift and the titre of the injected influenza viral particles. When these data are 
plotted on a logarithmic-linear scale, an apparent linear relationship between antigen 
and frequency shift was observed. The same relationship was observed when gold 
nanoparticle-conjugated antibodies were added to the antigen (Section  5.2.6). Based on 
this apparent linear relationship between frequency shift and virus concentration when 
followed a semi-logarithmic scale, it would be possible to use this calibration curve to 
determine unknown viral titres in samples within the range 107 - 104 pfu/mL. As 
discussed previously, addition of gold nanoparticle-conjugated antibody led to a 10-fold 
increase in the sensitivity of the detection method-corresponding to a detection range of 
107 -103 pfu/mL using the calibration curve shown in Figure 5.23 a and b. 
 
The basic parameters developed in this chapter for the QCM were applied to the 
detection of influenza A and B viruses in clinical specimens. 
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CHAPTER SIX  
 
EVALUATION OF QCM FOR THE DIAGNOSIS OF INFLUENZA IN 
CLINICAL SAMPLES 
 
The capacity of the QCM and QCM/nanoparticle methods to detect influenza virus in 
nasal washes were compared with other currently used methods. The conventional RT-
PCR method was shown to be the most sensitive for the detection of influenza viruses in 
nasal samples, followed by the standard cell culture method, the shell vial method, an 
ELISA and the Directigen Flu A test. The QCM/nanoparticle method was shown to be 
as a sensitive as the standard cell culture method. The QCM method was as sensitive as 
the shell vial method. 
 
The times for diagnosis were 20 min for Directigen Flu A test, 1 day for the 
conventional RT-PCR, 1 day for the ELISA, 2 days for the shell vial method and up to 
14 days for the standard cell culture method. The times for the QCM and 
QCM/nanoparticle methods were 2 days. However, direct detection of the influenza 
viruses in nasal samples was not possible by QCM because of frequency fluctuation that 
was probably caused by the viscosity of the sample. An additional culture step of 12 h 
was required to overcome the problem, which increased processing period to 2 days. 
Both the QCM and QCM/nanoparticle methods were highly sensitive (81 and 87%) and 
specific (100%), compared with RT-PCR. 
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6.1 Introduction  
The objective of this part of the study was to evaluate the suitability of the QCM 
biosensor for the diagnosis of influenza virus in nasal washes from infected patients in 
comparison with other methods. In Chapter 3 the RT-PCR, shell vial and standard cell 
culture methods were evaluated using egg-grown preparations of influenza A/PR/8/34 
and B/Lee/40. PCR was used as the gold standard for comparison. Their sensitivities 
were also determined in terms of the minimum genome copy number detectable by each 
method, using real-time quantitative PCR. In Chapter 4 antigen ELISAs were developed 
to detect influenza A and B viruses using type-specific M1 proteins of A/PR/8/34 and 
B/Lee/40, which do not vary between subtypes, using a polyclonal capture method. 
Optimal conditions for the detection of A/PR/8/34 and B/Lee/40 by two QCM 
biosensors are described in Chapter 5. The clinical usefulness of these biosensors was 
evaluated for the rapid detection of influenza A and B viruses in 67 nasal samples 
obtained during the 2005 Australian winter. Their sensitivity was compared with PCR, 
which was also used as the gold standard and against the shell vial and standard cell 
culture methods, an antigen ELISA and (for influenza A viruses) the commercially 
available Directigen Flu A kit. This work was conducted against the background of a 
continuing need for rapid sensitive methods for the diagnosis of influenza viruses in the 
detection of pandemics and for the use in antiviral chemotherapy (see Chapter 1).  
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6.2 Results  
6.2.1 Patients and specimens 
Nasal samples from 67 patients were received from the Victorian Infectious Disease 
Reference Laboratory (VIDRL) and the WHO collaborating Centre for Reference and 
Research on Influenza during the Australian winter of 2005.  Influenza viruses isolated 
at the time were A/New Caledonia/20/99–like (H1N1), A/Wyoming/3/2003 - like 
(H3N2); influenza B viruses were B/Brisbane/32/2002 – like. 
 
6.2.2 Attempted direct detection of influenza viruses by QCM using nasal washings  
Dilutions of purified A/PR/8/34 virus (103-108 pfu/mL) were prepared in a 20% (v/v) 
nasal wash specimen in PBS from a normal volunteer. The diluted sample was mixed 
and centrifuged for 5,000 x g for 20 min and the supernatant collected for analysis. 
Significant noise (frequency fluctuation) was observed in all samples including the 
negative control, which consisted of the diluted sample without virus. Fluctuation in the 
diluted nasal sample was compared with that of a control consisting of PBS alone 
(Figure 6.1) and similar results were obtained from later samples taken from the same 
volunteer. Therefore, detection of virus from diluted nasal washes by QCM does not 
appear practicable, possibly because of the viscosity of the samples. Viscosity has been 
shown to be responsible for fluctuations in QCM frequency shift by Rodriguez-Pardo et 
al., (2005). (All experimental figures are shown at the end of this chapter). 
 
However, when the same samples were inoculated to MDCK cell cultures as described 
in Section 2.14.1.2 and incubated overnight, typical signal frequency shifts for positive 
samples were observed by QCM (see Chapter 5). These signals appeared in the absence 
of CPE in the infected cultures (unpublished data) and this procedure was used in all 
subsequent QCM tests (Appendix 1). 
 
6.2.3 Detection of influenza viruses by currently available methods and QCM 
Appendix 2 shows results from tests on all 67 samples using RT-PCR, shell vial, 
standard cell culture, ELISA, Directigen Flu A, QCM and QCM/nanoparticle tests. The 
genome copy number detectable by each test by QPCR in each sample is also presented 
in the table. 
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The summarised results for all tests are shown in Table 6.1. RT-PCR, shell vial, cell 
culture and ELISA detected influenza A and B viruses in 52, 40, 45 and 34 specimens. 
The Directigen Flu A test detected influenza A in only 13 specimens. The QCM and 
QCM/ nanoparticle tests detected influenza A and B viruses in 40 and 43 specimens 
respectively.  However, 12, 7 and 18 RT-PCR-positive specimens were not detected by 
the shell vial, cell culture and ELISA methods respectively. Twelve and nine RT-PCR-
positive specimens were also not detected by the QCM and QCM/nanoparticle methods 
respectively. 
 
The sensitivities of tests for  detection of influenza A and B by the shell vial, standard 
cell culture, ELISA, Directigen Flu A test, QCM and QCM/nanoparticle tests were  76 
and 80, 81 and 100, 68 and 60, 35 (for influenza A only), 76 and 80 and 81 and 87%, 
respectively (Table 6.2). The specificity, positive and negative predictive values are 
shown in Table 6.2 for influenza A and B viruses. Three false-positives were detected 
by the shell vial method. The highest number of false-negative results (24) was obtained 
by the Directigen Flu A test.  
 
6.2.4 Detection of influenza viruses by the standard cell culture method 
The results for isolation by the standard cell culture method using haemadsorption to 
detect the presence of virus are shown in Table 6.3. Forty-five specimens were 
haemadsorption-positive (30 for influenza A, 15 for influenza B viruses). 
Haemadsorption was detected in 31 of 45 samples by 7 days. For influenza A and B 
viruses 16 (53%) and 15 (100%) positive samples were detected at 3-7 days. Negative 
influenza samples were re-passaged for a further 7 days and the number of positive 
increased to 30 (81%). 
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a The times for the tests were RT-PCR: 1 day, Shell vial: 2 days, Cell culture: 14 days, ELISA: 1 day; Directigen Flu A: 20 min, QCM: 2    
bDuring 2005 all influenza A viruses detected were A/New Caledonia/20/99 – like  (H1N1) (2/37) and A/Wyoming/3/2003 - like            
              influenza in clinical samples 
Table 6.1: Detection of influenza A and B viruses in the nasal wash samples from 67 patients during the Australian winter of 2005.  
No (%) of specimens found positive bya: Virus 
type RT-PCR Shell vial Cell culture 
 
ELISA Directigen Flu A QCM 
 
QCM/ 
nanoparticle 
Influenza Ab 37 (55) 28 (42) 30 (45) 25 (37) 13 (19) 28(42) 30 (45) 
Influenza Bc 15 (22) 12(18) 15 (22) 9 (13) NA 12(18) 13 (19) 
Totals 52 (77) 40 (60) 45 (67) 34 (50) 13(19) 40 (60) 43 (64) 
 
 
 
    days. 
     (H3N2) (35/37).   
cInfluenza B viruses were B/Brisbane/32/2002 – like. 
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Table 6.2: Results obtained for shell vial, standard cell culture, ELISA, Directigen Flu 
A and QCM methods in comparison with RT-PCR. 
No of specimens Test 
TPa TNb FPc FNd
Sensitivitye Specificityf PPVg NPVh
Influenza A 28  27 3 9 76 90 90 75 Shell vial  
Influenza B 12 52 0 3 80 100 100 95 
Influenza A 30 30 0 7 81 100 100 81 Cell 
culture Influenza B 15 52 0 0 100 100 100 100 
Influenza A 25 30 0 12 68 100 100 71 ELISA 
Influenza B 9 52 0 6 60 100 100 90 
Influenza A 13 30 0 24 35 100 100 56 Directige
n Flu A  Influenza B NA NA NA NA NA NA NA NA 
Influenza A 28 30 0 9 76 100 100 77 QCM  
Influenza B 12 52 0 3 80 100 100 95 
Influenza A 30 30 0 7 81 100 100 95 QCM 
nanoparti
cles) 
Influenza B 13 52 0 2 87 100 100 96 
A total of 67 nasal samples were compared with RT-PCR which was used as the reference 
method (gold standard). 
a TP, true-positives; b TN, true-negatives; c FP, false-positives; d FN, false-negatives. 
Bayesian statistics are often used to determine sensitivity, specificity and predictive values 
of new diagnostic tests (Stokes et al., 1988; Leonardi et al., 1994; Devore, 2004). 
e Sensitivity = number of TP specimens/ (number of TP + number of FN specimens) x 100; 
 f Specificity = number of TN specimens/ (number of TN specimens + number of FP 
specimens) x 100; g PPV  (positive predictive value) = TP/ (TP+ FP) x100 ; h NPV 
(negative predictive value) =  TN / (TN+ TN) x 100. 
Samples positive by shell vial, standard cell culture, ELISA, Directigen Flu A kit and QCM, 
but negative by RT-PCR, were considered FP.  Samples that were identified by RT-PCR 
assays were considered as TP. Samples that were negative by shell vial, standard cell 
culture, ELISA, BD Directigen Flu A kit and QCM but positive by PCR were regarded as 
FN. A sample that was negative by RT-PCR was a TN.  
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Table 6.3: Days to detection by haemadsorption. 
 
Detection in cell culture by day (% of total): Virus 
3  7c 10  14  
Influenza Aa
(n=37) 
3 (8%) 13 (43%) 8 (65%) 6 (81%) 
Influenza Bb
(n=15) 
6 (40%) 9 (100%) _ _ 
 
aDuring 2005 all influenza A viruses detected were A/New Caledonia/20/99 – like (H1N1) 
(2/37) and A/Wyoming/3/2003 – like (H3N2) (35/37).   
bInfluenza B viruses were B/Brisbane/32/2002 – like.  
 
c Haemadsorption-negative samples were re-passaged for a further 7 days (total 14 days). 
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Nasal sample 
PBS 
 
Figure 6.1: Frequency change with diluted nasal wash sample. 
 
 
 Significant frequency fluctuation was observed with diluted nasal samples compare 
with PBS buffer   
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6.3 Discussion 
In this chapter the capacity of the QCM and the QCM/nanoparticle methods to detect 
influenza viruses in the nasal washes of patients having influenza-like synptoms were 
compared with other currently used methods, including RT-PCR, the standard cell culture, 
shell vial, ELISA and the Directigen Flu A (for influenza A virus only) methods. Each 
method of influenza diagnosis has its own advantages and disadvantages. RT-PCR, which 
was used as the reference or gold standard, is more sensitive than the standard cell culture, 
shell vial, ELISA and QCM methods for both influenza A and B (Wright et al., 1995; 
Atmar et al., 1996a; van Elden et al., 2002). Disadvantages for RT-PCR include problems 
with cross-contamination, the need for specialised laboratory facilities and the inability to 
detect infectious particles. Infectivity can be detected in the cell culture but the method is 
more tedious and time-consuming. The shell vial method, although more rapid than 
standard cell culture (48 h), is labour intensive and requires high technical expertise to read 
end-points. ELISAs, including the Directigen Flu A test,  have been applied to the rapid 
detection of influenza viruses, but are less sensitive than the RT-PCR, cell culture and shell 
vial methods (Table 6.1) and also  cannot detect infectious virus.   
 
QCMs offer a number of advantages including the relatively small size of the equipment 
needed and its portability (Figure 5.3b), low cost and ease of operation. Results are easy to 
interpret and can be read in real-time using automated monitoring equipment. The QCM 
method developed in Chapter 5 was shown to be as sensitive as the shell vial method. The 
QCM/nanoparticle technique was more sensitive than the shell vial method and equally as 
sensitive as cell culture (Table 6.1), but required an additional step involving the use of a 
secondary nanoparticle conjugate.  However, direct detection of the virus from the nasal 
samples by QCM was not possible because of the significant noise (frequency fluctuation 
that occurred), due probably to the viscosity of the nasal wash samples. An additional 
culture step (12 h) was required which increased the processing time to 2 days. 
 
The sensitivities of tests for  detection of influenza A and B by the shell vial, standard cell 
culture, ELISA, Directigen Flu A test, QCM and QCM/nanoparticle tests were  76 and 80, 
81 and 100, 68 and 60, 35 (for influenza A only), 76 and 80 and 81 and 87%, respectively 
(Table 6.2). The sensitivity of Directigen Flu A method was shown to be only 35% 
compared with RT-PCR. These results differ from those of Quach et al., (2002) who 
reported sensitivities of 64.2-84.7% and specificities of 90-100% compared with RT-PCR.  
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However, in the present study frozen samples were used and virus in newly collected 
samples may be more readily detected. Proteolysis or denaturation of influenza antigens 
was observed in stored nasal washes (Quach et al., 2002).     
 
In this study, the sensitivity of each method in descending order was: RT-PCR (100%), 
QCM/nanoparticle (83%), QCM (81%), standard cell culture (81%), shell vial (77%), 
ELISA (69%), and Directigen Flu A (35%) (Table 6.2). The time for each test was: 
Directigen Flu A (20 min), RT-PCR (1 day), ELISA (1 day), shell vial (2 days), QCM and 
QCM/nanoparticle (2 days) and standard cell culture method (up to 14 days).  
 
These results indicate that QCM is a sensitive method for the detection of influenza viruses. 
In Chapter 5, egg-grown preparations of A/PR/8/34 and B/Lee/40 could be detected by the 
QCM and QCM/nanoparticle methods within 30 min and 1 h respectively. However, 
neither QCM test could be applied to the direct detection of influenza virus in nasal wash 
samples.  For use in rapid diagnosis, further improvements in the QCM method to remove 
frequency fluctuation are required. These are discussed in the Chapter 7.  
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Clinical diagnosis of influenza virus infections is often difficult because many respiratory 
viruses cause similar signs and symptoms. There is considerable interest in developing new 
methods for the quick and reliable detection of influenza that require minimum sample 
handling or the need for advanced laboratory skills. In Chapter 3 a preliminary study on the 
advantages and disadvantages of currently available methods for the diagnosis of influenza 
was carried out using egg-grown A/PR/8/34 and B/Lee/40 strains. In Chapter 4 antigen 
ELISAs were developed to provide an indication of the suitability of reagents for use in the 
development of a QCM biosensor. In recent years there has been much research in the 
development of biosensors for the detection of influenza virus. The QCM is one of the most 
popular transducers used in biosensing, because of its simplicity, convenience, low cost and 
capacity to allow rapid and real-time responses (Nakanishi et al., 1996; Uttenthaler et al., 
1998). Studies, based on interaction between viral antigens and specific antibodies, were 
initiated because of the potential of QCM for the diagnosis of influenza.   
 
In these studies, ELISA and the QCM methods were developed to detect influenza A or B 
viruses, using polyclonal and MAbs against type-specific and conserved viral M1 proteins 
(which do not vary between subtypes) for their eventual application to clinical specimens. 
The M1 proteins of A/PR/8/34 and B/Lee/40 were separated from other viral proteins 
(Figure 4.3) and polyclonal antisera were prepared in chickens (Figures 4.7 and 4.8). 
Initially, the sensitivity and the specificity of the M1-specific MAbs and polyclonal antisera 
against A/PR/8/34 and B/Lee/40 were analysed and compared for their suitability to detect 
influenza viruses by ELISAs (Chapter 4, Figures 4.9 and 4.10). The same reagents were 
used in preliminary studies to detect egg-grown preparations of A/PR/8/34 and B/Lee/40 by 
the QCM. Conditions were further adjusted to achieve the highest sensitivity. By ELISA 
the lowest concentration of  the detection of purified A/PR/8/34 and B/Lee/40 viruses was 
20 μg/mL and 14 μg/mL for polyclonal antibody (Figures 4.11a and b) and 30 μg/mL and 
20 μg/mL for MAbs (Figures 4.12 a and b).  
 
Under optimised conditions the sensitivity of the QCM for the detection of both purified 
A/PR/8/34 and B/Lee/40 viruses was 25 μg/mL for MAbs immobilised on Protein A, which 
corresponded to a titre for each virus of 104 pfu/mL (Figures 5.18a and b). The processing 
time for detection by the QCM was less than 30 min. The sensitivity of detection for the 
 185
T. Peduru Hewa      Chapter 7: Final discussion and conclusions 
 
QCM biosensor was increased by the use of antibody-conjugate gold nanoparticles as a 
mass amplification probe. The use of a Protein A-stabilised antibody monolayer on the 
crystal surface increased the sensitivity 10-fold and decreased the limits for detection from 
104 pfu/mL to 103 pfu/mL (10 μg/mL) (Figure 5.21). The processing time by the modified 
procedure was less than 1 h. 
 
The capacity of the QCM and QCM/nanoparticle methods to detect influenza virus in nasal 
washes were compared with other currently used methods, such as PCR, standard cell 
culture, shell vial, ELISA and Directigen Flu A test (for influenza A viruses only). Clinical 
trial data (Chapter 6) indicate that the sensitivities of tests for detection of influenza A and 
B by the shell vial and QCM were 76 and 80%, respectively (Table 6.2). The shell vial 
method is commonly used in diagnostic laboratories and has relatively high sensitivity. The 
QCM exhibited similar sensitivity, but its major drawback from the present studies was its 
inability to detect virus directly in nasal wash samples without passage in cell culture.  
 
When the QCM system was used for the detection of other analytes in liquid phase, a 
correction factor was applied to address problems arising from viscosity of the liquids used 
(Rodriguez-Pardo et al., 2004, 2005). This correction factor was found to be sufficient for 
most liquid samples with moderate viscosities. However, when nasal wash samples were 
tested in Chapter 6, the frequency fluctuations occurred due to the high viscosity of the 
nasal wash sample and the resonator used could not be programmed for such samples 
(Figure 6.1; Rodriguez-Pardo et al., 2005). It would be useful to design QCM sensor 
system with improved correction factors that can address fluctuations (Rodriguez-Pardo et 
al., 2007). Viscosity could not be eliminated from the nasal wash samples of infected 
patients by centrifugation or filtration (results not shown).  
 
However, QCM has the potential for use in clinical applications if these limitations could 
be overcome. Zuo et al., (2004), developed a QCM sensor for the detection of SARS-
associated coronavirus (SARS-CoV) in sputum samples, using polyclonal antibody against 
SARS-CoV virus immobilised onto a Protein A-coated crystal. An ultrasonic logical 
oscillator with a piezoelectric ceramic wafer (20 x 1mm) was used to convert the sputum to 
an aerosol, which was then directly injected into the immunological membrane to increase 
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the surface area available for detection (Zuo et al., 2004). By this method, stability and 
specificity were achieved, which allowed analysis within a short time (less than 2 min) and 
detection of antigen concentrations as low as 0.6-4 μg/mL (Zuo et al., 2004).  The same 
system could be used for the diagnosis of influenza using reagents developed in the present  
study A number of commercially available much improved versions of the QCM are now 
available in different fields of diagnosis, each of which has its own advanced features.  
 
For example, the QCM-Z500 developed by KSV Instruments Inc., Monroe, CT, USA has 
software which controlled working temperatures and a thermostat to control external 
temperature fluctuation in the field, allowing for use at 10-60oC (www.ksvltd.com/content 
/index/dissipativeqcm). 
 
Sigma instruments, Fort Collins, CO, USA, have developed a miniaturised version of the 
QCM instrument (Q-podTM) (www.sig-inst.com/qpodpage.htm) which is compatible with 
conventional instruments. The sensor can be directly connected to computer through a USB 
port. Such instruments could be very useful in the field surveillance programmes (www.sig-
inst.com/downloadfiles/litqpod.pdf). 
 
Further possible directions for research that could enhance the value of the QCM as 
diagnostic tools for influenza diagnosis are: 
a) Improvements to the software in the QCM, particularly in the resonator, in order to 
eliminate the random frequency fluctuations due to the presence of suspended particles in 
the nasal samples. 
b) Improvements to sample processing procedures that reduce the viscosity of the nasal 
wash samples.  
c) Further investigation of a recent report indicates that the QCM can be used with a high 
stability oscillator (Miller or Colppits), connected to the quartz crystal resonator to increase 
the sensitivity in the media with high viscosity (Rodriguez-Pardo et al., (2007). 
d) Possible approaches might include the use of sample incubations with suitable enzymes 
to remove viscosity without affecting the integrity of the virus. 
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Appendix 1: Results of QCM test conducted on 67 samples during the Australian 
winter.  
 
 
 
 
Frequency Shift (Hz)  
QCMa
 
Frequency Shift (Hz) 
QCM/nanopartcleb 
 
 
Sample No. 
 
 
 
QCM 
 
 
 
QCM/ 
nanoparticle 
 
 
Influenza Influenza 
B 
Influenza 
A 
 
Influenza 
A B 
1 - - 10 10 65 50 
2 B B 4 55 45 175 
3   A c A 40 10 160 70 
4 B B d 12 20 60 122 
5 - - 15 5 70 70 
6 A A 36 9 165 65 
7 A A 53 13 177 45 
8 A A 25 10 125 40 
9 A A 43 12 170 52 
10 A A 40 8 171 50 
11 A A 44 12 168 35 
12 A A 55 10 180 45 
13 B B 10 21 65 125 
14 B B 8 25 40 128 
15 A A 43 8 174 45 
16 A A 42 12 170 50 
17 A A 49 15 175 48 
18 A A 30 7 145 45 
19 - - 12 5 45 35 
20 A A 20 10 129 48 
21 A A 40 12 168 40 
22 B B 2 60 65 172 
23 B B 7 40 50 160 
24 - - 12 15 68 70 
25 B B 7 45 45 172 
26 - B 5 18 65 119 
27 B B 10 20 60 126 
28 - - 15 7 45 50 
29 - - 12 13 60 55 
30 - - 12 15 65 30 
31 - - 5 6 50 40 
32 - - 12 8 30 42 
33 B B 11 25 40 132 
34 - - 7 14 55 50 
35 B B 15 28 45 120 
36 - - 12 15 68 55 
37 B B 5 20 50 130 
38 B B 8 25 60 120 
39 - - 10 11 70 42 
40 - - 12 13 72 39 
41 A A 45 8 175 30 
42 - - 10 7 60 35 
43 - - 5 10 63 40 
44 - - 14 12 68 35 
45 A A 26 7 136 38 
46 A A 28 15 130 53 
47 A A 42 13 170 55 
48 A A 48 7 172 60 
49 A A 39 15 165 62 
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Appendix 1 (continued) 
 
50 A A 28 10 129 68 
51 - - 15 7 
 
 
 
 
 
a Negative samples in the QCM test (including –ve control) produced a frequency shift 
of >15 Hz, which was used as the cut-off value for clinical samples.  
b Negative samples in the QCM/nanopartcle test (including –ve control) produced a 
frequency shift of >75 Hz, which was used as the cut-off value for clinical samples.  
 
 
 
c  influenza A virus detected    
dinfluenza B virus detected 
 
 
53 - - 4 12 58 45 
54 A A 40 
47 70 
52 A A 25 8 150 65 
5 168 62 
55 A A 33 8 150 45 
56 A A 27 12 148 55 
57 A A 45 5 162 45 
58 A A 41 8 175 40 
59 - A 15 7 127 40 
60 A A 32 8 158 50 
61 - A 30 4 72 65 
62 - - 15 12 40 40 
63 - - 7 5 39 25 
64 - - 8 8 51 50 
65 - - 10 10 53 60 
66 - - 12 14 48 40 
67 - - 4 3 62 60 
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Appendix 2: Results of all tests conducted on 67 nasal wash samples during the 
Australian winter of 2005. 
 
Sample 
No.  
RT-
PCR 
QPCRc
 
Shell 
vial 
Cell 
culture 
ELISA 
 
Directigen 
Flu A 
QCM  
 
QCM  
(nanoparticles) 
1 Aa <2 - - - - - - 
2 B 8 Bb B B - B B 
3 A 5 A A A A A A 
4 B 3 B B B - B B 
5 A 3 - - - - - - 
6 A 5 A A A - A A 
7 A 9 A A A A A A 
8 A 3 - A - - A A 
9 A 5 A A A - A A 
10 A 6 A A A A A A 
11 A 6 A A A - A A 
12 A 9 A A A A A A 
13 B 3 B B B - B B 
14 B 3 B B B - B B 
15 A 5 A A A A A A 
16 A 5 A A A A A A 
17 A 9 A A A A A A 
18 A 4 A - A - A A 
19 A <2 - A - - - - 
20 A 3 A - A - A A 
21 A 5 A A A A A A 
22 B 8 B B B - B B 
23 B 5 B B B - B B 
24 B <2 - B - - - - 
25 B 7 B B B - B B 
26 B 3 - B - - - B 
27 B 3 B B B - B B 
28 - - - - - - - - 
29 - - - - - - - - 
30 - - A - - - - - 
31 - - - - - - - - 
32 - - A - - - - - 
33 B 4 B B B - B B 
34 - - A - - - - - 
35 B 3 B B - - B B 
36 - - - - - - - - 
37 B 3 B B - - B B 
38 B 3 B B - - B B 
39 - - - - - - - - 
40 A <2 - A - - - - 
41 A 6 A A A A A A 
42 - - - - - - - - 
43 - - - - - - - - 
44 A <2 - A - -  - - 
 
 215
T. Peduru Hewa  Appendix 2 
 
 
Appendix 2 (continued) 
 
45  A 3 - A -  - A A 
46  A 3 A A -  - A A 
47  A 6 A A A A A A 
48  A 5 A A A A A A 
49  A 5 A A A A A A 
50  A 3 - A -  - A A 
51  A <2 - - -  - - - 
52  A 4 A A A -  A A 
53  B <2 - B - -  - - 
54  A 5 A A A -  A A 
55  A 4 A A A -  A A 
56  A 4 - A A -  A A 
57  A 6 A A A A A A 
58  A 5 A A A  - A A 
59  A 3 - - - -  - A 
60  A 4 A A A -  A A 
61  A 5 A A A -  - A 
62  A <2 - - - -  - - 
63 - - - - - -  - - 
64 - - - - - -  - - 
65 - - - - - -  - - 
66 - - - - - -  - - 
67 - - - - - -  - - 
 
 
 
 
a  influenza A virus detected    
b  influenza B virus detected 
c QPCR results expressed as log10 genome  copies/mL 
 
During 2005 influenza A viruses were A/New Caledonia/20/99 – like (H1N1) and 
A/Wyoming/3/2003 - like (H3N2). All influenza A viruses, except samples 3 and 30, 
were A/Wyoming/3/2003 - like (H3N2)  
All influenza B viruses were B/Brisbane/32/2002 – like. 
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